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ABSTRACT ii 
ABSTRACT 
A relatively high dose of midazolam has to be administered orally to achieve 
the favourable effects of premedication in children and this could be associated with 
arterial oxygen desaturation. Pethidine has been commonly administered as a 
premedicant to children for many years, however its association with oximetric 
• desaturation has not previously been investigated. In this thesis the incidence, duration 
and severity of oximetric desaturation episodes was determined following 
premedication in children with midazolam and pethidine. To facilitate this research, 
SatmasterTM, a computer programme which permits storage, retrieval, signal 
evaluation and data compilation, was developedin conjunction with the software 
authors and subjected to artefact template analysis to reduce the inclusion of spurious 
oximetric data in the determination of the incidence of desaturation. It was found that 
neither pethidine nor midazolam premedication increased the incidence of episodic 
desaturation when compared to that occurring during normal sleep. If analgesia is not 
a premedication requirement, oral midazolam confers the advantage over pethidine of 
avoiding the pain of an intramuscular injection, without compromising oxygen 
saturation. 
The availability of flumazenil permits specific reversal of the unconsciousness 
and reflex depression associated with the hypnotic effect of midazolam 
administration. The combined pharmacokinetics and pharmacodynamics of 
midazolam and flumazenil in children have not previously been reported. Midazolam 
pharmacokinetics were shown to compare favourably with those of propofol in a 
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similar patient population and it was found that midazolam antagonism with 
flumazenil produced similar clinical awakening rates to those achieved after propofol 
induction. Blood pressure changes on induction were measured using a standard 
intermittent noninvasive technique and these were compared with continuous pressure 
measurements using a Finapres, modified for paediatric use and computerised data 
acquisition. Propofol induction was associated with hypotension of a significantly 
greater degree and duration compared to midazolam and thiopentone. 
Postoperative recovery after anaesthesia is particularly important for 
ambulatory surgery. The effect of midazolam on psychomotor performance, residual 
sedation and mood was shown to be related to plasma concentration. These indices 
were also used to assess recovery after anaesthetic induction with either midazolam, 
thiopentone or propofol. A post-box toy completion ratio (PBTR) was developed for 
assessment of psychomotor performance in children and compared with a standard 
component of the Wechsler intelligence scale (WISC-R). The PBTR was found to be 
as sensitive as the WISC-R in this assessment, but also has the advantage of ease of 
administration. The quality and rate of recovery following unantagonised midazolam 
induction in the immediate postoperative period is inferior to propofol and 
thiopentone but within one hour of awakening there is no difference in recovery 
characteristics between the agents. Recovery of orientation, co-operation and 
comprehension after flumazenil administration would appear to be as rapid as 
propofol and superior to thiopentone. 
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Midazolam (0.5 mg kg - ') administered orally is a suitable premedicant for 
children. The drug's bitter taste can be disguised, it is rapidly absorbed, producing 
peak sedative effects at 60 min, and has residual anxiolytic effects 120 min after 
administration. Premedication was not associated with episodic oximetric desaturation 
and the children entered the operating suite without overt distress, appearing calm and 
co-operative. Intravenous midazolam (0.5 mg kg - ') compares favourably to propofol 
and thiopentone as an induction agent in some respects, providing a intermediate 
onset of action, intraoperative amnesia, excellent operating conditions and when 
reversed with flumazenil, it has a short recovery period without unwanted residual 
effects. However propofol and thiopentone are both easier to administer because their 
onset of action occurs in one arm-brain circulation time and they demonstrate a 
definite end-point. Following anaesthetic induction with midazolam, psychomotor 
performance returned to preoperative unmedicated levels (recorded the previous 
evening), without flumazenil administration, within 4 hr of eye opening. There were 
no adverse side effects associated with the administration of midazolam. Midazolam 
therefore seems to be a very suitable agent for use in elective surgery in children. 
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I INTRODUCTION 2 
THESIS OBJECTIVES 
Midazolam has been widely used in adult anaesthetic practice as a 
premedicant and for sedation during minor surgical and invasive diagnostic 
procedures. The favourable physiochemical properties and the availability of the 
specific reversal agent, flumazenil, would seem to confer advantages to midazolam as 
an anaesthetic agent in children. The relationship between premedicant effect in 
children and midazolam serum levels has not previously been investigated. Induction 
pharmacodynamics of midazolam have not been compared with propofol and 
thiopentone, nor has the pharmacokinetic disposition, cardiorespiratory effects and 
clinical effectiveness of flumazenil administration in children been previously 
determined. 
The objectives of this thesis are, firstly to investigate the effect of midazolam 
premedication on psychomotor performance, sedative level, mood, memory and 
oximetric desaturation incidence in children. Secondly, to compare the induction 
pharmacodynamics of thiopentone and propofol with midazolam, and thirdly to 
compare the quality and rate of recovery after anaesthetic induction between 
midazolam (with and without flumazenil antagonism), propofol and thiopentone. 
It is hypothesised that midazolam is both a suitable premedicant and induction 
agent for elective paediatric anaesthetic practice. 
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PROPERTIES OF THE IDEAL ANAESTHETIC AGENT 
General anaesthesia is a drug induced state combining unconsciousness, 
analgesia, amnesia, reflex depression and muscle relaxation. The ideal anaesthetic 
agent should provide all aspects of anaesthesia, permitting rapid reversal and return to 
the preanaesthetic state, without unwanted effects. However, such an agent is not 
available, nor likely to be in the future and desired anaesthetic requirements are 
presently met only by a combination of vastly differing groups of drugs. 
To a large extent, tradition has determined the clinical use of premedication. 
Previously, anaesthetic induction was a slow, unpleasant process accomplished using 
pungent inhaled agents and accompanied by unwanted reflex stimulation. 
Premedication was employed to attenuate these responses and shorten induction time 
(Shearer, 1960). Today, intravenous induction produces a rapid, smooth transition to 
the second stage of anaesthesia and it could be argued that premedication is no longer 
necessary (Lindahl, 1990). Now, the most common reason given for administering 
premedication is to allay patient anxiety and induce patient quiescence (Sigurdsson et 
al, 1983, Walsh et al, 1987). The ideal premedication should be safe, easy to 
administer, anxiolytic, allow a smooth anaesthetic induction and have no undesirable 
effects. 
The ideal anaesthetic induction agent should combine desirable physical, 
pharmacokinetic and pharmacodynamic properties and there should be available a 
competitive, specific antagonist (Jones, 1989). The drug should be water soluble, 
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non-irritating to the tissues, stable in aqueous solution, have a long shelf life and be 
inexpensive to synthesise. The ideal induction agent should produce a rapid and 
smooth onset of hypnosis, without the unwanted effects of pain, Myoclonus or 
cardio-respiratory depression. The agent should possess analgesic and amnesic 
properties and recovery of consciousness should be rapid and smooth. 
Midazolam, prepared as a water soluble salt, is a powerful anxiolytic with a 
high clinical therapeutic index and can be administered by a wide variety of routes. It 
causes only slight ventilatory depression when the clinically recommended dosage is 
administered and can be specifically antagonised with flumazenil (Cook, 1992). 
Intravenous administration of midazolam does not seem to possess intrinsic analgesic 
activity but intrathecally deposited midazolam has been recently shown to possess 
analgesic properties (Goodchild and Noble, 1987). Use of midazolam as the sole agent 
to achieve satisfactory anaesthesia would induce a large number of unwanted and 
potentially lethal effects. 
Midazolam seems to be one of the few drugs that can be employed in clinical 
practice as both a premedicant and for induction of general anaesthesia (Fragen, 
1988). A clinical therapeutic index states how selective a drug is in producing a 
desired effect but is an inappropriate basis for comparison of anaesthetic agents 
because death resulting from respiratory depression may not be related to the clinical 
safety margin of induction agent administration. A comparison of the properties of 
midazolam with the characteristics of the ideal premedicant and induction agent will 
usefully illustrate the potential for use of this drug in general anaesthesia. 
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CURRENTLY AVAILABLE PREMEDICANTS AND 
INDUCTION AGENTS 
Premedication regimens have included a wide variety of sedative-hypnotic, 
narcotic and antisialagogue drug combinations and routes of administration. Often 
these drugs were administered intramuscularly by injection. Pethidine, morphine, and 
fentanyl are the most popular narcotics used for premedication. Unfortunately the 
primary effects of these drugs do not match the desired effects of premedication, viz. 
sedation and anxiolysis. Moreover, narcotic administration can be associated with 
dose-dependent side effects, such as skin reactions, postoperative nausea, dysphoria 
and respiratory depression. Attainment of an adequate level of sedation often requires 
concurrent administration of another agent such as trimeprazine or droperidol, 
increasing the likelihood of unwanted effects. Comparative adult studies have 
indicated that benzodiazepines are more effective in producing anxiolysis and amnesia 
and have also been shown to be superior hypnotics to barbiturates when administered 
on the evening prior to surgery (White, 1989). 
Recent changes in philosophy and clinical practice have resulted in a 
rationalisation of premedication. The emphasis on ambulatory surgery and a holistic 
approach to the preoperative preparation of the child have resulted in increasing use of 
the oral and nasal routes of administration in children (Feld et al, 1990). Oral 
administration is an important prerequisite for the ideal premedicant in children and 
water soluble drugs are well absorbed when given via this route (Nicolson et al, 
1989). Premedication with oral and intranasal ketamine provides satisfactory sedation 
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but this is also associated with dose related undesirable effects which include 
increased oral secretions and random limb movement (Gutstein et al, 1992). Other 
premedicant agents may be specifically indicated in certain circumstances such as for 
prevention of postoperative emesis, vagolysis and prophylaxis against acid aspiration, 
but these drugs do not have specific sedative and anxiolytic effects (Manchikanti et al 
1984, O'Sullivan et al 1985). 
Inhalational induction is the most commonly used technique in paediatric 
anaesthesia, however intravenous induction is the method of choice in most older 
children (Hannallah, 1992) and propofol has been shown to provide a decreased 
incidence of airway obstruction compared to inhalational induction in children aged 1 
to 7 years (Martin et al, 1992). Sedative-hypnotic, opioid analgesic and 
sedative-amnesic agents are used for intravenous induction of anaesthesia in children. 
They represent a wide variety of pharmacological compounds, of which the most 
popular sedative-hypnotic agents are thiopentone, etomidate, midazolam, ketamine 
and propofol (White, 1988). Propofol and etomidate are not water soluble and both 
are associated with pain on intravenous injection. Ketamine induction may be 
associated with excitatory phenomena and can cause cardiovascular stimulation 
(Moretti et al, 1984). Induction is rapid with propofol and thiopentone but is 
associated with cardiovascular depression in adults. Induction doses of thiopentone, 
midazolam and propofol are associated with respiratory depression but this is not so 
with ketamine, nor etomidate. Midazolam is the only induction agent which provides 
significant amnesia (White, 1988). Emergence after etomidate and propofol is rapid 
whilst that following thiopentone, midazolam and ketamine is intermediate. Unwanted 
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effects of induction agents include drowsiness, nausea and vomiting, psychomimetic 
phenomena and dizziness (Marshall and Longnecker, 1991). Although midazolam 
also causes postoperative drowsiness, this can be antagonised by flumazenil 
(Hunkeler et al, 1981). Thiopentone produces rapid and smooth loss of consciousness, 
but is associated with marked cardiorespiratory changes, lacks analgesic properties 
and recovery is slowed by drowsiness and sedation (Reyes 1986, Sebel and Lowdon 
1989). 
Obviously many of the desirable properties of the ideal induction agent have 
not been achieved with the currently available drugs. Thiopentone remains the most 
widely used intravenous induction agent despite its limitations and although it was 
introduced more than 50 years ago, it remains the induction agent against which more 
recent drugs must be compared (Dundee, 1984). 
I INTRODUCTION 8 
SPECIFIC REQUIREMENTS OF 
PAEDIATRIC ANAESTHESIA 
Children are excellent candidates for outpatient surgery (Hannallah, 1992). 
Frequently the paediatric surgical patient has no concomitant systemic disease and the 
proposed surgical procedure is relatively minor. Day surgery minimises both parental 
separation and exposure to hospital acquired infection for the child. It may appear that 
general anaesthesia in the child above the age of three years differs little when 
compared to adults, however there are some special considerations applicable to the 
child undergoing ambulatory anaesthesia. 
The narrowest part of the child's airway is at the cricoid cartilage and the 
tracheal mucosa in this area is easily damaged by a tracheal tube that is too large 
(Sumner and Facer, 1986). Small reductions in the internal diameter of the child's 
trachea cause relatively large increases in airways resistance and work of breathing 
(Brown and Fisk, 1979). In children under the age of 6 years, peripheral airways 
contribute about 50% of total airways resistance and therefore minor respiratory 
disease is likely to cause more substantial problems in these children when compared 
to adults (Hogg et al, 1970). Children have a runny nose for a significant part of the 
year and often present for minor surgery with prodromal or recovery symptoms of an 
upper respiratory tract infection (Hannallah, 1992). The smaller the child, the less is 
the respiratory reserve, and the higher the risk of postoperative respiratory depression. 
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Tiret and colleagues reported a prospective survey of anaesthesia-related 
morbidity and mortality following 40,240 anaesthetics in infants and children (Tiret et 
al, 1988). They found that circulatory failure was as frequent as respiratory failure in 
children and that complications were observed almost equally during induction, 
maintenance and recovery. The fact that the only death within the child age-group 
occurred during recovery, emphasises that this period is particularly critical (Tiret et 
al, 1986). 
Liver metabolism matures in infancy. The degree of protein binding of 
thiopentone and the steady state volume of distribution in children, are similar to adult 
values (Sorbo et al, 1984). Shorter recovery times are expected for children compared 
to adults because of the faster clearance of induction agents, which is in turn 
attributable to the relatively larger hepatic mass (Udkow, 1978). In general children 
seem to require a larger dose of drug on a mg kg -I basis for the induction of 
anaesthesia, either because they exhibit a decreased central nervous system sensitivity 
or there is a more rapid distribution from the central to the peripheral compartments 
(Gepts and Camu, 1991). Furthermore, the volumes of tissues belonging to the 
vessel-rich group are proportionally larger, accepting a larger fraction of the cardiac 
output, while muscle and fatty tissues represent a lesser percentage of total body 
volume compared to adults (Eger et al, 1971). 
In view of these anatomical, physiological and pharmacological characteristics 
in paediatrics, a drug which is both well absorbed following oral administration, and 
which when given as an anaesthetic induction agent has a high therapeutic index, 
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non-cumulative metabolism and has available a specific antagonist, would seem the 
most appropriate choice in children: 
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WHY CHOOSE MIDAZOLAM? 
The benzodiazepines have advantages over other sedative-hypnotics because 
they reliably induce sedation and anxiolysis, have an extremely wide therapeutic 
range and their administration is not associated with histamine release or 
adrenocortical secretion suppression. However most are unsuitable as anaesthetic 
induction agents, because of their unpredictable onset of action and the production of 
active metabolites with longer terminal half-lives than the parent drug, resulting in 
prolonged postoperative sedation. Furthermore, their lipophilicity and insolubility in 
aqueous solutions have resulted in propylene glycol formulations which cause pain on 
injection, venous irritation and thrombophlebitis. 
Midazolam (Ro 21-3981) was synthesised in 1974 by Fryer and Walser and is 
an imidazobenzodiazepine derivative (Walser et al, 1978) (Figure I.1). It was released 
for general use world-wide in 1986 with indications for use as a premedicant, 
intravenous sedative and for induction of general anaesthesia. Midazolam has a 
molecular weight of 362, a pKa of 6.15 and the parental solution is buffered to an 
acidic pH of 3.5. The drug has a fused imidazole ring that accounts for its basicity, 
stability in aqueous solution and rapid metabolism (Gerecke, 1983). Midazolam is 
different from other benzodiazepines because in acidic aqueous media it is water 
soluble, but at physiological pH an intramolecular rearrangement occurs and 
midazolam becomes highly lipophilic. This characteristic of midazolam permits a 
water soluble parenteral solution which causes minimal local irritation after either 
intramuscular or intravenous administration, and the high lipophilicity allows rapid 
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absorption from the gastrointestinal tract and entry into brain tissue. Midazolam is 
rapidly and extensively metabolised by hepatic microsomal enzymes, resulting in a 
short elimination half-life of 2-4 hours. The principle metabolite is 
1-hydroxymethylmidazolam but small amounts of 4-hydroxymidazolam and 
1,4-dihydroxymidazolam are formed in parallel which are then excreted in the urine as 
glucuronide conjugates (Arendt et al, 1984). 
C ' 
FIGURE I.1: Structural formula of midazolam. 
In contrast to diazepam, the hydroxylated metabolites of midazolam have 
minimal central nervous system activity (Ziegler et al, 1983). Midazolam produces 
amnesia, anxiolysis, sedative/hypnotic, anticonvulsant and muscle relaxant effects, 
typical of the general actions of the benzodiazepine group of drugs on the central 
nervous system (Pieri, 1983). The ideal benzodiazepine for anaesthesia should possess 
a predominant sedative/hypnotic effect, short duration of activity, no active 
metabolites, be stable and well tolerated and there should be available a pure 
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competitive antagonist to interrupt transiently or permanently the actions of the agent 
when the anaesthetist so desires (Athrein et al, 1988). Midazolam very nearly satisfies 
all these 'ideal' prerequisites and the discovery of flumazenil in 1979 (Hunkeler et al, 
1981) makes midazolam a very suitable anaesthetic agent, particularly for use in 
children. 
Flumazenil (Ro 15-1788) is a benzodiazepine antagonist with a molecular 
weight of 303 and a pKa of 1.7, which can reverse all the behavioural, neurological 
and electrophysiological effects of all the benzodiazepine agonists (Hunkeler et al, 
1981). Flumazenil is similar in structure to midazolam except that chloride and the 
phenyl group in midazolam is replaced by fluoride and a carbonyl group, respectively, 
in flumazenil (Figure 1.2). Flumazenil is less lipophilic and less water soluble than 
midazolam but can still be administered as an injectable aqueous solution. 
fl,,COOCH 2 CH, 
• 
CH 3 
FIGURE 1.2: Structural formula of flumazenil. 
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Flumazenil has a high affinity for the benzodiazepine receptor but with an 
apparent complete lack of pharmacological activity (Ritter et al, 1988). It has a 
distribution half-life of less than 5 minutes, an elimination half-life of 0.7-1.3 hours 
in adults and the drug achieves a relatively high plasma concentration compared to 
midazolam, because it is only 50% bound to plasma proteins (Roncari et al, 1986). 
The clinical applications of flumazenil require further evaluation but its ability to 
antagonise benzodiazepines could be advantageous where residual sedation exists 
beyond anaesthetic needs, accidental or iatrogenic oversedation occurs, following 
unexpected reactions to benzodiazepines and in the treatment of intentional 
benzodiazepine intoxication (Geller and Halpern, 1991). 
The powerful amnesic and anxiolytic properties of midazolam and use of the 
parenteral formulation orally, resulted in it rapidly becoming established as a suitable 
premedicant in children, despite the need to disguise the drug's bitter taste (Feld et al, 
1990). There are now numerous studies detailing pharmacokinetic, pharmacodynamic 
and clinical acceptance of various midazolam premedicant regimens in paediatric 
patients (Payne et al, 1989). A feature of benzodiazepines is the relationship between 
drug concentration and effect (Reyes, 1984). Pharmacokinetic-pharmacodynamic 
modelling has recently been re-evaluated in an attempt to explain inter-individual 
differences in dose response relationships (Henthorn and Avram, 1991). The 
relationship between serum midazolam levels, mood, level of sedation and 
psychometric performance following premedication with midazolam has not 
previously been investigated in children. 
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At the time when Salonen and colleagues initially investigated the place of 
midazolam in paediatric anaesthetic practice, neither the usefulness nor 
pharmacokinetics of the drug had been thoroughly described in children (Salonen et 
al, 1987). Indeed, there were only 4 original articles reporting the use of midazolam as 
an induction agent in children prior to 1989, before the work on this thesis 
commenced. There were no controlled trials of flumazenil administration to reverse 
postoperative hypnosis associated with midazolam induction of anaesthesia in 
children and only one case report of its use following benzodiazepine poisoning in 
children (Wood et al, 1987). The place of midazolam as a premedicant and induction 
agent in paediatric outpatient anaesthesia is controversial but the introduction of 
flumazenil permits reversal of any prolonged sedation and may therefore extend its 
use to this rapidly developing area of patient care (Westhorpe, 1990). However neither 
midazolam nor flumazenil have yet been licensed for use in paediatric patients. This is 
not unusual as few drugs are initially licensed for use in patient subgroups. Therefore 
the safety and efficacy of these drugs must be determined by clinical investigation to 
determine their place in this specialised field of anaesthesia. The simultaneous clinical 
pharmacokinetics of flumazenil and midazolam have not been studied in children and 
there are very few comparable studies in adults (Lauven et al, 1985). The quality of 
recovery after anaesthesia is related to the incidence of complications (Patel & Rice, 
1991) and a controlled comparative study with midazolam of recovery following the 
administration of common induction agents used in children, has not been undertaken. 
The situation described above is that which existed at the commencement of 
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the work on this thesis in 1989. The literature has expanded considerably over the past 
five years and the publications which have resulted from this research are listed in 
Appendix A. The following chapters present my research and a review of the use of 
midazolam as a premedicant and an induction agent for elective surgery in children. 
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PATIENT SELECTION AND ANAESTHESIA 
The selection criteria and standardised components of the anaesthetic 
technique are described below, with any differences in management being presented 
in the relevant chapters. 
Table II.!: 	 Drug studies reported from this thesis 
Number of 	 Study description 
children 
12 	 The pharmacokinetics of propofol (Diprivan) 
40 	 Antagonism of the hypnotic efect of midazolam 
12 	 The pharmacokinetics of flumazenil and midazolam 
20 	 The efect of premedication on oxygen saturation 
30 	 Premedication with oral midazolam - psychomotor function, 
anxiolysis, sedation and pharmacokinetics 
30 	 A comparison of three induction agents - cardiovascular effects 
and recovery 
In total, 144 children aged 1-12 years were studied (Table II.!). Al children were 
ASA grade I (Dripps et al, 1961)(Table 11.2) and al children, except those 
participating in the oximetric study, underwent circumcision for the treatment of 
phimosis. The studies were al approved by the Faculty of Medicine Ethics 
Commitee (The University of Hong Kong) and writen informed consent was 
obtained from the parents (Appendix A). Children were excluded from the study if 
there was a history of asthma or alergies, previous adverse anaesthetic experience, 
halothane anaesthesia within the previous one month, hepatic, renal, respiratory, 
cardiac or haematological disease or developmental disability. Children undergoing 
psychomotor assessment were excluded if aged less than 4 years. 
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Table 11.2: 	 American Society of Anesthesiologists (ASA) Physical Status 
Categories (modified from Dripps et al, 1961). 
Category 
II 
III 
IV 
V 
 
Description 
 
Healthy patient 
Mild systemic disease - no functional limitations 
Severe systemic disease * - definite functional limitation 
Severe systemic disease * that is a constant threat to life 
Moribund patient not expected to survive 24 hours with or without 
operation 
Emergency 
   
*Whether or not the system disease is the disease for which the patient is undergoing 
surgery. 
Al patients were premedicated with midazolam 0.5 mg kg-' (maximum dose 
15 mg) and atropine 0.02 mg kg-t given by mouth 2 hours before operation, except 
when midazolam premedication was compared with a group of children receiving 
intramuscular pethidine 1 mg kg-' and when propofol disposition pharmacokinetics 
were investigated. In this later group, oral trimeprazine was used because the ethics 
commitee would not authorise two drugs (midazolam and propofol), neither of 
which at that time were approved for use in children, to be administered to the same 
patient. To facilitate painless intravenous cannulation, EMLA emulsion cream 2 g 
(lignocaine 25 mg g"' and prilocaine 25 mg g-') was applied to either the dorsum of 
the hand or to skin overlying the basilic vein in the cubital fossa. In the operating 
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suite a 24 or 23-gauge cannula was inserted into the vein underlying the 
EMLA-pretreated areas. 
Induction of anaesthesia was accomplished with either midazolam 0.5 mg 
kg- ', propofol 2.5 mg kg. ' or thiopentone 4 mg kg-I injected intravenously over 30 
seconds following midazolam premedication. Patients induced with propofol were 
pre-treated with procaine hydrochloride 1 mg kg. ' intravenously 15 seconds before 
induction of anaesthesia. Children participating in the determination of the 
pharmacokinetic disposition of flumazenil and midazolam were given alfentanil 5 pig 
kg -` intravenously, followed 60 seconds later by midazolam, then atracurium 0.5 mg 
kg. ' and the trachea intubated and the child ventilated. Anaesthesia was maintained 
with 67% nitrous oxide and 0.5% isoflurane in oxygen via a Mapleson F breathing 
system with hand ventilation to an end-tidal carbon dioxide partial pressure of 5 kPa. 
Patients breathing spontaneously were given 67% nitrous oxide and 1-3% halothane 
in oxygen via a Mapleson F (<25 kg) or Mapleson A (>25 kg) breathing system as 
maintenance anaesthesia. A caudal injection of 0.25% bupivacaine 0.5 ml kg . ' was 
administered to all children undergoing circumcision, 6 min after induction agent 
administration. Effectiveness of caudal anaesthesia was tested in the recovery room 
during emergence. Any child demonstrating a response to pain during gentle 
compression of the neck of the penis was discarded from the study. A composite 
system of routine monitoring devices included an electrocardiograph, non-invasive 
arterial pressure recorder, pulse oximeter, capnograph and inspired oxygen 
concentration (Cardiocap CM-104, Datex Instrumentarium Corp., Helsinki, Finland). 
At the end of surgery, if a muscle relaxant had been administered, neuromuscular 
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block was antagonised with neostigmine and atropine, the trachea extubated and 
ventilation assisted with 100% oxygen by mask and a Mapleson F breathing system, 
until spontaneous ventilation resumed. Patients breathing spontaneously were given 
oxygen 28-34% via a Multi-Vent air entrainment mask (Hudson, Temecula, 
California, USA) until awake. 
For all studies, except the oxygen saturation and pharmacokinetic disposition 
of propofol, a test of recall was performed to evaluate the effect of medications on 
memory. This test was performed in the following manner. After premedication and 
just before transfer to the operating suite, the child was shown a simple picture of a 
school scene for 30 seconds and asked to name and remember five of the depicted 
objects. Four hours after the operation, the child's ability to recall these objects was 
tested and he was scored according to his degree of success (Williams, 1968). On 
arrival in the operating suite, the child was assessed as agitated or crying, aware and 
apparently anxiety free, drowsy, or asleep but responsive to command (Jones et al, 
1990). Induction was graded as good (absence of side effects), adequate (side effects 
present but not interfering with induction) and poor (side effects severe and 
protracted). The duration of anaesthesia and cardio-respiratory data during surgery 
and recovery were recorded. The time to spontaneous eye opening and 
self-identification were recorded, as was the child's mood using a structured 
observation score (Krane et al, 1987) (Table 11.3). The child's level of sedation was 
also recorded using the modified Steward coma scale (Robertson et al, 1977)(Table 
11.4). 
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Table 11.3: 	 Structured observation scale after Krane et al, 1987. 
MOOD 	 Score 
laughing, euphoric 
happy, playful 
calm, drowsy, sleepy 
iritable but calmed by mother 
screaming, inconsolable 
Table 11.4: 	 Modified Steward coma scale (Robertson et al, 1977) 
Airway Consciousness Activity 
opening mouth or coughing 
on command 
3 fuly awake, eyes open, 
conversing 
4 raising one arm 	on 	2 
command 
no voluntary cough, 	clear 2 lightly 	 asleep, 	 eyes 3 non-purposeful 	 1 
airway without support opening intermitently movement 
obstruction on neck flexion, 
airway clear without support 
1 eyes open on command 
or in response to name 
2 not moving 	 0 
on extension 
airway 	obstructed 	without 
support 
0 responding 	 to 	 ear 
pinching 
1 
not responding 0 
Add scores for Airway, Consciousness and Activity: 	 TOTAL SCORE: 
Any side effects of drug administration were noted and when flumazenil was 
administered, the child's behaviour and the speed of antagonism of midazolam were 
considered together by an independent observer in the recovery room and were 
graded as excelent, good, moderate or poor. Raw data are tabulated in Appendix C. 
1 
2 
3 
5 
H METHODS 23 
PSYCHOMOTOR ASSESSMENT 
Dundee and colleagues noted the need for a comprehensive assessment of the 
preoperative effects of drugs given prior to anaesthesia and sequelae attributed to 
their use to permit valid comparisons of the efficacy of premedicant regimens 
(Dundee et al, 1962). Tests of motor skills and co-ordination are used to assess the 
effects of anaesthetic agents and the speed of recovery in adults (Cashman and 
Power, 1989). Medicated children are difficult to study and the use of adult tests of 
psychomotor skill and cognitive function are inappropriate. Craig and colleagues 
used a post-box toy to assess recovery after anaesthesia in adult gynaecological 
patients (Craig et al, 1982). In this thesis, the post-box test was modified so that the 
child became his own control and thereby reduced the effect of interpatient 
variability and limited the practice effect, associated with this form of assessment. 
The day before surgery, each child was familiarised with a post-box toy 
(Figure II.!) and the completion time of his best performance on seven attempts 
recorded. After seven attempts the child's learning curve flattened and further 
attempts resulted in a decline in performance and boredom with the toy. On the day 
of operation, after midazolam premedication, the child was offered the post-box toy 
at different times after premedication and his fastest completion time at a single 
attempt recorded. A ratio of his best preoperative, unmedicated, practised 
performance, to his post-medication completion times at each assessment was 
computed as the toy completion ratio (PBTR) for premedication assessment. 
Similary, a postoperative PBTR was computed for recovery assessment: 
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immediately the child became co-operative post-operatively he was again encouraged 
to complete the post-box toy and his fastest completion time at a single attempt 
recorded. This was repeated hourly with each subsequent assessment of recovery, for 
4 hours. The data were then related to his best unmedicated performance, and a 
postoperative PBTR computed for each recovery assessment. 
413 • 
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FIGURE II.!: The post-box toy used for psychomotor assessment. 
Recovery from anaesthesia can also be assessed by a variety of intelligence 
tests which have been validated for assessment of pre- and postoperative cognitive 
function over a broad range of abilities in adults and children (Chung et al, 1989). 
The Wechsler intelligence scale (WISC), which can be matched for the child's age 
and race (WISC-R), measures verbal and motor performance (WISC-R, 1981). The 
scale has been used to assess the effects of premedication, as well as the recovery 
from anaesthesia in adults (Anderson et al, 1985, Rollason et al, 1971). The coding 
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test component of the WISC-R was performed by children participating in the 
comparative induction agent study, folowing each completed post-box assessment. 
Two coding worksheets were used, one for children aged 5 to 6 years and another for 
children aged 7 to 15 years (Figure 11.2). 
* ®A # Ii 
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FIGURE 11.2: 	 WISC-R coding test for children aged 5 and 6 years (upper) arid 
II 
7-15 years (lower). 
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The evening before surgery, each child is taught, within the strict guidelines 
of the test, how to complete the coding worksheet. After successful completion of the 
practice items in the sample area (5 items for the younger and 7 for the older 
children), the child is encouraged to complete as many items, in order, without 
omission, within 120 seconds. The child's performance is then scored with a bonus 
awarded for a perfect completion within the allotted time viz. 111 - 120" score 45, 
101 - 110" score 46, 91 - 100" score 47, 81 - 90" score 48, 71 - 80" score 49, and 70" 
or less 50. The best completion score after 7 attempts was recorded for later 
comparison with the child's medicated performance. A figure is scored as correct if it 
is clearly identifiable as the keyed figure, even if drawn imperfectly or if, after 
realising his mistake, the child draws the correct figure next to the incorrect one. A 
maximum raw score of 50 points is possible for the younger child and 93 points for 
the older child (including any time bonus). 
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OXIMETRIC DATA ACQUISITION 
The respiratory effects of anaesthetic medications have previously been based 
on intermittent observations of ventilatory rate or arterial blood gas tensions (Jones et 
al, 1990). Pulse oximetry has enabled continuous monitoring of arterial oxygen 
saturation, but data derived from pulse oximetry has inherent limitations, one of 
which is artefactual desaturation caused by patient movement (Langton and Hanning, 
1990). 
The same pulse oximeter (Nellcor N-200E, Nellcor Inc., California, USA) 
was used for all the patients during the study and connected to a Nellcor D-20/250 
OxisensorTM probe, attached to the great toe of each child. Proper function of the 
oximeter was checked by activating the oximeter's 'self-check' routine and 
attachment of the instrument to one of the investigators prior to commencement of 
the study. The serial communication port of the oximeter was connected to a 386SX 
laptop computer (ALT386SX, Amstrad Plc., Essex, UK). Oximetric, pulse rate and 
signal amplitude data were sampled 60 times a minute and displayed in real time by 
SatmasterTM (EMG Scientific, California, USA) on the computer screen. On 
completion of the study the data were then stored using Satmaster, a software 
package which allows the retrospective evaluation of desaturation episodes, signal 
amplitude and pulse rate together with various displays of their incidence and 
duration. 
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Data associated with a zero amplitude signal were automaticaly discarded by 
the Satmaster software. However, further evaluation was necessary to identify and 
remove the spurious decreases in arterial oxygen saturation (SO2) produced by 
motion artefact, which were not associated with zero amplitude. Observation of the 
patient and Satmaster display revealed that characteristic large variations in signal 
amplitude occured consistently during probe movement and that these heralded false 
reductions in S,02 (Figure 11.3). 
Scale: 2 min 	 16.23 
FIGURE 11.3: The S,02 tracing in the upper box illustrates an apparent 
desaturation to 83%. The amplitude tracing in the lower box 
demonstrates violent spiking (from 25 to 100 units) due to signal 
interference associated with patient movement. The time scale for 
the displayed tracing is two minutes. 
Scale: 30 min 
02 Sat 
Heart 
Amplitude 
II METHODS 29 
This patern was confirmed to be different from the display produced by true 
desaturations (Figure 11.4). 
2025 4 1.5 	 30 
FIGURE 11.4: 	 Ilustrates a valid desaturation episode to 80% with concurent rise 
in pulse rate (middle box), while the signal amplitude (when 
zoomed-in) remains relatively stable. The time scale for the 
displayed tracing is 30 minutes. 
A template was then constructed which was used to retrospectively identify 
and invalidate the periods of artefactual desaturation due to movement present in the 
patient data (Figure 11.5) (Jones at al, 1992). 
Scale: Zmin 
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FIGURE 11.5: 	 The template used to identify artefactual desaturation data due to 
patient or probe movement 
Reductions in SO2 were considered false if: 
1. there were changes in signal amplitude strength of ± two standard deviations 
(A) from the previous 60 second mean within 10 seconds prior to the fal in 
S,02 (B) and 
2. the maximum rate of change of signal amplitude occurred within 2 seconds of 
commencement of signal artefact (C) and 
3. the saturation signal stabilised to pre-artefact S,02 levels within 10 seconds of 
cessation of signal artefact (D). 
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Each oximetric profile was examined. The recording could be viewed as a 
whole or magnified so that a recorded segment of two minutes was displayed on the 
computer screen. Each period of desaturation was evaluated against its concomitant 
signal amplitude recording. Episodes of desaturation which conformed to the 
template criteria were discarded and the post-evaluation data compiled and analysed. 
Oxygen saturation and signal amplitude data recorded from the toe were very similar 
to that measured with finger probe placement (Reynolds et al, 1993). Furthermore, 
the temporal lag in desaturation seen in adults appears to be shorter in children 
because they are smaller, have a faster circulation and normal peripheral vascular 
perfusion. In another adult study performed contemporaneously with the work for 
this thesis, the template was shown to have a sensitivity of 96%, a positive predictive 
power of 98% and a specificity of 60% (Visram et al, 1993). Nearly one-third of all 
evaluated desaturations had a concurrent change in signal amplitude pattern that 
suggested both oximeter probes were affected by movement and for the 
determination of template specificity, these data were discarded. Postoperative 
oxygen therapy resulted in a small genuine desaturation sample size and this may 
have distorted the determination of specificity. A larger pool of genuine desaturations 
may have increased the ratio of true positives to false negatives and therefore 
increased specificity. An attempt was made to improve specificity of the template by 
altering the requirements for artefact recognition. Unfortunately, modifications of the 
template producing a useful increase in specificity were associated with a 
considerable decline in sensitivity. 
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HAEMODYNAMIC DATA ACQUISITION 
Continuous monitoring of arterial blood pressure is often desirable 
(Prys-Roberts, 1981) and is widely practised during anaesthesia. Arterial cannulation 
has associated morbidity (Slogoff et al, 1983) and a non-invasive alternative may be 
more appropriate, particularly in children. 
Haemodynamic data (pulse rate and non-invasive blood pressure) were 
recorded by transcription from a Cardiocap screen (Cardiocap CM-104, Datex 
Instrumentarium Corp., Helsinki, Finland) to data sheets every minute or at 5 minute 
intervals as appropriate, during the early midazolam and flumazenil studies 
(Appendix D). More recently, direct data acquisition was accomplished for 
haemodynamic data recording during the comparative investigation of the induction 
agents propofol, midazolam and thiopentone. The Cardiocap was interfaced with a 
Sigma PC/XT (Sigma Designs Inc., Fremont, California USA) via an 8-port 232c 
multi-serial card (Decision Computers International, Taipei, Taiwan). Systolic, mean 
and diastolic blood pressure, pulse rate and time data were stored to disc in ASCII 
format at 1 minute intervals in real time using data acquisition software written for 
this system (Chan, 1991). 
The peak haemodynamic changes which occur during intravenous induction 
of anaesthesia in children may be missed with a sampling rate of once per minute. 
The FinapresTM (model 2300e; Ohmeda, Denver, Colorado, USA) however permitted 
non-invasive measurement of the blood pressure, pulse rate and time data with 
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simultaneous data storage to disc in ASCII format at 10 second intervals, before and 
during induction of anaesthesia. The Finapres non-invasive continuous blood 
pressure monitor became available in 1989. It employs the technique of Penaz to 
continuously servocontrol the pressure in a finger cuff to equal the blood pressure in 
the digit (Pace and East, 1991). Initial uncontrolled studies in the clinical 
environment were favourable (Van Egmond et al, 1985) but recent performance has 
been criticised because of drift, poor agreement between the Finapres and arterial line 
mean/diastolic pressures •(Stokes et al, 1991 and Aitken et al, 1991), and 
unpredictable variability between the arterial line and the Finapres (Gibbs et al, 1991 
and Pace et al, 1991). Previous studies also demonstrate the Finapres to be as 
accurate as currently employed oscillometric techniques (Gorback et al, 1991). A 
second generation Finapres (2300e) with improved software was released and shown 
to be consistently more accurate than an intermittent non-invasive blood pressure 
monitor (Colin Compact Multi-monitor BP-408 Mark II, Nippon Colin Co., Ltd., 
Komaki City, Aichi, Japan) in adolescents and the earlier software version (Jones et 
al, 1992b). This alternative device should meet equivalent standards of reliability 
before recommendation as a substitute for invasive blood pressure monitoring or 
other current intermittent non-invasive blood pressure monitors (American National 
Standards Inc.). In the haemodynamic study described in this thesis, a prototype 
paediatric Finapres cuff was applied to the middle phalanx of the middle finger 
strictly according to the manufacturer's instructions, and the output from the Finapres 
2300e was interfaced to the computer (Jones et al, 1993a). The data files were 
imported into Lotus 123W ver 1.0 (Lotus Development Corporation, Cambridge, 
Massachusetts, USA) for display and basic statistical computation. 
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To further illustrate the limitation of intermittent non invasive blood pressure 
measurement, haemodynamic data were recorded using both the Cardiocap and the 
Finapres simultaneously during the comparative investigation of midazolam, 
propofol and thiopentone induction of anaesthesia. 
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DRUG ASSAYS AND PHARMACOKINETIC ANALYSIS 
The concentrations of midazolam, flumazenil (Jones et al, 1993) and 
thiopentone (Stanski et al, 1983) in serum, and propofol in whole blood (Plummer, 
1987), were determined by high performance liquid chromatography (HPLC). HPLC 
is a separation technique used to identify and measure the concentration of 
compounds in solution. Separation is achieved by passing the solute through a column 
which selectively slows down the velocity of the various compounds. The solute and 
solvent are then passed through a detecting device for the measurement of compound 
concentration. 
The components of the HPLC system for the assay of propofol were the 
delivery system (Waters M501 pump, Millipore Corporation, Milford, Massachusetts, 
USA), automatic gradient controller (Waters 680), injector (Waters WISP712 
autosampler), a C 18 reversed phase column (Resolve C 18 , Waters) linked to a C 18 
pre-column (Hibar, E. Merck, Darmstadt, Germany), a fluorimetric detector (Waters 
M470 scanning fluorescence detector) with excitation and emission wavelengths set at 
276 nm and 310 nm respectively and an integrator/recorder (Waters746 data module). 
The components of the HPLC system for the assay of midazolam, flumazenil 
and thiopentone included a delivery system (Waters M501 pump), an injector (Waters 
WISP712 autosampler), a C 18 reverse phase cartridge column (Nova-pak, Waters) 
linked to a C 18 pre-column and the eluate was measured with a programmable 
multiwavelength UV detector (Waters M490E) set at 220 nm for midazolam and 
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flumazenil, and 290 nm and 254 nm for thiopentone, with the integrator/recorder 
replaced by the Waters MAX810 HPLC system workstation. 
All chemicals were of analytical grade. Thymol and sodium dihydrogen 
phosphate were supplied by British Drug House, Poole, England; cyclohexane, 
acetonitrile (HPLC grade), glacial acetic acid, dichloromethane (HPLC grade) and 
methanol were supplied by Mallinckrodt Inc, Paris, Kentucky, USA; triethylamine 
and diethyl ether were supplied by E. Merck, Darmstadt, Federal Republic of 
Germany, and tetramethylammonium hydroxide by the Sigma Chemical Company, 
St. Louis, USA. 
Propofol assay 
The propofol assay for the pharmacokinetic and induction studies were 
performed at different times and in different laboratories. The assay methodology for 
the induction study is described below and the pharmacokinetic assay method is 
described in Chapter IV. The technique described by Plummer was modified to 
accommodate small volume blood samples appropriate for children (Plummer, 1987). 
Samples were collected for measurement of whole blood concentration of propofol 
and mixed thoroughly in tubes containing lithium-heparin (LH/5, Sarstedt, 
Numbrecht, West Germany) and stored at +4°C until assayed. Prior stability tests 
showed that propofol in whole blood samples was stable for a period of three months 
(Gin et al, 1990). The average recovery of propofol from whole blood was 91% 
(ranging from 90 - 96%) at 500 ng ml 1 . Propofol in 0.5 ml whole blood samples and 
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internal standard thymol (120 ng), buffered with (1 ml) 0.1M sodium dihydrogen 
phosphate (pH 4.6), were extracted into cyclohexane (5 m1). After 15 minutes mixing, 
the samples were centrifuged at 20°C for 15 minutes at 3000 rpm. The organic layer 
was alkalinised with tetramethylammonium hydroxide (50 [il) and evaporated to 
dryness at 40°C under nitrogen. The residue was redissolved in methanol (100 Ill) and 
the concentrate (20 IA) was analysed by HPLC. The mobile phase consisted of 60% 
(v/v) acetonitrile in distilled water containing 0.3% (v/v) glacial acetic acid, with a 
flow rate set at 0.7 ml min-I . An external standard (whole blood with a known 
concentration of propofol) was used at the beginning and end of each run of 
approximately 30 samples. Each sample run took 15 minutes with the internal 
standard appearing at 3.8 minutes and propofol at 5.1 minutes. 
Calibration graphs were used for each batch and constructed from the mean of 
three trials at seven concentrations of propofol. The calibration graphs were linear 
over the propofol concentration range 10 to 1000 ng with coefficients of variation 
ranging from 0.1 - 12.6%. The between-batch coefficient of variance was 1.7% at 10 
ng m1 1 and 4.1% at 500 ng m1 -1 , with the limit of detection being approximately 10 ng 
(Figure 11.6). Complete methodology data are shown in Appendix E. 
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FIGURE 11.6: Typical chromatogram of propofol in whole blood (sample), external 
standard and blank, 1 = thymol and 2 = propofol. 
Thiopentone assay 
Thiopentone concentration in plasma samples was determined using an HPLC 
technique with a programmable multiwavelength UV detector set at 290 nm and 254 
nm (Waters 490E) based on the technique described by Stanski et al (1983). 
Thiopentone in plasma (0.2 ml) and internal standard methohexitone (20 1.1g) were 
precipitated with 300 IA of acetonitrile. The solution was alowed to mix and stand for 
H METHODS 39 
5 minutes and then centrifuged for 20 minutes at 5000 rpm, and approximately 40 il 
injected into the HPLC system. The mobile phase consisted of 60% (v/v) 10 mM 
phosphate buffer (pH 7.0) and 40% (v/v) acetonitrile, with a flow rate set at 1.8 ml 
min-' (Figure 11.7). 
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FIGURE 11.7: Typical chromatograms of thiopentone in plasma, standard and blank 
(X=290 run) and internal standard methohexitone in plasma, standard 
and blank (X=254 run), 1 = thiopentone and 2 = methohexitone. 
A range of external standards (serum with a known concentrations of 
thiopentone and methohexitone) was measured at the beginning and end of each run 
of 25 samples. Each sample run took 15 minutes with thiopentone appearing at 6.0 
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minutes and the internal standard at 9.0 minutes. The five calibration graphs were 
linear over the range 0.05 to 10 jig m1 -1 with coefficients of variation ranging from 0.2 
to 10.6%. The between batch coefficients of variance for the thiopentone assay were 
9.0% and 6.9% at 0.05 j.ig ml - ' and 5 jig ml- ', respectively, and the limit for detection 
for thiopentone was 0.05 pg m1 4 . Complete methodology data for thiopentone are 
shown in Appendix E. 
Midazolam assay 
Midazolam concentration in plasma samples, obtained during the induction 
agent study, were determined employing an HPLC technique with UV detection set at 
220 nm using a programmable multiwavelength detector (Waters 490E) based on the 
assay technique described by Vletter et al (1990). Midazolam in plasma and internal 
standard flurazepam (200 ng) buffered with sodium dihydrogen phosphate (0.1M) at 
pH 9, were extracted into 5 ml organic solvent mixture (diethyl ether and 
dichloromethane in the ratio 60:40 v/v). The solution was allowed to mix for 15 
minutes and then the samples were centrifuged at 20°C for 15 minutes at 3000 rpm. 
The organic extract was evaporated to dryness under nitrogen and the residue was 
re-dissolved in methanol (80 pi) and approximately 30 1.11 of the methanolic 
concentration was injected into the HPLC system. The mobile phase consisted of 32% 
acetonitrile in 0.04M sodium dihydrogen phosphate buffer (containing 0.1% 
triethylamine) at pH 7.0. The flow rate was set at 1.5 ml min -1 . A range of external 
standards (serum with a known concentration of midazolam) was measured at the 
beginning and end of each run of approximately 30 samples. Each sample run took 40 
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minutes with the internal standard appearing at 20.7 minutes and midazolam at 35.3 
minutes. Four calibration graphs were produced for each batch, which were linear 
over the range 40 to 2000 ng 	 with coefficients of variation ranging from 1.5 to 
11.8%. The between-batch coeficient of variance at 40 ng 	 was 4.8% and 1.5% at 
500 ng 	 with the limit of detection for midazolam was 10 ng m11. Complete 
methodology data for midazolam are shown in Appendix E. 
Midazolam and flumazenil assay 
The midazolam assay for the simultaneous determination of midazolam, 
flumazenil and metabolites and the assay used in the induction study were performed 
at different times and in different laboratories. The folowing is a general description 
of the simultaneous midazolam and flumazenil assay. Blood samples (1.0 ml) were 
colected into tubes containing lithium heparin (LH/5, Sarstedt, Numbrecht, West 
Germany). Urine samples (1.0 ml) from a bulked 24 hour urine colection were placed 
into plain tubes for simultaneous determination of midazolam and flumazenil with 
HPLC and UV detection at 220 nm using a programmable photodiode array detector 
(Waters 994). Plasma was obtained from blood after centrifugation for 15 minutes at 
3000 rpm. Flumazenil and midazolam in plasma or urine sample (0.5 ml) and internal 
standard flurazepam buffered with 0.1M sodium dihydrogen phosphate (pH 9) were 
extracted into 5 ml of organic solvent mixture (diethyl ether and dichloromethane 
60:40 v/v). The organic extract was evaporated to dryness under nitrogen and the 
residue was re-dissolved in methanol 80111 and approximately 301_11 of the methanolic 
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concentration was injected into the HPLC system. The mobile phase consisted of 
32% acetonitrile in sodium dihydrogen phosphate buffer 0.04M (containing 0.1% 
triethylamine) at pH 7.2. The flow rate was set at 1.5 ml min'. A C18 reversed-phase 
cartridge column (Nova-pak, Waters) linked to a C8 pre-column (Nova-pak, Waters) 
was used and the eluate was measured by a UV detector set at 220 nm. An external 
standard (serum with a known concentration of flurazepam, flumazenil, midazolam 
and metabolites) was run at the beginning and end of each run of 20 samples. Each 
sample run took 40 minutes with flumazenil appearing at 4.4 minutes, 
4-hydroxymidazolam at 11.7 minutes, 1-hydroxymidazolam at 14.6 minutes, the 
internal standard flurazepam at 20.7 minutes and midazolam at 35.3 minutes (Figure 
II.8a & II.8b). 
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FIGURE II.8a: Typical chromatograms from the analysis of plasma for flumazenil 
(1), 4-hydroxmidazolam (2), 1-hydroxymidazolam (3), flurazepam 
- internal standard (4) and midazolam (5) 
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FIGURE II.8b: Typical chromatograms from the analysis of urine extract for 
flumazenil (1), 4-hydroxymidazolam (2), 1-hydroxymidazolam (3), 
flurazepam -internal standard (4) and midazolam (5) 
The calibration graphs were linear over the ranges 4 to 200 ng ml-I for 
flumazenil, 20 to 1000 ng ml"' for midazolam and 10 to 500 ng ml-' for both 
1-hydroxymidazolam and 4-hydroxymidazolam. The between-batch coefficients of 
variance for flumazenil 10 ng m1-1, midazolam 50 ng ml-', 1-hydroxymidazolam 25 ng 
ml-' and 4-hydroxymidazolam 25 ng ml-' were 4.8%, 5.6%, 4.3% and 4.0%, 
respectively. The limit for detection for flumazenil was 4 ng ml-' and for midazolam 
and its metabolites, 10 ng ml-'. Urine samples were analysed for unchanged drug and 
metabolites, and for their glucuronides after p-glueuronidase treatment for 18 hours at 
37 °C. The HPLC assay was found to be specific and selective. During development 
of the assay procedure, it was established that flumazenil, its carboxylic and 
demethylated metabolites did not interact with each other under the conditions stated. 
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Pharmacokinetic analysis 
Flumazenil profiles were analysed using the statistical moment theory to 
obtain pharmacokinetic parameters (Gibaldi and Perier, 1982a). Terminal elimination 
half-life (t1/2), areas under plasma concentration-time curves (AUC), and apparent total 
body clearance (Cl) were calculated. Using the trapezoidal rule, the AUCl20 was 
calculated from zero to 120 min; the resident area (t = 120 min to CO) was calculated as 
the ratio, C120: elimination rate constant. Plasma clearance was calculated from : 
Dose  CI — P A U Cc0° (1) 
where Clp is the plasma clearance and AUC: is the area under the plasma 
concentration against time curve. The first order rate constants for the decline of 
plasma concentration after administration were obtained by linear squares regression 
of the logarithm of the plasma concentration against time. The steady state volume of 
distribution was calculated from equation : 
Vs = Clp x MRT 	 (2) 
where V„ is the steady state volume of distribution and MRT is the mean residence 
time. 
Plasma concentration time profiles of midazolam were analysed by the BITRI 
computer program (Chan et al, 1987, Jones et al, 1990a) which utilises the method of 
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residuals, whereby each curve is fitted with experimental data in terms of a 
bi-exponential or tri-exponential function. BITRI chooses the best fit such that the 
logarithms of squared deviation between exponential and computer _values are 
minimised (Boxenbaum et al, 1974). Distribution and elimination half-lives (TA', 
TO, apparent central volume of distribution (V), apparent volume of distribution at 
steady state (V"), apparent volume of distribution in the elimination phase (V'' ) and 
• total body clearance (Cl) were calculated using standard formulae (Gibaldi and 
Perrier, 1982b). 
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STATISTICAL METHODS 
Data sheets for each trial are shown in Appendix H and the raw data for all 
studies are included in Appendices C, D, E, F and G. Data in the text, tables and 
figures are displayed as mean (SD) and [range] and a statistical method of analysis 
was chosen as appropriate to the type of data to be analysed. In general, data were 
analysed according to their scale of measurement and the type of study being carried 
out. Interval scale data compared between two treatment groups of different 
individuals underwent analysis using an unpaired t test; comparison before and after a 
single treatment in the same individuals used a paired t test; if three treatment groups 
consisted of different individuals, an analysis of variance with Newman-Keuls post 
hoc analysis was used and multiple treatments in the same individuals used 
repeated-measures analysis of variance. For significance of association between two 
variables, Pearson product-moment correlation was used when both variables were 
continuous and normally distributed. 
If it was considered that the data did not represent a normal distribution, the 
observations were ranked and statistical methods appropriate for data measured on an 
ordinal scale were employed. Comparison of ordinal scale data between two treatment 
groups consisting of different individuals used the Mann-Whitney U rank-sum test; 
before and after treatment comparison in the same individuals was performed with the 
Wilcoxon signed-rank test; comparison of three treatment groups consisting of 
different individuals used the Kruskal-Wallis analysis of variance and multiple 
treatments in the same individuals used the Friedman statistic. Statistical significance 
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for the degree of association between two variables representing ordinal scale data 
was determined using the Spearman rank correlation. 
Nominal scale data were analysed using chi-square analysis-of-contingency 
table with Yates correction, except for 2x2 tables which were analysed using Fisher's 
exact test. Data considered suitable for parametric testing were age, weight, blood 
pressure, heart rate, respiratory rate, oximetric saturation values, eye opening and self 
identification times, anaesthetic duration, toy completion and WISC-R completion 
times. Data analysed using non-parametric procedures were sex, operative procedure, 
coma scale, sedation score, drug antagonism, incidence of side effects, time within a 
saturation range and desaturation incidence per hour within a saturation range. 
Use of the Finapres 2300e for haemodynamic studies in children required a 
prior clinical comparison of its performance with other methods of blood pressure 
measurement (Jones et al, 1992). The strength of agreement between the noninvasive 
devices and the arterial line, employed a statistical method described by Bland and 
Altman (1983), which analysed the differences between contemporaneous arterial line 
measurements and the blood pressure readings from the Finapres and an oscillometric 
device. 
Statistical analysis was executed on a 33MHz Comtech 486 personal computer 
using the computer interactive statistics programs MinitabTM  ver 7.2 (Minitab Inc., 
State College, Pennsylvania, USA) and CSS:StatisticaTm ver 3.1 (Statsoft Inc., Tulsa, 
Oklahoma, USA). 
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A p value of 0.05 was chosen as the Type I or a error for all studies. The 
methods used are described in full in the manuals accompanying the statistics 
software (Ryan et al, 1985; Minitab reference manual, 1989; CSS:Statistica Vol I-III, 
1991) and for general statistical guidance Glantz (1989) and Swinscow (1983) were 
used. 
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EFFECT OF PREMEDICATION ON OXYGEN SATURATION 
The pulse oximeter has become a vital instrument in the detection of 
perioperative hypoxaemia (Severinghaus and Kelleher, 1992). Previous studies of the 
effect of premedication on arterial oxygenation using intermittent blood gas sampling 
have reported conflicting results (Jones et al, 1990; Pierce and Carofalo, 1965; 
Kopman and Ramirez-Inawat, 1980) and few workers have employed continuous 
pulse oximetry to examine the preoperative period (de Santos et al, 1991; Roelofse 
and de-V-Joubert, 1990). Continuous oximetric data acquisition should overcome the 
limitations of intermittent data sampling and permit a more accurate comparison of 
the effect on blood oxygenation of premedicant drug regimens. However, to ensure 
accurate inferences are drawn from the saturation data, retrospective evaluation of 
perioperative desaturation data, employing the computer programme Satmaster Tm 
(Einstein et al, 1992), is necessary (Jones et al 1992). 
To be an effective oral premedicant, midazolam has to be given in a relatively 
large dose per body weight to children because of the first-pass effect through the 
liver (Feld et al, 1990). Intramuscular pethidine and atropine has been used as a 
standard premedication in children for many years because it supposedly causes less 
respiratory depression than morphine (Feychting, 1985). The aim of this study was to 
compare the effect of these two premedication regimens on arterial oxygen saturation 
in the post premedication period and the influence, if any, of premedication on the 
episodic desaturation incidence during the first postoperative 8 hour period, 
employing evaluated, continuous pulse oximetry in children undergoing minor 
surgery. 
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MATERIALS AND METHODS 
Twenty ASA grade I, Chinese children aged 1-8 years undergoing elective 
orthopaedic or a minor general surgical procedure were investigated. Subjects were 
selected according to the criteria set out in the chapter II. In this particular study 
children were excluded if the predicted operation time was less than half or greater 
than two hours. 
Oximetry data were recorded continuously during four time periods: whilst 
asleep, on the night before surgery; the period after the premedicant was administered 
and before transfer to the operating suite; postoperatively in the recovery room; and 
for a further 8 hours after the child had returned to the general ward (Figure III.!). 
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Period 1 2 3 4 
Fi02 0.21 0.21 0.28 - 0.35 0.21 
8 hours 
„  	
1 - 2 hours 
„  	
20 minutes 
during sleep on the 	 ost premedicatio 	 recovery room 1  1 	 gene8rhal ward 	 I
preoperative night 	 in general ward 	 in operating suite t 	 1 	 T 	 t 	 1 commence 	 return to premedication 	 transfer to Sp02 recording 	 general ward administration 	 operating suite 
FIGURE 111.1: Periods of data colection showing approximate duration of saturation data acquisition, concurrent Fi3O2 administered and 
patient location 
stop Sp02 
recording 
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A Nellcor D-20/250 OxisensorTM  probe was attached to the great toe of each 
child and the same Nellcor N-200E oximeter was connected to each patient 
throughout the study. Proper function of the oximeter was checked by activating the 
oximeter's 'self-check' routine and prior attachment of the instrument to one of the 
investigators. The serial communication port of the oximeter was connected to an 
Amstrad 386DX laptop computer. Oximetry, pulse rate and signal amplitude data 
were sampled 60 times a minute and displayed by SatmasterTM  (EMG Scientific) on 
the computer screen. On completion of the study the data were downloaded to disk for 
subsequent analysis. Satmaster was programmed to invalidate zero signal strength 
data occurring with probe disconnection. Each oximetry profile was examined by one 
of the investigators and artefactual desaturation episodes attributed to probe 
movement were discarded before compilation of the data (Jones et al, 1992). An acute 
desaturation episode for the purpose of this study was defined as a decrease in oxygen 
saturation of more than 2% to less than 95% for more than 15 sec duration. 
Patients were randomly allocated to receive either pethidine 1 mg kg - ' and 
atropine 0.02 mg kg - ' intramuscularly one and a half hour before surgery (n=10), or 
midazolam 0.5 mg kg-1 and atropine 0.02 mg kg 1 orally, two hours before surgery 
(n=10). EMLA emulsion cream 2 g (lignocaine 25 mg g - ' and prilocaine 25 mg g - ') 
was also applied to the dorsum of the hand with premedication administration to 
facilitate painless i.v. cannula insertion in the operating suite. In the operating suite a 
standard anaesthetic technique was administered to both groups of patients. Induction 
was with fentanyl 1 lig kg -1 and propofol 2 mg kg - ', the patient was paralysed with 
atracurium 0.5 mg kg -I , the trachea intubated and the lungs ventilated to normocapnia. 
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A subjective assessment of tonsillar size and a graded view of glottal exposure were 
noted during direct laryngoscopy (Cormack and Lehane, 1984). Thereafter anaesthesia 
was maintained with 67% nitrous oxide and 1.0-1.5% isoflurane in oxygen, with 
additional increments of fentanyl 1 j.tg kg -I hr-1 and atracurium 0.2 mg kg - ' every 30 
min, administered as required. At the completion of surgery neuromuscular blockade 
was antagonised with neostigmine 0.05 mg kg"' and atropine 0.04 mg kg - ', extubated 
'awake' observing the usual clinical criteria for adequate neuromuscular function 
(Viby Mogensen, 1982), transferred to the recovery room and given oxygen (F 102 
0.28-35) via a Hudson mask until discharge to the ward, thereafter breathing air. 
Statistical significance (p < 0.05) was determined for age, weight and 
anaesthetic time data by unpaired t-test; sex and operative procedure data by the 
Fisher exact probability test, comparison of oxygen saturation data between treatment 
groups were analysed by the Mann-Whitney rank-sum test and the Wilcoxon 
signed-rank test was employed for before and after premedication comparison of data 
in the same patient. 
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RESULTS 
Both groups were comparable for age, weight, sex, anaesthetic time, operative 
procedure and no child had a history of previous respiratory disease (Table II.!). At 
direct laryngoscopy al children were found to be Cormack and Lehane grade 1 
(Cormack and Lehane, 1984) and no child had tonsilar tissue projecting beyond the 
palatopharyngeal and palatoglossal arches into the oropharynx. 
TABLE HU Demographic data. Interval scale data are mean (SD) and were 
analysed using the unpaired t test. Nominal scale data were 
analysed using the Fisher exact probability test. 
Patient data Pethidine group 
(n =10) 
Midazolam group 
(n = 10) 
p value 
Age (yr) 3.8 (1.8) 4.6 (2.6) 0.44 
Weight (kg) 16.3 (5.7) 16.3 (2.3) 1 
Anaesthetic time (min) 63.5 (39.9) 58.0 (21.4) 0.71 
Sex (male) 9 6 0.15 
Operative procedure: 
orthopaedic 4 6 	 - 
general surgical 6 4 0.32 
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A total of 335 hours of oximetric data was collected from 20 children. The 
total raw data time recorded with a - saturation less than 95% in all children was 951.5 
min, which after evaluation with the template, resulted in a total of 228 minutes of 
valid desaturation time during the four study periods (p<0.001). The raw desaturation 
time in the period after premedication before operation was 132.5 min which after 
evaluation resulted in 33.5 min of valid desaturation time (p< 0.03). There was no 
difference in mean oxygen saturation between the two groups during the four periods 
under investigation, nor the mean percentage of time the oxygen saturation was less 
than 95% (Table 111.2). 
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TABLE 111.2 Saturation data during the four study periods. Data are mean (SD) 
Data Duration of data collection Mean SpO, (%) P Mean percentage of time 
P 
value 
collection period value with an (Mann 
period per patient (hr) (t-test) SO2 < 95% Whitney 
U-test) 
Groups Pethidine Midazolam Pethidine Midazolam Pethidine Midazolam 
Preoperative 
night 
11.04 (1.22) 9.63 (0.84) 98.9 (0.57) 98.7 (0.67) 0.48 0.2 (0.63) 1.1 (1.85) 0.08 
After 
premedication 
1.29 (0.34) 1.80 (0.31) 98.6 (0.84) 98.7 (0.94) 0.81 1.6 (2.90) 2.8 (5.00) 0.49 
Recovery 
area 
0.26 (0.13) 0.35 (0.19) 99.4 (0.70) 99.1 (1.20) 0.50 0.6 (1.30) 5.7 (12.10) 0.35 
General 
ward 
7.05 (1.05) 6.52 (1.96) 98.5 (0.70) 98.4 (0.84) 0.78 0.8 (1.30) 1.1 (1.40) 0.60 
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Within group comparison of the percentage of time recorded with an oxygen 
saturation < 95% during the preoperative night and during the period after 
premedication, prior to transfer to the operating suite, revealed no significant 
difference (Table 111.3). 
TABLE 111.3 A comparison of saturation data before and after premedication. Data 
are mean (SD). 
Groups Pethidine group 
n = 10 
Midazolam group 
n = 10 
Data collection 
periods 
Mean % of 
time with an 
S02< 95% 
Desaturation 
episodes hr"' 
with an 
S02< 95% 
for> 15 sec 
Mean % of 
time with an 
Sp02< 95% 
Desaturation 
episodes hr"' 
with an 
Sp02< 95% 
for > 15 sec 
Preoperative 
night 
After 
premedication 
p value 
(Wilcoxon) 
0.2 (0.63) 
1.6 (2.90) 
0.11 
0.36 (0.62) 
1.48 (2.60) 
0.37 
1.1 (1.85) 
2.8 (5.00) 
0.34 
0.65 (0.73) 
1.82 (3.47) 
0.51 
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Furthermore, a between group comparison in the post premedication period of 
the incidence of desaturation episodes per hour below 95% and of greater than 15 
seconds duration, revealed no significant difference (p=0.8), nor was the patient's 
post-premedication incidence of desaturation episodes significantly different from the 
preoperative incidence (Table 111.3). Twenty four (65%) of the 37 valid post 
premedication desaturation episodes occurred 45 to 105 minutes after premedication 
administration. 
Following premedication, only two patients (one from each group) recorded 5 
or more desaturation episodes per hour with an S,0 2 < 95% and >15 sec duration, 
and a genuine desaturation less than 80% for longer than 15 seconds was not recorded 
in any patients, at any time during the study. The minimum SO 2 recorded after 
premedication in either group was 85% and the longest duration of a particular 
episode was 75 seconds to a lowest saturation of 91%. 
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DISCUSSION 
This study demonstrates that in otherwise healthy children, the use of two 
common premedication regimens employing either pethidine or midazolam, does not 
significantly depress oxygen saturation. These findings are at variance with previous 
studies in healthy children, one of which showed that both intramuscular and 
intranasal midazolam (0.2 mg kg- ') caused a significant decrease in arterial oxygen 
saturation from baseline values (de Santos et al, 1991). However Rose and colleagues, 
using intranasal midazolam demonstrated no change in oxygen saturation levels 15 
minutes after administration (Rose et al, 1990). In another study, premedication with 
rectal midazolam (0.35-0.45 mg kg - ') lowered oxygen saturation thirty minutes after 
administration when compared with a placebo (Roelofse and de-V-Joubert, 1990). 
These apparently conflicting results can be explained by our ability to exclude 
movement-induced artefactual desaturation data before determining the incidence of 
genuine desaturation episodes (Langton and Hanning, 1990). Patient movement 
resulted in an overestimation of desaturation time by 75% in this study, confirming 
similar findings in patients following spinal surgery (Jones et al, 1992). Oxygen 
desaturation which induces a motor response will not result in rejection by application 
of the template because the desaturation pattern will not be preceded by a concomitant 
change in signal amplitude. However genuine oxygen desaturation and probe 
movement could occur together and these data would be rejected by the template. The 
route of administration of midazolam in children significantly alters bioavailability 
and the time to peak serum concentration, making comparison with other studies 
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difficult. Bioequivalence should be present between a 0.2 mg kg"' intramuscular and 
0.5 mg kg"' oral dose of midazolam (Payne et al, 1989). Atropine was administered 
intramuscularly to the pethidine group and orally to the midazolam group. A 
differential effect on anatomical dead space resulting from different atropine 
concentration profiles is a possibility (Olsson et al, 1983), however anatomical dead 
space reportedly increased by only 12% following intravenous atropine in adults 
(Nunn et al, 1964) and therefore it is unlikely that the different route of administration 
of atropine significantly influenced oxygen saturation in this study. Peak serum 
concentration of midazolam occurs 15 minutes after intramuscular and nasal 
administration, and 45 to 120 minutes after oral administration. Peak serum 
concentrations should coincide with the onset of sedation and any decrease in arterial 
oxygen saturation should be most obvious at this time (de Santos et al, 1991). Other 
investigators have demonstrated that slow intravenous administration of midazolam to 
healthy volunteers provides no independent protection from respiratory depression, 
and respiratory complications are more closely related to the total dose of midazolam 
(Alexander et al, 1992, Dahan and Ward, 1991). The peak incidence of the recorded 
minor desaturation episodes in our study occurred 45 to 105 minutes after 
administration of both pethidine and midazolam. It is possible that our premedication 
regimen was not as sedative as those used in the Spanish study and did not depress 
respiration to the same degree, therefore resulting in a lower incidence of recorded 
desaturation episodes. Also, this study population may not match those in the other 
series, but a pharmacokinetic explanation of our oximetry findings is difficult to 
establish. The small lean body mass of Chinese children should result in a smaller 
central volume of distribution, higher peak serum concentration of midazolam, a more 
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intense level of sedation of shorter duration, and consequently a higher incidence of 
episodic desaturation (Greenblatt et al, 1984). This was not the case, and in separate 
work, it was shown that the serum concentration of midazolam 2 hours after oral 
administration in Chinese children was similar to the serum concentration reported by 
other workers using a similar dosing regimen in Caucasian children (Jones et al, 
1993). Furthermore, none of the children in this study had any predisposition to upper 
airway obstruction or arterial oxygen desaturation and all were ASA class I. There are 
no published desaturation studies following pethidine premedication but a low 
clinically relevant incidence would be expected because the drug has been used for 
many years and significant data would have been previously reported. Peak 
respiratory depression in adults is observed within an hour of receiving intramuscular 
pethidine and there is a return towards baseline values commencing at about 2 hours 
(Edwards et al, 1982). Pethidine premedication did not depress ventilation in the 
children in this study to a degree where significant arterial oxygen desaturation 
occurred, nor to a level that was clinically or statistically significantly different from 
each child's own sleep S,02 . 
This study showed that neither oral midazolam 0.5 mg kg', nor intramuscular 
pethidine 1.0 mg kg - ' given as premedicants, significantly depressed S,0 2 in otherwise 
healthy children presenting for minor surgical procedures. These findings have 
recently been endorsed by the work of Tyler and colleagues (Tyler et al, 1995). 
• Furthermore, raw oximetry data requires careful evaluation and elimination of 
movement artefact before conclusions regarding the incidence of desaturation can be 
drawn. If analgesia is not a premedication requirement, then oral midazolam confers 
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the advantage over pethidine of avoiding the pain of an intramuscular injection, 
without compromising oxygen saturation. 
Having established that midazolam 0.5 mg kg is an effective premedication 
regimen in children and that no dangerous effects were detected during the study, the 
next chapter investigates its sedative and anxiolytic properties. The association 
between these effects and serum midazolam concentrations was also determined. 
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Et ECT OF MIDAZOLAM PREMEDICATION 
ON PREOPERATIVE 
PSYCHOMOTOR PERFORMANCE, MOOD AND SEDATION 
Anaesthesia for paediatric ambulatory surgery aims to rapidly return the child 
to a "home-readiness" state and agents with suitable pharmacokinetics are now 
applied in the outpatient setting (White, 1986). Pharmacological attenuation of the 
normal response to fear presents a child who is co-operative and calm when separated 
from his parents and during induction of anaesthesia, and this controlled behaviour 
also helps allay parental anxiety immediately prior to surgery (Westhorpe, 1990). 
Circumcision is a suitable surgical procedure for paediatric ambulatory surgery 
because of the reduction in displacement anxiety for the child, decreased exposure to 
nosocomial infection, short operative duration, low incidence of complications, and 
the ease and reliability of providing effective postoperative pain relief (Hannallah and 
Epstein, 1991). Oral, sweetened midazolam is considered a suitable agent for inducing 
anxiolysis but some anaesthetists hold the view that preoperative midazolam 
administration delays recovery and that proper psychological preparation makes 
premedicant drug administration to a child unnecessary (White, 1985). 
The aim of this study was to evaluate the premedicant effect of midazolam on 
sedation, mood and psychomotor performance in children undergoing circumcision. 
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MATERIALS AND METHODS 
Thirty ASA grade I Chinese children, aged 4-12 yr, undergoing circumcision 
for treatment of phimosis were investigated. Children were excluded from the study if 
there was a history of asthma or allergies; previous adverse anaesthetic experience; 
halothane anaesthesia within the previous 1 month; hepatic, renal, respiratory, cardiac 
or haematological disease; developmental disability or age less than 4 yr. The day 
prior to surgery, each child was familiarised with a post-box toy and the completion 
time of his best seven attempts recorded. The children also underwent a Wechsler 
intelligence scale (WISC-R) coding performance assessment, matched for race 
(HK-WISC Manual, 1981). These assessments were performed by the same 
investigator at all assessment times, for all patients in the study. 
On the day of surgery, EMLA emulsion cream 2 g (lignocaine 25 mg g -1 and 
prilocaine 25 mg g - ') was applied to the cubital fossa of the non-dominant arm 2 hr 
before premedication with midazolam 0.5 mg kg-1 (maximum dose 15 mg) and 
atropine 0.02 mg kg1 by mouth. On administration of the premedicant, a 23-gauge 
cannula was inserted into a vein underlying the EMLA-pretreated area. Blood samples 
(1.0 ml) were collected into tubes containing lithium-heparin (Sarstedt LH/5) for 
measurement of the plasma concentration of midazolam at 30, 60, 90 and 120 min 
after oral premedication administration. At each of the blood collection times the child 
was offered the post-box toy and his fastest completion time at a single attempt 
recorded. The child was also asked to complete the WISC-R coding test within 2 min 
and scored according to his performance. The raw WISC-R data was then scaled to 
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produce score equivalents adjusted for the child's age. The child's best, preoperative, 
unmedicated performance was divided by the child's postmedication performance at 
each assessment point for both the PBT and WISC-R, and the data expressed as the 
post box toy completion ratio (PBTR) and WISC-R scale ratio. 
The child's co-operation and mood level were recorded using a structured 
observation score (Krane et al, 1987)(Table 111.4). 
TABLE 111.4: Structured observation score (modified from Krane et al, 1987) 
MOOD 	 Score 
laughing, euphoric 	 1 
happy, playful 	 2 
calm, drowsy, sleepy 	 3 
iritable but calmed by mother 	 4 
screaming, inconsolable 	 5 
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Level of sedation was assessed using the modified Steward coma scale 
(Robertson et al, 1977)(Table 111.5). 
TABLE 111.5: Modified Steward coma scale (Robertson et al, 1977) 
Airway Consciousness Activity 
opening mouth or coughing on 
command 
3 fuly awake, eyes open, 
conversing 
4 raising 	 one 	arm 	on 
command 
2 
no 	voluntary 	cough, 	clear 
airway without support 
2 lightly 	 asleep, 	 eyes 
opening intermitently 
3 non-purposeful 
movement 
1 
obstruction 	on 	neck 	flexion, 
airway clear without support on 
1 eyes open on command 
or in response to name 
2 not moving 0 
extension 
airway 	 obstructed 	 without 
support 
0 responding 	 to 	 ear 
pinching 
1 
not responding 0 
Add scores for Airway, Consciousness and Activity: 	 TOTAL SCORE: 
On arrival in the operating suite, al children were assessed by the same 
anaesthetist as agitated or crying, aware and apparently anxiety free, drowsy, or asleep 
but responsive to command (Jones et al, 1990). The awake children were then asked if 
they felt frightened and if so, to specify the cause of their anxiety. 
Plasma samples were obtained from blood after centrifugation for 15 min at 
3000 r.p.m. and stored at -20°C before assay for midazolam employing an HPLC 
technique with UV detection at 220 nm using a programmable multiwavelength 
detector (Waters 490E). Midazolam in plasma and internal standard flurazepam 
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buffered with sodium dihydrogen phosphate (0.1M) at pH 9, were extracted into 5 ml 
organic solvent mixture (diethyl ether and dichloromethane in the ratio 60:40 v/v). 
The organic extract was evaporated to dryness under nitrogen and the residue was 
re-dissolved in methanol (80 p.1) and approximately 30 pl of the methanolic 
concentration was injected into the HPLC system. The mobile phase consisted of 32% 
acetonitrile in 0.04 M sodium dihydrogen phosphate buffer (containing 0.1% 
triethylamine) at pH 7.0. The flow rate was set at 1.5 ml min - '. A C 18 reverse phase 
cartridge column (Nova-pak, Waters) linked to a C 18 pre-column was used and the 
eluate was measured by a UV detector set at 220 nm. The calibration graphs were 
linear over the range 40 to 2000 ng ml -I with coefficients of variation ranging from 1.5 
to 11.8%. The between-batch coefficient of variance at 40 ng ml-I was 4.8% and 1.5% 
at 500 ng ml - '. The limit for detection for midazolam was 10 ng ml - '. The HPLC assay 
was found to be specific and selective. 
Correlation between the post box toy and WISC-R raw data was determined 
using Pearson product-moment correlation. To test any association between serum 
midazolam concentrations and the psychomotor performance ratios, Spearman rank 
correlation was employed using the computer interactive statistical program 
C SS : 
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RESULTS 
The 30 children had a mean age of 7.1(2.3)[4-12] yr and a mean body weight 
of 20.6(8.7)[15-37] kg. On arrival in the operating suite only one child was asleep and 
no child was crying or appeared distressed. On specific questioning, 20 children 
endorsed their objective appearance, stating that they were not frightened. The 
remaining children were frightened of either pain and needles, going to sleep and 
dying, strangers, or being separated from their mother Table 111.6. 
TABLE 111.6 Preoperative mood following oral midazolam (0.5 mg kg- `) 
premedication (n = 30). 
Objective preoperative 
premedication assessment (n) 
Subjective preoperative 
premedication assessment (n) 
asleep/drowsy 1 not frightened 20 
awake 29 pain/needles 10 
crying 0 dying/sleeping 9 
leaving mummy 
strangers 
5 
The mean fastest preoperative post box toy completion time for the 30 
children was 18.1(5.9)[11-37] sec and the mean highest preoperative WISC-R scale 
performance was 17.1(2.4)[11-19]. The preoperative PBTR and WISC-R ratio at 
different times after premedication are shown in Table 111.7. The relationship between 
Time after 
premedication (min) 
WISC-R ratio PBTR 
0.67(0.18)[0.30-0.97] 
0.69(0.16)[0.36-0.94] 
0.74(0.16)[0.43-1.10] 
0.75(0.15)[0.48-1.10] 
0.84(0.23)[0.33-1.17] 
0.79(0.2 1)[0.21-1.06] 
0.88(0.20)[0.38-1.20] 
0.91(0.25)[0.16-1.55] 
30 
60 
90 
120 
III PREMEDICATION 70 
midazolam concentrations, PBTR and WISC-R scale ratio are shown in Figure 111.2. 
Raw preoperative serum midazolam concentration data for the 30 children are 
tabulated in Appendix G. 
TABLE 111.7 Preoperative PBTR and WISC-R ratio at different times after 
premedication. Data are mean (SD) [range  
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time (min) 
FIGURE 111.2 Preoperative serum midazolam concentration, post box toy ratio 
(PBTR) and WISC-R scale ratio (n = 30). 
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There was a significant decline from preoperative unmedicated, fastest performance 
for both PBT and WISC-R, 30 minutes after midazolam administration (p <0.001, 
0.003 respectively), however there was improvement over the folowing 90 min with 
WISC-R performance almost returning to unpremedicated levels. Midazolam 
concentrations peaked to 72.2(18.7) ng m11 at the 60 minute sample point and 
declined to a mean preoperative level of 35.7(7.9) ng ml-' at 2 hr. Ploting the log of 
the PBTR and the WISC-R scale ratio data for al the preoperative assessments 
demonstrated poor correlation (r=0.3) (Figure 111.3). Correlation between serum 
midazolam concentration and the WISC-R assessment was also poor (r = 0.01) and 
with PBTR, only slightly beter (r = 0.2) (Figure 111.4 & .5). 
0.4 
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FIGURE 111.3 Preoperative logarithmic data plot of WISC-R scale ratio and PBT 
ratio (n = 30). Doted lines represent 95% confidence intervals. 
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FIGURE 111.4 Preoperative logarithmic data plot of serum midazolam 
concentration (ng ml-') and WISC-R scale ratio (n = 30). Doted 
lines represent 95% confidence intervals. 
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Only one child refused assessment on two occasions when presented with the 
psychomotor tests after premedication. The two youngest children in the study were 
classified as irritable on a further 3 occasions but were calmed by mother and 
performed the assessment. Al other children were either happy and playful or sleepy. 
Nine children went to sleep folowing administration of midazolam with the 
incidence being evenly distributed throughout the two hour study period (Table 111.8). 
TABLE 111.8 	 Sedative effect and mood of the children at the times of assessment 
folowing midazolam premedication, 
Incidence of 
Time after midazolam children asleep unhappy children PBT refusal happy / playful 
premedication (min) , (n =9) (n = 2) (n = 1) (n = 28) 
30 2 1 28 
60 4 0 1 29 
90 4 1 0 28 
120 4 2 0 28 
n = the total number of children asleep, unhappy or unco-operative, 
happy and co-operative. 
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DISCUSSION 
The aim oral premedication is to obtain a co-operative patient prior to 
induction of anaesthesia who will accept the face mask or insertion of a venous 
cannula 'without distress. The place of midazolam 0.5 mg kg -1 as an oral premedicant 
in children appears now to be established as effective (McMillan et al, 1992) and the 
results of this study endorse this view. The incidence of sleep at each preoperative 
assessment point was equally distributed over the two hour period and appeared 
unrelated to serum midazolam levels. Midazolam is extensively bound to plasma 
proteins (94-98%) and small changes in binding may cause large alterations in clinical 
response (Amrein et a1,1988). There are no published data describing the variation 
between children in midazolam binding, and although the unbound fraction of 
midazolam may show a correlation with sedation. Sleep incidence data in this study 
may have been confounded by other factors, such as, the age of the child, the time of 
day when surgery was conducted and the position of the child on the operating list. 
Furthermore, the relatively frequent psychomotor assessments and blood sampling 
combined to produce a relatively stressful preoperative environment for the child 
which was not conducive to sleep. Weldon and colleagues found the sedative effect of 
midazolam to be maximal 30 min after oral administration (Weldon et al, 1992). 
Although most of the children in this study were not asleep at the 30 min sample 
point, 56% of them scored their poorest psychomotor performance at this time. 
Patient co-operation lowers anxiety levels during induction of anaesthesia and 
this improves performance of the staff delivering care. The pre-induction serum 
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midazolam levels in this study were in the adult anxiolytic range of 20-50 pig ml - ' 
(Lauven and Kulka, 1990; Nilsson, 1991). All children arrived in the operating room 
appearing quiet and calm and specific fears were difficult to elicit. Even with explicit 
questioning of the older children, 66% denied feeling frightened. The mean 
preinduction midazolam concentration was 35.7 lig ml"' and children who expressed 
their fears did not demonstrate low serum midazolam concentrations. Younger 
children who admitted fear demonstrated a non-specific anxiety, usually responding in 
the affirmative to all questions. Weldon and colleagues showed that 95% of the 
children separated from their parents within 45 min of premedication had satisfactory 
separation scores, compared to only 66% of those separated after 45 min (Weldon et 
al, 1992). Parnis and colleagues found that patients who received midazolam 0.5 mg 
kg-1 were more likely to be asleep or awake and calm than those receiving a placebo, 
diazepam or midazolam 0.25 mg kg- ' (Parnis et al, 1992). Fifty two subjects 
investigated in studies described in Chapter IV were also premedicated with 
midazolam 0.5 mg kg - ' and atropine administered orally 2 hr preoperatively and were 
assessed preinduction. Ninety percent were awake and apparently anxiety free, two 
patients were asleep and three children were visibly distressed when presenting for 
induction of anaesthesia. Vetter compared children receiving midazolam, diazepam or 
placebo and concluded that even without premedication, a majority of the children did 
not react negatively to an impending anaesthetic (Vetter, 1993). However Vetter 
found midazolam to be superior to the placebo in facilitating the initial acceptance of 
the anaesthetic induction mask. The results of our premedication assessments are 
more in line with the findings of McMillan and colleagues (McMillan et al, 1992) 
than those of Feld et al (Feld et al, 1990) who reported a relatively low incidence of 
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"excellent" anxiolysis following midazolam premedication. There are many 
differences between each of the studies referred to. The age range of the patients, 
differing times of evaluation and crude method of mood assessment, all limit the 
usefulness of "separation anxiety" comparisons (Hindmarch and Bhatti, 1987). Coma 
score was recorded but computed data provided no relevant clinical information, as 
even children who fell asleep were easily awakened. 
This study confirms the work of Payne and co-workers who measured peak 
serum concentrations at 60 minutes following oral administration of midazolam 0.5 
mg kg -1 (Payne et al, 1989). The mean peak midazolam concentration measured 
during this study at 60 min was 72.2 tg ml - ', which falls within the sedative range and 
well below hypnotic levels. The occurrence of sleep at 60 min was randomly observed 
and no relationship between serum midazolam concentrations and sleep incidence was 
demonstrated. Furthermore, peak serum levels did not correlate closely with the 
maximum decline in psychomotor performance, which occurred 30 minutes after drug 
administration in this study. The early maximum decline in performance may have 
been due to lack of practice rather than drug effect; the latter being masked by 
subsequent performance improvement despite the increasing serum midazolam 
concentration. The degree of performance impairment was the same for both tests but 
correlation between the WISC-R and PBTR data was weak. This may be explained by 
the relative weighting of the cognitive and physical components of each test (Sanders, 
1991). The WISC-R required sophisticated matching of symbols and shapes but was 
not physically demanding, requiring only legible writing in a designated space. The 
PBT required recognition of simple shapes but placement in the matching holes 
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required small muscle control and co-ordination. An observed postoperative 
improvement in correlation between the WISC-R and PBTR may be attributed to a 
reduction in effect of this cognitive and physical difference, due to the residual 
influence of general anaesthesia. Although the PBTR lacks discriminant efficiency, 
better methods of assessment such as critical flicker fusion threshold or choice 
reaction time, are very difficult to assess in children (Hindmarch and Bhatti, 1987). 
Most studies in children have simply used clinical parameters such as awakening or 
eye opening, to assess recovery (Weldon et al, 1992). However, children seem to 
enjoy post box toy completion assessment and the test is relatively easy to perform, 
and as such provides a useful assessment of "street-readiness" for discharge and a 
measurement of the gross effect of premedication on psychomotor performance. 
This study suggests that the optimal timing for oral administration of the 
premedicant midazolam 0.5 mg kg- ' is one hour prior to tranfer to the operating room 
so that serum drug concentrations will be maximal and anxiolytic at the time of 
induction. However, maximal serum drug concentrations and desired effect do not 
always correlate. The lowest post box toy performance occurred at 30 minutes, 
endorsing the parental separation and face mask acceptance data of Weldon and 
colleagues, who recommend timing of premedication 30 to 60 minutes prior to 
induction of anaesthesia (Weldon et al, 1992). The sedative and anxiolytic effects of 
the drug help to provide a quiet environment for a smooth induction of anaesthesia, 
particularly on those occasions when it is impossible to avoid parental separation. 
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PHARMACOKINETICS OF 
1VHDAZOLAM AND FLUMAZENIL 
The previous chapters have endorsed the findings of other workers and 
demonstrated that midazolam is a suitable premedicant for use in paediatric patients 
(Tolia et al, 1991; Feld et al, 1990). Flumazenil has been shown to provide rapid, 
effective and safe antagonism of the hypnotic effects of midazolam (Sanders et al, 
1991). The disposition of midazolam in children has been studied by a number of 
workers (Salonen et al, 1987; Payne et al, 1989; Rey et al, 1991) but the 
contemporaneous disposition of flumazenil in children has not previously been 
reported. 
This present study was undertaken to measure simultaneous midazolam and 
flumazenil pharmacokinetics and their relationship to psychomotor performance in 
children in the early postoperative period. 
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MATERIALS AND METHODS 
Twelve ASA grade I Chinese children, aged 5-9 yr, undergoing circumcision 
for the treatment of phimosis were studied. Children were excluded from the study if 
there was a history of asthma or allergies; previous adverse anaesthetic experience; 
anaesthesia within the previous month; hepatic, renal, respiratory, cardiac or 
haematological disease; developmental disability or age less than 4 years. 
The day prior to surgery, each child was familiarised with a post-box toy and 
the completion time of his best performance on seven attempts recorded. On the day 
of surgery, the patient was premedicated with midazolam 0.5 mg kg-1 (maximum dose 
15 mg) and atropine 0.02 mg kg -1 by mouth 2 h before operation. EMLA emulsion 
cream 2 g (lignocaine 25 mg g- ' and prilocaine 25 mg g- ' ) was applied to the dorsum 
of the hand and the contralateral cubital fossa. On arrival in the operating suite, all 
children were assessed by the same anaesthetist and recorded as agitated or crying, 
aware and apparently anxiety free, drowsy, or asleep but responsive to command 
(Jones et al, 1990). A 23-gauge cannula was inserted into a vein underlying each 
EMLA-pretreated area. Anaesthesia was induced with alfentanil 5 IA kg - ' i.v. followed 
60 sec later by midazolam 0.5 mg kg- ' administered over 30 seconds (Salonen et al, 
1987). Time zero was taken at completion of the midazolam injection. The child was 
given atracurium 0.5 mg kg- ', intubated and thereafter, anaesthesia was maintained 
with 67% nitrous oxide and 0.5% isoflurane in oxygen via a Marileson F breathing 
system with hand ventilation to an end-tidal carbon dioxide tension of 5 kPa. A caudal 
injection of 0.25% bupivacaine 0.5 ml kg - ' was administered to all patients. Routine 
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monitoring devices included an electrocardiograph, non-invasive arterial pressure 
recorder, pulse oximeter, capnograph and inspired oxygen concentration (Datex, 
Cardiocap). At the end of surgery, muscle relaxation was reversed with neostigmine 
and atropine, the patient extubated and ventilation assisted with 100% oxygen by 
mask and Mapleson F circuit until spontaneous respiration had resumed. Six minutes 
after the administration of neostigmine, a 10 jig kg- ' flumazenil bolus was given 
followed 60 seconds later by commencement of a 5 pg kg - ' min' flumazenil infusion 
which was continued until the child could positively identify himself. 
The duration of anaesthesia and cardio-respiratory data during surgery and 
recovery were recorded. The dose of flumazenil injected, the time from flumazenil 
bolus injection to spontaneous eye opening and the time until the patient could 
identify himself were recorded. The child's mood on awakening was assessed by an 
independent observer using a structured observation score (Krane et al, 1987) and 
systolic arterial pressure, heart rate, ventilatory frequency and modified Steward coma 
scale (Robertson et al, 1977) were recorded at each blood sampling time after 
awakening. Any side effects occurring during and following flumazenil administration 
were noted and the time at which any child went back to sleep after eye-opening in 
recovery. Immediately when the patient became co-operative he was encouraged to 
complete the post-box toy in the quickest possible time. The child was offered the toy 
at 10, 30, 60, 120, 180 and 240 min after flumazenil administration and his fastest 
completion time on a single attempt recorded by the same investigator. At each 
assessment, a post-box toy completion-time ratio (the postoperative post-box toy 
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completion time / the child's best timed performance on the day prior to surgery) was 
calculated. 
Blood samples (1.0 ml) were collected into tubes containing lithium heparin 
for measurement of the plasma concentration of midazolam immediately prior to 
induction of anaesthesia and then at 2, 4, 6, 8, 10, 15, 20, 30 min and immediately 
before flumazenil was given. Subsequent samples were then taken at 2, 4, 6, 8, 10, 
15, 20, 30, 60, 120, 180, and 240 min after flumazenil administration. 
Post-operatively a bulked, 24 h urine specimen was collected from each of the 
patients. Plasma was obtained from blood after centrifugation for 15 min at 3000 
r.p.m.. Plasma samples were then stored at -20°C before assay. Flumazenil and 
midazolam in plasma and urine samples were determined simultaneously using a high 
performance liquid chromatographic (HPLC) technique with UV detection at 220 nm 
using a programmable photodiode array detector (Waters 994) as described in the 
Chapter II. Flumazenil profiles were analysed using the statistical moment theory to 
obtain pharmacokinetic parameters as described in the methods section of this thesis 
(Gibaldi and Perrier, 1982). 
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RESULTS 
On arrival in the operating suite all children were assessed as awake and 
appearing calm, but on specific questioning two of the children were frightened of 
intravenous cannula placement for induction and two children expressed fear of 
postoperative pain. The mean (SD) [range] maximum increase in pulse rate and 
systolic pressure calculated during the induction period were 22.3 (24.4)[-28 to 54] 
beats min - ' and 27.3 (28.3) [108 - 2] mm Hg respectively. The induction of 
anaesthesia was otherwise devoid of side effects. The awakening and 
cardio-respiratory data associated with flumazenil administration are given in Table 
IV.!. All patients opened their eyes within 5 min of the commencement of flumazenil 
administration and were able to give their name within a further 2 minutes. The 
average dose of flumazenil administered was 27 (6.1) i_tg kg - ' and the mean (SD) 
concentration of midazolam on awakening was 163.1 (43.7) ng ml-'. 
Age (yr) 
Weight (kg) 
Anaesthesia duration (min) 
Time from giving flumazenil to eyes 
open (min) 
Time from giving flumazenil to self-
identification (min) 
Mean 	 dose 	 of 	 flumazenil 
administered (ng kg-1) 
Mean concentration of flumazenil 
on awakening (ng m14) 
Mean concentration of midazolam 
on awakening (ng ml-') 
Mean increase in heart rate after 
flumazenil (beat mind) 
Mean increase in systolic blood 
pressure after flumazenil (mmHg) 
Mean increase in respiratory rate 
after flumazenil (breaths mind) 
6.5 (1.4) [5 -9] 
22.0 (6.7) [14-38.5] 
37.4 (8.4) [29-58] 
3.1 (1.1) [1-5] 
4.4 (1.4) [2-7] 
27.0 (6.1) [16.8-39.6] 
29.9(16.1) [7-62] 
163.1(43.7) [92-257] 
8.0 (16.2) [-24 to +37] 
11.5 (17.0) [-8 to +53] 
4.3 (5.5) [-8 to +10] 
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TABLE IV.! Demographic, anaesthetic and awakening haemodynamics data in the 
12 children. Data are mean (SD) and [range]. 
Psychomotor testing using the post-box toy completion-time ratio showed that, 
although the children tested had a faster completion time 3 hours postoperatively 
compared to their own unpractised preoperative performance, only one child could 
match his best preoperative performance four hours after operation (Table IV.2). 
The mean pre-induction midazolam level was 47.1(15.8)[29-38] ng 
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TABLE IV.2 Assessment of the antagonism of midazolam by flumazenil. Data are 
mean (SD) and [range]. 
Time after flumazenil 
administration 
Toy completion 
ratio 
Mean midazolam 
level (ng mil 
Mean flumazenil 
level (ng ml-') 
10 min 	(n = 7) 0.31(0.12)[0.17 - 0.50] 147 (34.4) [83 - 197] 32.1(21.5)[14-97] 
20 min (n = 2) 0.41 (0.15)[0.31 - 0.52] 131 (29.7) [72 - 184] 19.5(9.5)[8-42] 
30 min (n = 8) 0.40(0.12)[0.18 -0.58] 120 (27.1) [70- 170] 15.7(9.1)[7-38] 
60 min (n = 5) 0.39(0.12)[0.25 -0.55] 91 (24.6) [52- 138] 10.1(6.3)[3-23] 
120 min (n = 5) 0.44(0.15)[0.17 -0.55] 59 (15.4) [40 - 87] 4.3(5.6)[0-16] 
180 min (n = 5) 0.63(0.16)[0.44 -0.83] 41(9.5) [29- 55] not detected 
240 min (n = 10) 0.65(0.18) [0.34 - 0.95] _ 27 (10.6) [15 - 52] not detected 
not detected = flumazenil concentration below limit of detection 
Half the children awoke irritable, crying and refusing to play with the toy and 
in total, 9 children refused to play on 30 occasions during the four hour postoperative 
study period. Although the study group is smal, the children who were happy on 
awakening had the highest mean (SD) midazolam levels 181 (62.9) ng ml-'; those 
children that were sleepy had the lowest mean (SD) flumazenil levels 17.3 (7.6) ng 
and those that were crying had the highest flumazenil levels 37.8 (13.6) ng 
Six children fel asleep again after giving their name and playing with the post-box 
toy but al were easily awakened (Table IV.3). 
Midazolam level 
on awakening (ng 
Flumazenil level 
on awakening (ng 
Average time of resedation 
after flumazenil (n=6) 
80 (20.6) [60 - 120] (min) 
Toy refusal on awakening 
(n =6) 
Mood on awakening: 
happy, playful (n = 3) 
calm, drowsy (n = 3) 
irritable, crying (n = 6) 
181 (62.9) 
[103 - 257] 
168.7 (25.80 
[133 - 193] 
151.3 (34.5) 
[92 - 208] 
158.2 (19.5) 
[133- 183] 
139.4 (25.8) 
[164 - 92] 
29.3 (15.0) 
[7 - 52] 
25.4 (11.4) 
[7- 42] 
26.7 (17.9) 
[14 - 52] 
17.3 (7.6) 
[7 - 25] 
37.8 (13.60 
[62 -23] 
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TABLE IV.3 Resedation and mood assessment following flumazenil 
administration Data are mean (SD) and [range]. 
Mean blood concentrations of midazolam and flumazenil declined in all 
patients (Figures IV.! and IV.2). Flumazenil was not detectable at three hours and in 
7 patients at 2 hours. Compartmental analysis of midazolam revealed a 
three-compartment model with elimination from a central compartment. The 
pharmacokinetic findings are summarised in Table IV.4. 
-e- Midazotern 
Fkrnazeril 
500 
a) 
50 
0 10 
5 
2 
Time after antagonist (h) 
(zero) 	 (zero) 
3 	 4 
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FIGURE IV.! Mean (SD) serum midazolam concentrations 
FIGURE IV.2 Simultaneous mean (SD) serum flumazenil and midazolam 
concentrations. 
Midazolam Flumazenil 
V' (litre) 
(litre kg- `) 
V7 (litre) 
(litre kg- ') 
V (litre) 
(litre kg-1) 
Cl (litre min') 
(ml min-Ike) 
Terminal T,A 
T yza (min) 
T: (min) 
Ty: (min) 
k3 , 
(11- ') 
k i3 
k i2 (h- 
1(2 , (11-1 ) 
k3 , : 
41.1 (18.9) [21.5 - 93.7] 
1.87 (0.57) [1.15 -2.93] 
48.8 (22.2) [25.2 - 106.5] 
2.2 (0.7) [1.2 - 3.3] 
7.2 (5.6) [1.8 -23.3] 
0.31 (0.17) [0.09 - 0.73] 
344 (150) [199 - 736] 
15.37 (3.16) [11.02 -23.00] 
101.7 (31.9) [59.7- 179.4] 
2.55 (1.37) [0.84 - 5.00] 
16.1 (6.8) [3.9- 26.0] 
107.0 (30.2) [65.0- 189.0] 
1.03 (0.37) [0.55 - 1.84] 
3.53 (1.74) [1.76 - 7.06] 
4.5 (3.83) [0.89 - 14.20] 
8.17 (6.93) [1.49 - 24.38] 
8.30 (5.52) [3.49 -23.67] 
0.35 (0.18) [0.12 - 0.75] 
21.0 (7.1) [10.3 - 32.7] 
1.0 (0.2) [0.7- 1.6] 
20.5 (6.7) [9.8- 31.2] 
0.9 (0.2) [0.7- 1.6] 
469.83 (239.52) [136.27 - 963.17] 
20.57 (6.92) [7.29 - 30.85] 
35.3 (13.8) [21.5 - 75.5] 
1.14 (0.80) [0.06- 3.00] k 12 : 
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TABLE IV.4 Pharmacokinetic findings in the 12 children. Vss =Volumes of 
distribution at steady state, P=equilibrium, V=volume of the central 
compartment, Cl=total body clearance, Ph', TV?, T,2=half lives of 
the three phases and rate constants mean (SD) [range]. 
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Bulked (0 - 24 h) urine samples were successfully obtained in 10 out of the 12 
children. No unchanged midazolam was detected in these samples. A wide variation 
in the recovery, as a percentage of dose, of the hydroxyl metabolites and their 
glucuronides was observed: a - hydroxymidazolam (0 to 0.23%), a 
hydroxymidazolam glucuronide (0.64 to 13.2%), 4 - hydroxymidazolam (0.03 to 
1.12%) and 4 - hydroxymidazolam glucuronide (0.01 to 1.15%). One child was an 
extensive hydroxylator having a high recovery of hydroxyl metabolites and the 
glucuronide (denoted by the upper range). Unchanged flumazenil was recovered in all 
the urine samples ranging from 5.84% to 13.8% {mean (SD) 9.07 (2.96)1 of the dose 
administered. The demethylated metabolite, desmethylflumazenil, was detected but 
was not measurable by the HPLC method because its analytical peak was too close to 
the solvent front of the chromatogram. The carboxylic acid metabolite of flumazenil 
was not resolved by the HPLC method described. The child demonstrating extensive 
hydroxylation of midazolam also excreted the largest amount of unchanged 
flumazenil in the urine (i.e. 13.8%), however his other pharmacokinetic and 
pharmacodynamic data were unremarkable. 
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DISCUSSION 
The clinical pharmacokinetics of drugs in anaesthetic practice may be 
influenced by the mutual pharmacokinetic interactions of drug distribution, 
metabolism and excretion. In their studies in healthy volunteers, Breimer and 
co-workers observed that flumazenil and midazolam at repeated therapeutic doses did 
not show any accumulation or saturation kinetics (Breimer et al, 1991). Therefore, it is 
unlikely in this present clinical study, that pharmacokinetic interaction occurred when 
midazolam and flumazenil were administered together. The effect of caudal epidural 
anaesthesia on midazolam pharmacokinetics in children has not been studied but 
central blockade is reported to protect the child from the stress (Giaufre et al, 1985) 
and metabolic responses associated with surgery (Gouyet et al, 1991). Central blocks 
produce minimal haemodynamic changes in children and no changes at all in those 
under 8 years old (Giaufre, 1990) and therefore it is unlikely that caudal anaesthesia 
altered hepatic blood flow in this study to such an extent as to effect drug disposition 
(Giaufre et al, 1990a, Giaufre et al, 1990b). 
In all the Chinese children in this study, clearance of midazolam from the 
plasma may be best described by a tri-exponential function, however other workers 
have described a bi-exponential decline in plasma midazolam levels (Tolia et al, 1991; 
Salonen et al, 1987; Payne et al, 1989). This may be explained by the 2 min sampling 
interval during the initial distribution phase and the measurement of plasma 
concentrations for nearly 300 mm compared to shorter sampling times in other 
studies. The kinetics of intravenous midazolam were superimposed on a 'background' 
concentration of the oral midazolam premedication. This was considered valid if, 
IV INDUCTION 92 
within the constraints of clinical practice, it is assumed that first order kinetics existed. 
The midazolam pharmacokinetic data in this study show a mean T, AT of 107 min 
(non-compartmental analysis), total body clearance of 15 ml kg 1min" and an apparent 
central volume of distribution of 0.3 1 kg". The smaller central volume of distribution 
and higher clearance in the subjects of this study should have resulted in a rapid initial 
and subsequent distribution half-lives, however the mean terminal elimination 
half-life data are intermediate when compared to other studies (Tolia et al, 1991; 
Clausen et al, 1988; Pentikainen et al, 1989). This may be explained by the different 
fat distribution in Chinese children, the differing anaesthetic techniques employed and 
the age related variation in metabolism of benzodiazepines which undergo oxidation 
as their main metabolic pathway of elimination (Greenblatt et al, 1984). The mean 
(SD) ratio of k 12 : k21 was 1.14 (0.8) suggesting a rapid distribution of the i.v. 
midazolam from the central plasma compartment to the shallow compartment, and the 
mean (SD) ratio of k31 : k lo was 0.35 (0.18), suggesting a slow return from the deep fat 
and muscle compartments before elimination. 
Flumazenil pharmacokinetic data were suitably interpreted by non-
compartmental analysis because of the bolus and infusion administration regimen 
used in this study. The mean plasma levels of the drug after the infusion appear to 
decline bi-exponentially (Figure IV.2), although this was not observed in several 
patients whose drug levels declined almost mono-exponentially in a similar manner to 
that described in adults (Klotz et al, 1984; Klotz and Kanto, 1988). The present HPLC 
assay was not sufficiently sensitive to measure flumazenil in plasma in these patients 
120 min after dose administration. The terminal elimination half-life of flumazenil 
may therefore be underestimated. Nevertheless the kinetic data were derived using 
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statistical moment analysis which takes into account the total dose administered. The 
V„ in the children studied was about half that reported in adults, clearance values 
were similar and the flumazenil terminal half-life was 35 min in children compared to 
reported values of 60 -77 min in adults (Klotz et al, 1984; Breimer et al, 1991; Geller 
and Halpern, 1991). Both flumazenil and midazolam are water soluble drugs at low 
pH, but at physiological pH the imidazole ring forming part of the midazolam 
structure closes and lipid solubility is enhanced (Nilsson, 1991). The V„ and VY for 
flumazenil was approximately half that of midazolam reflecting the latter drug's wider 
distribution and greater lipid solubility within the body. This is endorsed by the low 
k31 : kw ratio for midazolam and the absence of unchanged midazolam in the urine, 
implying that the slow release of the drug from the deep fat compartment enables 
complete metabolism by the liver before elimination (Greenblatt et al, 1984; Wills et 
al, 1990). The clearance of flumazenil from the plasma was more rapid compared to 
midazolam and unchanged flumazenil was recovered in the urine. Flumazenil rapidly 
attains equilibration in the central compartment, is only slightly bound to plasma 
proteins compared to midazolam and it is likely that more of the drug remains in the 
plasma compartment for a longer time because its lipid solubility is less than that of 
midazolam at physiological pH (Klotz et al, 1984). The small volume of distribution 
and high clearance of flumazenil resulted in a terminal half-life which was one third 
of the terminal half-life of midazolam in our children. Flumazenil levels in the plasma 
were minimal at 2 hr and not detectable by our method of analysis at 3 hr. The mean 
dose of flumazenil administered to the children in this study to attain awakening (27 
p.g kg- ') was similar to that given by Klotz and colleagues (approx. 35 lig kg -1 ) to 
adults and the measured levels of flumazenil at awakening were higher than the steady 
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state levels used by Breimer and coleagues in adults to reverse a single i.v. dose of 
midazolam (approx. 0.25 - 0.75 mg kg') (Breimer et al, 1988; Klotz et al, 1984). 
Two hours after oral midazolam administration al of the children arrived in 
the operating suite awake, co-operative and apparently anxiety free, but on specific 
questioning 30% of the children expressed some fear. Their mean (SD) midazolam 
concentration was 47 (15.8) ng 	 (Figure IV.3) which is close to the lower range 
of concentrations at which sedative effects are seen in adult intensive care patients 
(Michalk et al, 1986; Westphal et al, 1987; Maitre et al, 1989; Reyes, 1984) but wel 
below the amnesic threshold reported by Persson and coleagues (Persson et al, 1988). 
Each benzodiazepine has its own plasma decay curve and patern of threshold 
concentrations (Reyes et al, 1984). The anxiolytic efect of midazolam occurs at lower 
serum concentrations than those required for sedation and therefore most of the 
children were calm on arrival in the operating suite (Nilsson, 1991). To achieve a 
hypnotic effect with midazolam in adults, a plasma concentration of 300-500 ng 
is required (Lauven et al, 1985; Persson et al, 1987). Children require a rapid, 
pleasant, smooth induction of anaesthesia but the variability in clinical response to a 
given dose of midazolam requires that either a large dose is administered, or that a 
narcotic (in this series alfentanil) is also given to ensure these favourable 
characteristics (Kissin et al, 1990). The relatively smal dose of alfentanil 
administered during induction (Hiler and Saamivaara, 1992), it's short elimination 
half-life in children (Meistelman et al, 1987) and evidence that recovery is not 
prolonged after daycase anaesthesia (Milar and Jewkes, 1988) would suggest that 
alfentanil had litle influence on the recovery characteristics recorded during this 
study. In al the children the induction was smooth, rapid and without incident and 
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the peak measured mean plasma midazolam level at 2 min was 1000 ng ml - ' which 
declined to levels less than 300 ng m1 -1 at 20 mm (Figure IV.!). At the time of 
antagonist administration, the children's mean plasma midazolam level (180 ng ml - ') 
(Figure IV.2) was at the adult mid-range sedative level but was easily reversed with 
flumazenil 0.03 mg kg'. Half of the children awoke crying and refused to play with 
the post-box toy which may imply a mild inverse agonistic effect, reported by other 
workers in adults (Chiolero et al, 1986; Higgitt et al, 1986). Interestingly, these 
children also had the highest mean serum levels of flumazenil on awakening. These 
findings are in contrast to those described in the next chapter. Following flumazenil 
administration to children undergoing the same surgical procedure but using a 
spontaneously breathing anaesthetic technique employing halothane, only 20% of the 
children refused the toy or cried on awakening. The halothane supplemented children 
awoke more slowly but were given a lower mean dose of antagonist (0.024 mg kg - ') 
than in this study. This is in accord with the findings of Geller and colleagues who 
demonstrated that flumazenil improved the quality of emergence from anaesthesia in 
patients given halothane anaesthesia without benzodiazepines (Geller et al 1987). 
Midazolam produces marked reduction of halothane MAC in humans at serum 
concentrations lower than that required to cause sleep (Inagaki et al, 1993) and to 
reduce the influence of the volatile agent on recovery and pharmacokinetic 
disposition, isoflurane was employed as the volatile agent in this study. The children 
who were happy and co-operative on awakening had higher serum midazolam levels 
compared to the children who were irritable, crying and refused to play with the 
post-box toy. Moreover, the children who were drowsy on awakening had a lower 
mean serum flumazenil level (Table IV.3). The sample size is too small for any 
statistical comparison, however the data are blind and lend credence to 
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pharmacokinetic-pharmacodynamic model of midazolam plasma concentration and 
effects which is being presently developed by other workers (Breimer et a1,1991). 
Flumazenil is distributed into the brain within minutes of i.v. administration 
and attains brain concentrations which are higher than those in plasma but then is 
rapidly cleared from the brain and excreted (Geller and Halpern, 1991). The clinical 
effect of flumazenil is dependent on the dose of midazolam, dose of flumazenil, 
pharmacokinetics of both drugs and the timing of antagonist administration. Despite 
being fully awake, the children who were willing to perform the post-box toy 
demonstrated mild residual psychomotor impairment for the first 2 hr postoperatively. 
At 4 hr all of the children tested performed close to their best, practised, unmedicated 
preoperative attempt. The sensitivity of the assay did not permit measurement of 
plasma flumazenil levels at 3 hr but the mean midazolam levels of the children at that 
time were in the adult anxiolytic range. The resedation seen in 6 of the patients was 
presumably due to the residual midazolam hypnotic effects being relatively 
unopposed by flumazenil (Table IV.3). These children went back to sleep 
approximately 80 minutes after initial awakening but were easily roused, albeit crying 
and irritable and similar to the "normal" small child who is abruptly awoken. The 
awakening mean plasma level of midazolam in the resedated children was less than 
the awakening mean midazolam levels in the happy or sleepy children inferring that 
midazolam was redistributed more rapidly to the deep compartment in these children 
resulting in later sedation when the midazolam returned to the central compartment, 
and furthermore that resedation per se was not due to the rapid redistribution of 
flumazenil from the central compartment. Relative plasma concentrations of agonist 
and antagonist seem to determine the quality of emergence from anaesthesia. A mild 
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inverse agonistic effect of flumazenil has been reported in adults and may also occur 
in children with large plasma concentrations of flumazenil (Higgitt et al, 1986). 
A smooth induction of anaesthesia with midazolam in children is achieved 
only with high plasma drug concentrations, with the resultant drawback of prolonged 
sedation during the early recovery period. Flumazenil antagonised the hypnotic effects 
of midazolam rapidly and effectively and the pharmacokinetic disposition of 
flumazenil in children was similar to that defined in adults (Klotz et al, 1984). The 
popularity of the new induction agent propofol infers that it may confer advantages 
over midazolam, however a more complete description of the pharmacokinetic 
disposition of propofol in children is required before comparing these two drugs as 
induction agents. 
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PHARMACOKINETICS OF PROPOFOL 
Rapid recovery after general anaesthesia may be an advantage in paediatric 
patients, particularly those undergoing minor day care surgery. Propofol, the latest 
induction agent to be introduced into clinical practice seems to possess some advantage 
over other available agents in this respect (Mackenzie and Grant, 1985). The 
pharmacology of propofol has been recently reviewed by White (White, 1988) and 
there has been a rapid accumulation of clinical and pharmacological data but the 
description of the pharmacokinetics of propofol in children is incomplete (Valtonen et 
al, 1989; Saint-Maurice et al, 1989). 
Age-related changes in body water, lean body mass, regional blood flow, renal 
and hepatic function (Friis-Hansen, 1971; Greenblatt et al, 1984, Bjorkman et al, 1987) 
affect drug distribution, metabolism and excretion (Cockshott, 1985; Kay et al, 1986; 
Servin et al, 1986). Furthermore, physiological changes associated with general 
anaesthesia and the racial characteristics of the study group may alter the disposition of 
anaesthetic drugs (Kumana et al, 1987). This study reports the pharmacokinetics of 
propofol in Chinese children. 
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MATERIALS AND METHODS 
Twelve Chinese children aged between 4 and 12 years were studied. All 
patients were ASA grade I and underwent circumcision for the treatment of phimosis. 
Children were specifically excluded from the study if there was a history of asthma or 
allergies, a previous adverse anaesthetic experience, halothane anaesthesia within the 
last month, hepatic, renal, respiratory, cardiac or haematological disease, 
developmental disability and if under two years of age. 
Patients were premedicated with trimeprazine 3 mg kg- ' (to a maximum of 90 
mg) and atropine 0.03 mg kg- ' by mouth two hours preoperatively. Two grams of 
EMLA emulsion cream (lignocaine 25 mg g - ' and prilocaine 25 mg g- ') was also 
applied to the dorsum of the left hand. In the operating suite, a 24-gauge cannula was 
inserted into a vein underlying the EMLA pretreated area. Procaine HC11 mg kg- ' was 
administered 15 seconds prior to anaesthesia being induced with the aqueous emulsion 
formulation of propofol ('Diprivan') 2.5 mg kg -1 injected over 30 seconds. Time zero 
was taken to be the incidence when the injection was completed. An 18-gauge cannula 
(for venous sampling) was then inserted into a vein in the contralateral antecubital 
fossa. Thereafter, anaesthesia was maintained with the patient spontaneously breathing 
nitrous oxide 67% in oxygen with halothane 1-3% delivered via a Mapleson F 
breathing system if under 25 kilograms and by a Mapleson A breathing system if more 
than 25 kilograms in body weight. The surgeon infiltrated each dorsal nerve at the root 
of the penis with 1.5 mls of 0.5% bupivacaine. 
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The sedative effectiveness of the premedication on arrival in the operating suite 
was assessed, categorised and recorded as one of the following: agitated or crying; 
aware and apparently anxiety free; drowsy; asleep but responsive to command (Jones 
et al, 1990). Induction was graded as good (absence of side effects), adequate (side 
effects present but not interfering with induction) and poor (side effects severe and 
protracted). Any evidence of excitatory phenomena on induction of anaesthesia was 
also recorded. During anaesthesia all patients were monitored with an E.C.G., 
non-invasive blood pressure cuff, pulse oximeter, capnograph and inspired oxygen 
concentration (Datex Cardiocap). Post operatively the patients' coma scale (Robertson 
et al, 1977) and a structured observation score (Krane et al, 1987) were assessed and 
noted at each of the blood sampling times detailed below. Also recorded in recovery 
were the awakening time (elapsed time from the discontinuation of general anaesthesia 
in the operating room to spontaneous eye-opening in recovery) and the time elapsed 
until the patient could identify himself. 
Whole blood samples were collected for propofol estimation at the following 
times: 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 and 180 minutes and 4, 6, 8, 10, 12, 18 and 
24 hours. Each sample was thoroughly mixed in tubes containing lithium-heparin 
(Sarstedt LH/5) and stored at +4°C until assayed. Propofol concentration in whole 
blood was determined by a modified liquid chromatographic method (Gin et al, 1990). 
Propofol in whole blood [(0.5 ml samples rather than the 1.0 ml samples used by 
Plummer (Plummer, 1987)] and internal standard thymol, buffered with 0.1 M sodium 
dihydrogen phosphate, were extracted into cyclohexane. The mobile phase consisted of 
75% (v/v) acetonitrile in distilled water containing 1% (v/v) glacial acetic acid. A C18 
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reversed phase column (Nova-Pak), linked to a C18 pre-column was used and the eluate 
was measured by a fluorometric detector with excitation and emission wavelengths set 
at 276 nm and 310 nm respectively (Chan and Gin, 1990). The calibration graphs were 
linear over the range 2 to 3000 ng mr' with coefficients of variation ranging from 1.0 
to 8.0%. The between batch coefficient of variance was 6.7% at 50 ng ml' and 4.8% at 
3000 ng while the limit of detection was approximately 2 ng ml'. 
The blood concentration-time profiles of propofol were analysed by the BITRI 
computer programme (Gin et al, 1990; Chan et al, 1987) which utilises the method of 
residuals, whereby each curve is fited with experimental data in terms of a 
bi-exponential or tri-exponential function. BITRI chooses the best fit such that the 
logarithms of squared deviation between exponential and computer values are 
minimised (Boxenbaum et al, 1974). 
Distribution and elimination half-lives (T.Aa T 	apparent central volume 
of distribution (V), apparent volume of distribution at steady state (V"), apparent 
volume of distribution in the elimination phase (V/) and total body clearance (TB C) 
were calculated using standard formulae (Gibaldi and Perier, 1982). 
Association between age, clearance and elimination half-life was determined 
using linear regression with computer interactive statistical software (Minitab 1989). 
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RESULTS 
On arrival in the operating suite, 2 of the children were awake and apparently 
anxiety free, 7 patients were drowsy with intermittent eye opening and the remaining 3 
children were asleep, but awoke on command. A fixed dose of propofol of 2.5 mg kg - ' 
was given to all patients and resulted in induction being graded as free of side effects in 
50% of patients and satisfactory in the remaining six. Five episodes of semi-purposeful 
movement occured, combined with breath holding, tremor and rigidity in two patients, 
and 1 patient developed hiccup. The demographic, haemodynamic changes during 
induction and anaesthesia details for the 12 boys are presented in Table IV.5. 
TABLE IV.5 Demographic, induction-haemodynamics and anaesthetic data in the 12 
children. Data are mean (SEM[range]. 
Age (yr) 
Weight (kg) 
Mean increase in heart rate from 
pre-induction values (beats min') 
Mean decrease in systolic blood pressure 
from pre-induction values (mm Hg) 
Maximal end-tidal carbon dioxide 
recorded during anaesthesia (kPa) 
Anaesthesia time (min) 
Awakening time (min) 
7.9 (0.8) 
25.8 (7.9) 
4.3 (6.4) 
-7.1 (4.4) 
6.8 (0.3) 
28.8 (1.5) 
30.5 (4.0) 
[4-12] 
[16-39] 
[-42 to +42] 
[-28 to +16] 
[5.3-7.8] 
[21-36] 
[11-61] 
Time after induction (min) 
Coma score <7 
Asleep 
Coma score 7 
Lightly asleep, eyes open on 
command 
Coma score 9 
Fuly awake, eyes open, 
conversing 
Total number of children 
45 	 60 	 90 	 120 	 240 
10 	 1 	 1 	 0 	 0 
1 	 8 	 6 	 1 	 0 
0 	 3 	 5 	 11 	 12 
12 	 12 	 12 	 12 	 12 
IV INDUCTION 103 
The maximum change in heart rate and systolic blood pressure from 
pre-induction values during the first five minutes of the induction period was 
computed. The mean maximum end tidal carbon dioxide value recorded during the 
surgical procedure was 50.9 mmHg, and the mean anaesthetic time for this group of 
children was 28.8 minutes. The mean awakening time was 30.5 minutes which 
occured at a mean blood propofol concentration of 165 ng.m1-1. In al cases the children 
could adequately identify themselves within two minutes of opening their eyes 
spontaneously. Coma scores post-induction time are shown in Table IV.6. 
TABLE IV.6 Relationship between awakening and time after propofol 
administration. (Values are the number of children) 
The mean (SEM) duration of anaesthesia was 30.5(5.13) min. The mean blood 
propofol concentration-time profile for the children is shown in Figure IV.3. 
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Time after induction (hours) 
FIGURE IV.3: The mean (SEM) blood propofol concentration-time relationship in 
Chinese children. 
Propofol concentrations declined in al patients but secondary peaks were 
present at 3 and 12 hours. Propofol concentrations were detectable in only 5 patients at 
10 hours and only 2 patients at 24 hours. In al patients compartmental analysis of 
propofol concentrations revealed a three compartment model with elimination from a 
central compartment and the pharmacokinetic findings are summarised in Table IV.7. 
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TABLE IV.7 Propofol pharmacokinetic findings in the 12 children. Fc= Volumes of 
distribution at steady state, r= equilibrium, V=volume of central 
compartment, Cl=total body clearance, T Tzfl, Tzr=halfIlives of the 
three phase and rate constants. Results are mean (SEM)[range]. 
V" (litre) 133.34 (25.56) [20.25-345.40] 
(litre Kg-) 5.01 (2.66) [1.68-10.16] 
V (litre) 325.47 (61.22) [44.63-570.11] 
(litre KO 12.38 (1.98) [2.23-23.50] 
V (litre) 16.31 (3.77) [2.45-41.94] 
(litre Kg-') 0.597 (0.10) [0.08-1.23] 
Cl (litre min') 1.11 (0.18) [0.53-1.43] 
(litre min"' Kg -) 40.35 (3.60) [25.70-66.75] 
T.: (min) 3.05 (0.43) [1.01-6.44] 
T,P (min) 24.33 (5.13) [5.26-74.99] 
(min) 209.22 (29.26) [37.88-285.97] 
(If) 0.55 (0.22) [0.18-2.97] 
(11 -1) 6.40 (1.52) [1.81-19.55] 
k„ (14) 2.84 (0.72) [0.64-9.47] 
k„ (10 5.79 (1.11) [0.31-11.98] 
k 4.85 (0.82) [1.31-9.96] 
k„ : k 1 , 
k„ : k„ 
0.169 (0.074) 
1.435 (0.224) 
[0.02-0.89] 
[0.03-2.58] 
The mean ratio of k 12 : k21 was 1.435 ± 0.224 (mean ± SEM), suggesting a rapid 
distribution of the intravenous propofol bolus to the shallow compartment, and the 
mean ratio of k31 : kw was 0.1692 ± 0.074 (mean ± SEM) suggesting that the third 
Age (Y•ars) 
Elimination 
t i (min) 
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exponential phase was constrained by its slow return from the deep to the central 
compartment. Linear regression demonstrated a significant increase in the rate of 
elimination of propofol with increasing age (p < 0.001) (Figure IV.4), but there was 
no significant relationship between propofol clearance and age (Figure IV.5). No 
relationship was found between age and V", V or V Y with linear regression analysis. 
Anaesthesia and recovery proceeded smoothly in all patients and there were no 
complications. 
FIGURE IV.4: Relationship between age (years) and elmination half-life (minutes) 
for propofol. The two outlying data points enclosed in the boxes were 
excluded from linear regression analysis ( r = 0.73, p <0.001). 
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FIGURE IV.5: Relationship between age and clearance (ml kg-I min') of propofol. 
The two outlying data points enclosed in the boxes were excluded 
from linear regression analysis ( r = 0.41, p = 0.046). 
80 - 
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DISCUSSION 
Pharmacokinetic studies in children are often restricted by the limited amount 
of blood that can be removed from the patient; a consequence of which is a lack of 
definition of the elimination phase. Recently new strategies such as naive pooled data 
and the non-linear mixed-effects modelling approach have been introduced in an 
attempt to overcome this problem (Fisher, 1994). However the pharmacokinetics of 
propofol are well described by the standard two-stage method and the 'best' estimates 
of the pharmacokinetic parameters estimated using the mixed-effects approach did not 
offer any increased accuracy over the simpler two staged approach (Kateria et al, 
1994). In this study blood propofol concentrations in the 12 children have been 
determined, using small volume samples, up to 24 hours post induction. Peripheral 
venous samples were used because the risk to the paediatric patient of arterial 
cannulation is not justified for a minor surgical procedure, like circumcision. In all 
these children, the clearance of the drug from the blood can best be described by a 
tri-exponential function. The pharmacokinetic data show a mean T y? of 209 minutes 
and a mean total body clearance of 1.11 litre.mie. This large total body clearance 
combined with a relatively small mean volume of equilibrium (325.5 litres) for a 
highly lipophilic drug, results in a fast elimination of propofol from the blood in 
children. As in another study in young adults (Kirkpatrick et al, 1988), the mean 
volume of distribution at steady state was less than half of the mean equilibrium 
volume of distribution, suggesting that after distribution from the blood to the tissues, 
and metabolic clearance from the blood, elimination is constrained by a slow return of 
propofol to the blood from the deep compartment. 
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Data from this study are compared with the pharmacokinetic findings of 
Valtonen (Valtonen et al, 1989) and Saint-Maurice (Saint-Maurice et al, 1989) and are 
summarised in Table IV.8. 
TABLE IV.8 Comparison of three pharmacokinetic studies of single dose propofol 
in children 
Valtonen 
(n = 8) 
Mean (SD) 
Saint-Maurice 
(n = 8 + 2 for 4h) 
Mean (SEM) 
Present study 
(n =12) 
Mean (SEM) 
Tx" (min) 1.50 (1.56) 4.15 (0.78) 3.05 (0.43) 
T,AP (min) 9.3 (3.78) 56.1 (6.30) 24.3 (5.13) 
T,7 (min) 214.6 (168.8) 735.0 (82.7) 209.22 (29.3) 
V (litre kg-1) 0.530 (0.65) 0.722 (0.11) 0.597 (0.10) 
V" (litre kg-1) 2.16 (1.49) 10.90 (1.20) 5.01 (2.66) 
Cl (ml mie kg4) 32.0 (16.8) 30.6 (2.9) 40.4 (3.6) 
Sampling times 
(min) 2, 4, 6, 10, 15, 30, 
45, 60 
2, 5, 10, 15, 20, 30, 40, 
60, 90, 120 
2, 5, 10, 15, 20, 30, 
45, 60, 90, 120 
(hr) 3, 6, 12,24 3, 4, 5, 6, 7, 8, 10, 12, 
24 
3, 4, 6, 8, 10, 12, 18, 
24 
Surgery Elective surgery Minor visceral Circumcision 
Minor orthopaedic 
Other drugs Atropine Atropine 
administered Flunitrazepam Trimeprazine 
Lignocaine Procaine HCI 
Fentanyl Fentanyl 
Pancuronium Vecuronium 
Suxamethonium 
Halothane (n = 9) Halothane 
Enflurane (n = 1) 
02 : N20 02 : N20 02 : N20 
Caudal bupivacaine 
The initial distribution half life determined in this study and that of 
Saint-Maurice are similar, perhaps reflecting the similar sampling times. The SD of 
Valtonen's data is equal to their mean T,Aa . The elimination half life, central 
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compartment volume and plasma clearance values from Valtonen's study and this one 
are similar. The V" in Saint-Maurice's study is twice the value found in this study and 
five times that of Valtonen's data, and the elimination half-life determined by 
Saint-Maurice's group is three times as long. The differences between these studies 
may be attributable to the different anaesthetic techniques employed, different types 
of surgical procedure, the different sample collection times and the small populations 
examined. 
The smaller lean body mass of Chinese children may decrease V", leading to a 
shorter elimination half life. Similar results have been found with the 
pharmacokinetics of diazepam in Chinese adults (Kumana et al, 1987). The influence 
of ethnic origin on metabolism may also contribute to these differences, as it does for 
example, with the increased oxidative demethylation of pethidine in oriental subjects 
(Chan et al, 1990). The present study was performed with a prescibed anaesthetic 
technique, the same simple surgical procedure in all cases and 24 hour sampling in 
twelve patients. 
Despite the small population sample, and the exclusion of two outlying points 
from the linear regression analysis, the decrease in elimination half life with 
increasing age was statistically significant (Figure IV.4). Each of the outlying points 
belong to a different patient and do not show any relation to the clinical or blood 
analysis data. The only constant feature in these two patients was that propofol could 
not be detected in their blood samples after the 10 hour post induction blood sample. 
The patient blood samples were randomly assayed, standardised pre and post batch, 
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and collected in the same manner by the same investigator throughout the study. It is 
likely in this group of young children that their metabolising capacity is rapidly 
developing, as reflected by the inverse relationship of elimination half life and age. 
Propofol is primarily rapidly metabolised to the inactive glucuronide conjugate and 
the corresponding quinol glucuronide. Not only is glucuronidation an age dependent 
enzyme process but both hepatic mass and hepatic blood flow increase towards 
adulthood (Stanski et al, 1982). Two children aged seven years took the longest to 
fully awaken and both were included in the elimination / age regression data (LAY 262 
and 276 min). Unfortunately the awakening data are confounded by the long half-life 
of the premedicant trimeprazine; nevertheless, 91% of the children had awoken within 
30 minutes of termination of anaesthesia and could be returned from the recovery area 
to the ward. With the anaesthetic technique used in this study, awakening occurred at 
approximately twice the T,A13 with a mean blood concentration of 165 ng.m1 -1 . There 
are no comparable data in the literature, but it can be noted that adults premedicated 
with hydroxyzine (Destibats et al, 1987) or promethazine (Hartung and Freye, 1988), 
had mean recovery times (22 and 16.3 minutes respectively) approximately double 
those of unpremedicated adults. 
Both this study and that of Valtonen's group (Valtonen et al, 1989) 
demonstrate a tri-exponential relationship between blood concentrations and time. The 
data from two patients in Saint-Maurice's study (Saint-Maurice et al, 1989) were not 
available after four hours and their pharmacokinetic parameter estimates for these 
patients were based on a two-compai talent open mamillary model. However it is 
possible to make a comparison of propofol half-lives between non-pregnant adults and 
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children (Briggs et al, 1985; Kay et al, 1985; Mather et al, 1987), though 
interpretation should be prudent in view of the varying anaesthetic techniques. The 
present study on children demonstrated a similar Ty,a to adults. Estimation of the 
initial distribution half life of propofol is liable to error because the first sample was 
drawn at two minutes post induction and the initial distribution half life value is 3.05 
(0.43) minutes. However it was shown that when blood sampling at 2,4,6,8, and 10 
minutes, post induction with propofol, in women undergoing laparoscopy was 
compared to sampling at 2,5,10 and 15 minutes in women undergoing caesarean 
section, there was no significant difference in their kinetics (Gin et al, 1990). The 
T 1/2 15 of the children in this study was approximately half and their elimination half-life 
three times shorter than those of the young adults in Kirkpatrick's study (Kirkpatrick 
et al, 1988). Only two patients in this study had detectable propofol levels at 24 hours. 
This may imply that these Chinese children had rapid metabolic elimination of the 
drug. The volume of the central compartment when normalised for body weight did 
not differ significantly from the young adults, but V" was approximately half. This 
may reflect the proportionately larger lipid content of the Caucasian adult compared to 
the Chinese child. 
The rapid hepatic clearance of a highly protein bound drug like propofol 
(Mather et al, 1987) is primarily hepatic blood flow limited. Halothane reduces 
hepatic blood flow and may inhibit drug-metabolising liver enzymes (Bjorkman et al, 
1987), but in Brigg's series the propofol levels in a group of patients whose 
anaesthesia included halothane were not significantly different from those in other 
groups (Briggs et al, 1985). However, unlike the children investigated in later studies, 
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the recorded haemodynamic changes on induction in this group were minimal. The 
effect of caudal epidural anaesthesia on propofol pharmacokinetics in children has not 
been studied but central blockade is reported to protect the child from the stress 
(Giaufre et al, 1985) and metabolic responses associated with surgery (Gouyet et al, 
1991). Central blocks produce minimal haemodynamic changes in children and no 
changes at all in those under 8 years old (Giaufre, 1990) and therefore it is unlikely 
that caudal anaesthesia altered hepatic blood flow in this study to such an extent as to 
effect drug disposition (Giaufre et al, 1990a, Giaufre et al, 1990b). 
This study has demonstrated that propofol pharmacokinetics in children are 
similar to adults and are consistent with a three compartment model with elimination 
from a central compartment. The elimination half-life of propofol in children is 
similar to that reported with a bolus intravenous administration of methohexitone in 
paediatric patients (Bjorlcman et al, 1987), and approximately one third that reported 
with thiopentone (Sorbo et al, 1984). The rapid elimination of propofol and the 
minimal haemodynamic perturbation during induction qualify this agent as suitable 
for induction of anaesthesia in children. 
The pharmacokinetic profile of midazolam described earlier in this chapter 
shows that although propofol clearance is twice as fast as midazolam, the elimination 
half-life of midazolam is half the duration of propofol and the terminal half-lives of 
the two drugs are very similar. Awakening times should only be compared if the 
patients were initially at the same depth of anaesthesia. This can be easily determined 
with inhalational agents by MAC equivalence but the analogous end point with 
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intravenous agents is not available. To some extent, the choice of a single surgical 
procedure •and the very similar, durations of anaesthesia may allow tentative 
conclusions to be considered. Halothane would also be expected to have some 
influence on the elimination of propofol and therefore care must be taken when 
comparing results, but awakening times were much faster following 
midazolam-induced anaesthesia antagonised with flumazenil, compared to awakening 
after propofol induced anaesthesia. In view of these results, a controlled comparison 
of midazolam and propofol would be valuable in assessing the place of midazolam as 
an induction agent in paediatric anaesthesia. 
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HAEMODYNAMIC CHANGES 
ON INDUCTION OF ANAESTHESIA WITH 
MIDAZOLAM, PROPOFOL OR THIOPENTONE 
The previous sections discussed the pharmacokinetic suitability of midazolam 
and propofol as anaesthetic induction agents in children. A number of authors have 
compared the induction characteristics of propofol and thiopentone (Runcie et al, 
1993, Mirakhur, 1988, Purcell-Jones et al, 1987) but there have been no comparative 
studies with midazolam in children. Induction characteristic dose-equivalence studies 
for propofol and thiopentone in children have been determined (McCollum et al, 
1986) but again there have been no comparative studies with midazolam in children 
and therefore a recommended induction dosage regimen was chosen for comparison 
(Salonen et al, 1987). Induction of anaesthesia in children is often associated with 
rapid cardiovascular change, the degree and duration of which depends upon the agent 
used and the physiological status of the patient. The aim of this study was to compare 
the haemodynamic perturbation associated with induction of anaesthesia with either 
midazolam, propofol or thiopentone in children using the FinapresTM , a non-invasive 
continuous blood pressure monitor which was adapted to record continuous 
haemodynamic data for analysis. Exclusion criteria for the study were designed to 
provide subjects who would permit comparison of induction agent effect on 
haemodynamics, independent of patient pathology. 
IV INDUCTION 116 
METHODS 
Thirty ASA grade I Chinese children, aged 4-12 yr, undergoing circumcision 
for treatment of phimosis were investigated in this study. The study was approved by 
the Faculty of Medicine Ethics Committee (The University of Hong Kong) and 
written informed consent obtained from the parents. Children were excluded from the 
study according to the criteria detailed in Chapter II. 
On the day of surgery, EMLA emulsion cream 2 g (lignocaine 25 mg g - ` and 
prilocaine 25 mg g 1) was applied to the cubital fossa of the non-dominant arm 2 hr 
before premedication with midazolam 0.5 mg kg - ' (maximum dose 15 mg) and 
atropine 0.02 mg kg -1 by mouth. Immediately following administration of the 
premedicant, a 23-gauge cannula was inserted into a vein underlying the 
EMLA-pretreated area. Routine monitoring devices included an electrocardiograph, 
intermittent non-invasive arterial pressure recorder and pulse oximeter (Datex, 
Cardiocap CM-104). A small size Finapres cuff was applied to the middle phalanx of 
the middle finger of the hand strictly according to the manufacturer's instructions, and 
the output from the Finapres 2300e (Ohmeda, Colorado) was interfaced with an AST 
Premium exec 386SX125 computer. On arrival in the operating suite, the child was 
assessed as agitated or crying, aware and apparently anxiety free, drowsy, or asleep 
but responsive to command. Before induction, pulse rate, blood pressure and time data 
were simultaneously stored to disc in ASCII format every 10 sec for 3 min and then 
during and after induction for a further 10 min, using data acquisition software written 
for this system (BPM, 1991). The children were randomly allocated to receive either 
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propofol 2.5 mg kg -1 without lignocaine (Aun et al, 1992; Patel et al, 1988), 
midazolam 0.5 mg kg"' (Salonen et al, 1987) or thiopentone 4.0 mg kg . ' (Sorbo et al, 
1984) intravenously over 30 sec. Thereafter, anaesthesia was maintained with the 
patient breathing spontaneously 67% nitrous oxide and 1% halothane in oxygen via a 
Mapleson F (< 25kg) or a Mapleson A (>25 kg) breathing system. A caudal injection 
of 0.25% bupivacaine 0.5 ml kg' was given to all children, 6 minutes after 
intravenous induction agent administration. 
The haemodynamic data were treated as ordinal scale data and analysed using 
the computer interactive statistical program CSS:StatisticaTM . A statistical significant 
(p < 0.05) difference between the three induction agent groups was determined using 
the Kruskal-Wallis statistic incorporating consideration of Bonferroni inequality. 
Patient's demographic data were analyzed by general ANOVA and statistical 
significant differences before and after induction in the same individuals was 
determined using the Wilcoxon signed-rank test. 
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RESULTS 
There was no significant difference between the midazolam, propofol and 
thiopentone groups when comparing patient characteristics or mood immediately prior 
to induction (Table IV.9). One child presented to the operating suite asleep and the 
remainder were awake and apparently anxiety free. 
TABLE IV.9 Patient characteristics and premedicant effect in the induction agent 
groups. Data are mean (SD) range] 
Midazolam 
(n = 10) 
Propofol 
(n = 10) 
Thiopentone 
(n = 10) 
p 
value 
Statistical 
test 
Age (yr) 7.2(2.5)[4-11] 7.4(2.0)[5-11] 7.4(2.3)[5-12] 0.97 general 
anova 
Weight (kg) 21.4(4.5)[15-27] 23.9(5.3)[16-33] 23.7(7.4)[17-37] 0.57 
Anaesthetic 
duration (min) 
35.5(6.0)[27-48] 29.9(4.6)[25-39] 32.5(7.6)[21-47] 0.15 general 
anova 
Preoperative 
assessment 
asleep/drowsy 0 1 0 
awake 10 9 10 
crying 0 0 0 
Haemodynamic changes on induction were compared between the three 
induction agents using conventional intermittent non invasive blood pressure 
measurement every minute (Cardiocap) and Finapres blood pressure measurement 
every 10 seconds (Figure IV.6). Due to various technical recording and data 
manipulation errors, complete data were only available for 25 patients. Subsequent 
analysis excludes the 5 patients for whom data were not available. 
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time (sec) 
FIGURE IV.6 Mean arterial pressure data measured by Finapres during induction with midazolam, thiopentone and propofol. 
Data are mean (SD). (n = 25). 
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Maximum change in blood pressure and heart rate from the preinduction baseline 
were analysed during the first minute and the subsequent 5 minutes after induction 
(Table IV.10). 
TABLE IV.10 Haemodynamic data recorded by Finapres during the first and 
subsequent five minutes after induction. Data are mean 
(SD) [range] blood pressure (mmHg), heart rate (beats min-'). 
Midazolam 	 I 	 Propofol 
(n = 8) 	 (n = 9) 
I 	 Thiopentone 	 I p value I Statistical 
(n = 8) 	 test 
Mean maximum change in haemodynamic data recorded at first minute 
after induction 
systolic 
pressure 
-12.6(27.9)[-58 to 17] -25.7(23.8)[-59 to 20] -0.3(25.6)[-26 to 47] 0.14 
Kruskal- 
diastolic 
pressure 
-15.0(19.6)[-47 to 8] -21.9(20.6)[-54 to 12] 5.8(18.8)[-14 to 34] 0.07 Walis statistic 
mean -16.0(21.4)[-53 to 10] -28.4(17.4)[-53 to -101 6.1(24.3)[-20 to 43] 0.03 
pressure 
heart -2.5(28.9)[-23 to 59] -18.3(31.9)[-78 to 25] 15.3(22.1)[-24 to 49] 0.05 
rate 
Mean maximum change in haemodynamic data recorded at subsequent 
five minutes after induction 
systolic 
pressure 
-24.7(32.4)[-58 to 49] -50.2(21.8)[-91 to-11] -27.1(44.0)[-71 to 70] 0.16 
Kruskal- 
diastolic 
pressure 
-19.9(23.3)[-47 to 30] -37.2(27.6)[-67 to 24] -14.3(30.7)[-40 to 59] 0.05 Walis statistic 
mean -24.1(24.0)[-54 to 29] -49.8(19.9)[-76 to -25] -17.5(40.6)[-58 to 66] 0.04 
pressure 
heart -1.6(41.0)[-42 to 72] -19.1(42.8)[-78 to 49] 6.1(33.9)[-45 to 49] 0.4 
rate 
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The maximum decline in mean arterial pressure recorded with the Finapres showed a 
significant difference between the three induction agent groups at both 1 min and 5 
min. Post-hoc analysis revealed a significant difference between the propofol and 
thiopentone groups at 1 minute (p=0.01), and between the propofol and midazolam 
groups at 5 minutes (p=0.02). Overal, thiopentone caused the least, propofol the 
greatest, fal in blood pressure, and midazolam was intermediate. The changing 
patern in blood pressure and heart rate before and after induction is shown in figures 
IV.7, IV.8 and IV.9. 
time (sec) 
FIGURE IV.7 Blood pressure and heart rate data measured by Finapres during 
induction of anaesthesia with thiopentone 
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FIGURE IV.8 Blood pressure and heart rate data measured by Finapres during 
induction of anaesthesia with propofol 
time (sec) 
FIGURE IV.9 Blood pressure and heart rate data measured by Finapres during 
induction of anaesthesia with midazolam. 
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The Cardiocap data failed to demonstrate any significant difference between the 
groups during either time period (Table IV.!!). 
TABLE IV.!! Haemodynamic data recorded by Cardiocap during the first and 
subsequent five minutes after induction. Data are mean (SD) [range], 
blood pressure (mmHg), heart rate (beats min'). 
Midazolam 	 I 	 Propofol 	 Thiopentone 	 I P 	 Statistical 
(n = 8) 	 (n = 9) 	 (n = 8) 	 value I 	 test 
Mean maximum change in haemodynamic data recorded in the first 
minute after induction 
systolic 
pressure 
-5.0(8.8)[-19 to 6] -9.9(20.4)[-37 to 27] -7.0(13.1)[-26 to 15] 0.78 
Kruskal- 
diastolic 
pressure 
-5.5(16.4)[-30 to 18] -8.7(15.2)[-31 to 20] -9.4(13.8)[-37 to 6] 0.90 Walis statistic 
mean -5.1(14.8)[-34 to 20] -8.9(15.1)[-31 to 20] -8.0(12.9)[-33 to 7] 0.77 
pressure 
heart rate 8.1(17.6)[-I1 to 41] 6.3(16.6)[-18 to 34] 15.5(15.9)[-7 to 35] 0.75 
Mean maximum change in haemodynamic data recorded in the subsequent 
five minutes after induction 
systolic 
pressure 
-23.4(17.3)[-40 to 15] -23.3(21.4)[-42 to 27] -27.8(25.6)[-56 to 26] 0.68 
Kruskal- 
diastolic 
pressure 
-16.5(22.8)[-37 to 19] -I6.9(16.3)[-37 to 20] -19.5(19.3)[-40 to 25] 0.53 Walis statistic 
mean -14.9(22.1)[-34 to 20] -18.7(15.8)[-33 to 20] -20.9(19.3)[-42 to 24] 0.70 
pressure 
heart rate 13.0(28.3)[-33 to 45] _ 	0.6(22.1)[-24 to 34] 4.3(27.2)[-28 to 37] 0.48 
When al Finapres and Cardiocap data were compared there was a significantly 
greater fal in mean arterial pressure recorded by the Finapres (p=0.02) (Table IV.12). 
-13.4(26.9)[-59 to 47] -7.4(14.7)[-37 to 27] 0.43 
-10.8(22.4)[-54 to 34] -7.9(14.6)[-37 to 20] 0.62 Wilcoxon 
-13.4(24.9)[-53 to 43] -7.4(13.8)[-33 to 20] 0.38 
-2.5(30.4)[-78 to 59] 9.8(16.5)[-18 to 41] 0.06 
systolic pressure 
diastolic pressure 
mean pressure 
heart rate 
-34.7(34.2)[-91 to 70] -24.8(20.9)[-56 to 27] 0.23 
-24.3(28.1)[-67 to 59] -17.6(18.7)[-40 to 25] 0.12 Wilcoxon 
-31.2(31.5)[-76 to 66] -18.1(18.5)[-42 to 24] 0.02 
-5.4(39.4)[-78 to 72] 5.7(25.3)[-33 to 45] 0.23 
systolic pressure 
diastolic pressure 
mean pressure 
heart rate 
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TABLE IV.12 Comparison of haemodynamic data recorded by Cardiocap and 
Finapres during the first and subsequent five minutes after 
induction, for al patients. Data are mean (SD)[range], blood 
pressure (mmHg), heart rate (beats min-9. 
FINAPRES 	 I 	 CARDIOCAP CM-104 
(n = 25) 	 (n = 25) 
lp value I Statistical 
test 
Mean maximum change in haemodynamic data recorded at first minute after induction 
Mean maximum change in haemodynamic data recorded at subsequent five minutes after 
induction 
There was poor correlation between Finapres and Cardiocap recorded blood 
pressures during each time period because of the difficulty in matching exact times of 
measurement between the two instruments and the limited number of Cardiocap 
measurements possible within the time period (correlation coefficients 0.07, 0.14, 
0.16 and 0.17 for heart rate, systolic, diastolic and mean blood pressure), however 
there was less bias as more Cardiocap data became available for analysis during the 5 
minute period (corelation coeficients being 0.24, 0.37, 0.37 and 0.46). 
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DISCUSSION 
A combined comparison of the induction agents midazolam, thiopentone and 
propofol has not previously been reported in children. Propofol caused the greatest 
and most protracted fall in blood pressure after an induction dose of 2.5 mg kg - ' 
administered over 30 seconds into an antecubital vein. Thiopentone caused the least 
haemodynamic perturbation with the majority of changes being an increase in blood 
pressure. Midazolam administration was associated with a 15% decrease in mean 
arterial pressure (MAP) during the first minute after induction but the maximal 
decline in all pressures occurred at approximately 2 minutes when MAP was 20% 
below baseline values. Systolic, mean and diastolic blood pressures all declined by 
approximately 25% of baseline values following propofol administration, while 
pressures rose 0-5% following thiopentone induction. Propofol and thiopentone 
administration were associated with an average rise in heart rate of approximately 
10% above baseline values, while the increase in pulse rate in midazolam group was 
5%. 
Continuous monitoring of arterial pressure is often desirable (Prys-Roberts, 
1981, Kaplan, 1987) and is widely practised during anaesthesia, but arterial 
cannulation has associated morbidity (Slogoff et al, 1983, Runcie et al, 1989) and a 
noninvasive alternative is appropriate in ASA status I children undergoing minor 
surgical procedures. Although the Finapres demonstrates a wide variability in discrete 
values, it accurately reflects changes in pressure and was therefore able to display the 
haemodynamics in these children during the first minute following induction (Jones et 
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al, 1992b). The relatively slow sampling rate of the Cardiocap could not display these 
blood pressure changes during the early induction phase, and even though both 
instruments achieved more favourable correlation as more data points were acquired 
with time, this does not imply an improved ability to detect transient changes in blood 
pressure from a mean resting value. Blood pressure monitoring during the midazolam 
pharmacokinetic study discussed in the first section of this chapter was also 
performed with the Cardiocap. Recordings could only be made at 60 second intervals, 
and results showed an average increase of approximately 10% above baseline heart 
rate and blood pressure values. However, direct comparison between the two studies 
is inappropriate, as patients in the previous investigation were intubated. 
There are few comparative data reported in the literature. The wide variation 
of ASA class, clinical condition, anaesthetic technique and interpatient response 
makes comparative interpretation of these results difficult. Early reports demonstrated 
no haemodynamic difference between midazolam and thiopentone, but data were 
collected at 5 minute intervals (Holloway et al, 1982). A comparative study of the 
haemodynamic sequelae associated with midazolam and propofol induction have not 
been reported but there are a number of controlled studies comparing thiopentone and 
propofol in children (Miralchur, 1988, Purcell-Jones et al, 1987, Valtonen et al 1988). 
These studies showed the reduction of blood pressure to be less in the thiopentone 
groups compared to propofol but of less magnitude than the present study due to 
relatively infrequent data sampling. However, uncontrolled administration of propofol 
1-3 mg kg' over 10-30 seconds resulted in a decrease by more than 20% of baseline 
values in 48% of children who received halothane (Hannallah et al, 1991). Studies in 
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adults with ischaemic heart disease have demonstrated the relatively mild hypotensive 
effects of midazolam (Reyes et al, 1979, Schulte-Sasse et al, 1982, Heildcila et al, 
1984). Wilmot and colleagues found a 15% decrease in systolic blood pressure 
following propofol compared to a 0.7% decrease following a thiopentone induction in 
adults (Wilmot et al, 1993). Further factors confounding literature comparison are 
dose administered and rate of injection. Induction agents in this study were 
administered over 30 seconds. Unlike an increased dose of drug (Heildcila et al, 1984), 
fast rates of injection of propofol and midazolam do not appear to magnify the degree 
of hypotension associated with induction in ASA class I patients (Rolly et al, 1985,   
Alexander et al, 1992, Gillies and Lees, 1989). 
Significant cardiovascular depression in terms of a decrease in arterial pressure 
is well documented in the elderly (McCollum et al, 1986, Fahy et al, 1985, Mirakhur 
et al, 1987) and more recently in children (Mirakhur, 1988, Hannallah, 1 991) 
following propofol administration. A direct cardiac depressant effect, peripheral 
vasodilation and a reduction in ventricular preload have been proposed as likely 
causes of this hypotension (Coetzee et al, 1989). Decreasing diastolic pulmonary 
arterial pressure has been proposed as evidence of venous pooling after midazolam 
administration in adults, but a direct cardiac depressant effect has not been 
demonstrated in man in clinical doses (Massaut et al, 1983, Yip et al, 1992). Caudal 
anaesthesia in this series of children caused minimal haemodynamic disturbance and 
effectively abolished the usual increase in blood pressure associated with the 
commencement of surgery (Mirakhur, 1988). 
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This study demonstrates the clinically acceptable haemodynamic changes 
associated with midazolam induction in healthy children. Extrapolation of these data 
to other patient sub-groups is inappropriate. Care should be exercised if hypovolaemia 
is suspected because an exaggerated hypotensive response would be expected due to 
the venous pooling effect. Propofol administration in the presence of hypovolaemia or 
an otherwise compromised myocardium may result in severe, prolonged hypotension 
(Foex et a1,1991). On the other hand, a thiopentone induction undertaken in the 
manner described in this study should not be chosen, if an increased rate-pressure 
product is to be avoided. 
When administered according to the described protocol, thiopentone caused 
the least average haemodynamic change on induction and propofol administration was 
associated with the greatest fall in blood pressure for the longest duration, in patients 
who were ASA I and undergoing a minor surgical procedure. The cardiovascular 
depressant effect of midazolam was intermediate between thiopentone and propofol. 
V RECOVERY 129 
CHAPTER V 
RECOVERY FROM ANAESTHESIA 
Antagonism of the hypnotic efect of midazolam 	 130 
Recovery folowing induction of anaesthesia with 	 146 
midazolam, propofol or thiopentone 
V RECOVERY 130 
ANTAGONISM OF THE HYPNOTIC EFFECT OF MIDAZOLAM 
The previous chapters show that midazolarn may have a place as an induction 
agent. However a wide variability in response and difficulty in predicting an induction 
end-point results in large doses of midazolam (0.6 mg kg - ') being required for reliable 
induction of anaesthesia in children (Salonen et al, 1987; Gamble et al, 1981). There 
is therefore a consequent risk of prolonged post operative sedation. These risks can be 
reduced if the sedative effects of midazolam could be reliably antagonised and 
therefore provide greater safety in the recovery room and a more efficient usage of the 
operating suite. 
The clinical efficacy and safety of flumazenil in rapidly antagonising the 
sedative effects of benzodiazepines administered to facilitate gastroscopy (Sanders et 
al, 1989), bronchoscopy (Geller et al, 1986) and other minor investigative procedures 
has been well established. The dose of flumazenil required for reversal of 
midazolam-induced anaesthesia, the incidence of resedation or incomplete respiratory 
depression reversal in children has not previously been reported. 
Following midazolam induction of anaesthesia, this study assessed the 
efficacy of sedation antagonism in a flumazenil-treated and a placebo group, by 
comparing psychomotor performance with a modified post box toy test (Craig et al, 
1982), using each patient as his own control. 
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MATERIALS AND METHODS 
Forty ASA grade I Chinese children, aged 3-12 yr., undergoing circumcision for 
the treatment of phimosis were studied. Children were excluded from the study if 
there was a history of asthma or allergies, previous adverse anaesthetic experience, 
halothane anaesthesia within the previous month, hepatic, renal, respiratory, cardiac or 
haematological disease, developmental disability and age less than 3 yr. 
The day before surgery each child was familiarised with a post-box toy in the same 
manner as described in chapter III. The completion time of his best performance on 
seven attempts was recorded. On the day of surgery, the patients were premedicated 
with midazolam 0.5 mg kg1 (maximum dose 15 mg) and atropine 0.02 mg kg -1 by 
mouth 2 hr before operation. EMLA emulsion cream 2 g (lignocaine 25 mg and 
prilocaine 25 mg g-I) was applied to the dorsum of a hand. On arrival in the operating 
suite the children were assessed and recorded as agitated or crying, aware and 
apparently anxiety free, drowsy, or asleep but responsive to command (Jones et al, 
1990). 
In the operating suite, a 24-gauge cannula was inserted into a vein underlying the 
EMLA-pretreated area. Anaesthesia was induced with midazolam 0.5 mg kg - ' injected 
over 30 sec. Thereafter, anaesthesia was maintained with the patient breathing 
spontaneously 67% nitrous oxide and 1-3% halothane in oxygen via a Mapleson F (< 
25 kg) or a Mapleson A (> 25 kg) breathing system. A caudal injection of bupivacaine 
0.25%, 0.5 ml kg' was given to all patients, 6 minutes after induction agent 
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administration. Routine monitoring devices included an electrocardiograph, 
non-invasive arterial pressure recorder, pulse oximeter, capnograph and inspired 
oxygen concentration (Datex, Cardiocap). 
The duration of anaesthesia and the cardio-respiratory data during surgery were 
recorded. Three minutes after the child was transferred to the recovery room he was 
given 0.1 ml kg' of a blinded solution intravenously, followed by 0.05 ml kg' miff' 
until either the patient awoke or the 10 ml ampoule was exhausted. The blinded 
solution contained either fiumazenil 1.0 mg in 10 mls or saline as placebo. The 
volume of blinded solution injected, the eye-opening time (time from the 
commencement of blinded solution injection to spontaneous eye opening) and the 
time until the patient could identify himself were recorded. During the administration 
of the blinded solution, the systolic blood pressure, heart rate, respiratory rate, 
modified Steward coma scale (Robertson et al, 1977) and a structured observation 
score (Krane et al, 1987) were assessed and recorded each minute for 10 min and then 
each 5 minutes until the patient awoke. Any untoward effects occurring during the 
recovery period were noted. The child's behaviour and speed of reversal were 
considered together by an independent observer in the recovery room and were graded 
as excellent, good, moderate or poor, determined by the eye opening time of <6 mm, 
>6 < 12 min, >12 < 18 mm and >18 min respectively. 
Immediately the patient became cooperative he was encouraged to complete the 
post-box toy in the quickest possible time. The child was offered the post-box toy at 5, 
10, 30, and 60 min and 2, 4, and 18 hr after operation and his fastest completion time 
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on a single attempt recorded by the same investigator with all children at all 
assessment times. The child's best, preoperative, unmedicated performance was 
divided by the child's postmedication toy-completion time at each assessment point, 
and the data expressed as the post box toy completion ratio (PBTR). The induction 
injection site was inspected at 18 hr post operatively for evidence of erythema, pain or 
venous thrombosis. 
Statistical significance (p<0.05) was determined for patient characteristic data, 
duration of anaesthesia, awakening times, toy completion ratios and cardiorespiratory 
data comparison between the groups by analysis of variance. Premedication score and 
the efficacy of sedation antagonism was determined by Chi-square analysis (with 
Yates' correction) using the computer interactive statistical program MINITAB Tm . 
Correlation between awakening data and flumazenil administration was determined 
by calculating Spearman's rank correlation coefficient (adjusted for ties) and 
multivariate analysis of variance was determined using MRSPTM  (Bacon-Shone and 
Laurent, 1989). 
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RESULTS 
The premedication scores for the two groups were significantly different 
(p<0.02)(Table V.1). On arrival in the operating suite, three of the children in the 
flumazenil group were crying, whereas two of the placebo group were asleep but 
awoke on command. The mean duration of anaesthesia was 36(14) min in the 
flumazenil group and 33(11) min in the placebo group (p=0.4)(Table V.1). 
TABLE V.1 A comparison of the demograhic data, duration of anaesthesia and 
premedication score in the Flumazenil and placebo groups. Data are 
mean (SD) [range]. 
Flumazenil group 
(n = 20) 
Placebo group 
(n = 20) 
P 
value 
Age (yr) 7.2 [3.5-11.5] 6.9 [3.0-12.5] 0.9 
Weight (kg) 21.2 (5.1) [13.5-30.5] 22.7 (6.9) [15.5-44.0] 0.5 
Premedication score 
Asleep 0 2 
Drowsy 0 0 
Awake 17 18 
Crying 3 0 0.02 
Duration anaesthesia 
(min) 
36 (14) [17-80] 33 (11) [19-69] 0.4 
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The average dose of flumazenil administered to the children was 0.024 (0.019) 
mg kg'.' Fifty five percent of the children receiving flumazenil were given 10 mls of 
the blinded solution prior to awakening, compared to 100% of the placebo group. The 
time to eye opening and identification was significantly faster in the flumazenil 
treated patients (p<0.001). The effectiveness of anaesthesia reversal was qualitatively 
assessed by a second anaesthetist as superior in al but one of the flumazenil group 
(Figure V.1). 
<6 	 >6<12 	 >12<18 	 >18 Time (min) 
Excelent 	 Good 	 Moderate 	 Poor Independent Observer Reversal Rating 
FIGURE V.1 Effectiveness of the reversal solution assessed by the independent 
observer and by eye-opening time. (Spearman's corelation p<0.001). 
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The coma scores at 5 and 10 min were significantly higher in the flumazenil group 
(p<0.008 and p<0.001) (Table V.2). 
TABLE V.2 Awakening data after reversal. Data are mean (SD) [range] 
Flumazenil group 
(n = 20) 
Placebo group 
(n = 20) 
p 
value 
Volume of antagonist 
solution administered (m1) 
8.6 (1.7) [5.0-10.0] 10 (10) <0.001 
Time to eye-opening (min) 10.4 (6.6) [2-32] 37.9 (15.5) [21-76] <0.001 
Time to self-identification 
(min) 
17.1 (12) [6-52] 45.1 (15.5) [22-77] <0.001 
Assessment of antagonism 
Excellent 6 0 
Good 7 0 
Moderate 6 0 
Poor 1 20 <0.001 
Modified Steward Coma 
Scale at: 
5 min 4.5 (2.0) [2-9] 1.7 (0.9) [0-4] <0.001 
10 min 7.4 (2.1) [3-9] 1.9 (0.9) [0-4] <0.001 
There was a significant increase in the coma score associated with the 
lightening of consciousness within the flumazenil group between the 5 and 10 minute 
assessments but not in the placebo group (p<0.001). There was a significant increase 
in systolic arterial pressure on awakening during flumazenil administration compared 
to those patients receiving placebo (p<0.02) but other measured cardio-respiratory 
parameters were similar (Table V.3). 
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TABLE V.3 Changes in cardiorespiratory data during administration of the blinded 
solution. Data are mean (SD) [range]. 
• Flumazenil group 
(n = 20) 
Placebo group 
(n = 20) 
P 
value 
Ventilation frequency 
(b.p.m.) 
-1.2 (2.4) [-4 to 2] -0.3 (1.6) [-4 to 2] 0.1 
Systolic arterial pressure 
(mmHg) 
11.5 (12.7) [-11 to 35] 2.6 (10.8) [-11 to 31] 0.02 
Heart rate 
(beat miff') 
5.8 (29.4) [-44 to 66] -5.4 (16.4) [-45 to 22] 0.14 
The postoperative assessment of the children's mood on awakening is shown 
in Table V.4 and a comparison of post box toy completion ratios between the 
flumazenil and placebo groups is shown in Table V.5. 
TABLE V.4 Postoperative assesssment of the mood of the children on awakening. 
Postoperative assessment 
Flumazenil group 
(n = 20) 
Placebo group 
(n= 20) 
Toy refusal on awakening 3 5 
Crying on awakening 4 2 
Resedation 4 5 
Dissociated 1 0 
Antagonism assessed as 
satisfactory 17 0 
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TABLE V.5 Post-box toy completion assessment. Data are mean (SD) [range]. 
Assessable 
children 
at 
prescribed 
times 
Flumazenil 
group 
(n = 20) 
Assessable 
children 
at 
prescribed 
times 
Placebo 
group 
(n = 20) 
P 
value 
(1 ) ' (n) 
Fastest 
completion before 
operation (sec) 
20 (10) [8-52] 19 (8) [9-43] 0.9 
Completion ratio 
after operation 
10 min 12 0.34(0.08) [0.20-0.48] 0 
30 min 16 0.48(0.16) [0.17-0.74] 2 0.08(0.06) [0.04-0.13] <0.001 
60 min 16 0.49(0.15) [0.29-0.72] 12 0.18(0.10) [0.07-0.41] <0.001 
2 hr 18 0.57(0.20) [0.25-1.08] 15 0.47(0.17) [0.18-0.72] 0.14 
4 hr 20 0.69(0.32) [0.31-1.80] 20 0.65(0.19) [0.30-1.07] 0.95 
18 hr 20 0.84(0.25) [0.43-1.42] 20 0.84(0.26) [0.56-1.61] 0.8 
There was no difference between the two groups in the preoperative fastest 
completion time. However, during the first 2 hr postoperation, the flumazenil group 
performed significantly better than the placebo group. (p<0.02)(Figure V.2). 
n=18 n=16 	 n=16 
n=40 n=12 
0• log toy 
completion 
ratio -0.5 
0.5 
n=15 
-1 
flumazenil 
placebo 
10 	 30 	 60 	 120 	 240 	 1080 
-1.5 
n=12 
n=2 
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Time after administration of antagonist (min) 
FIGURE V.2 Log toy completion ratio at different times after administration of 
reversal solution. Data are mean (SD) [range], n = number of patients 
assessable at the prescribed times. 
Postoperatively one child in the flumazenil group appeared dissociated for a 
period of approximately 3 min. An equal number of children in both groups went back 
to sleep after eye-opening but al of the flumazenil treated children were easily 
awakened. None of the children who received flumazenil became resedated. There 
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were no significant differences between the placebo and flumazenil groups in relation 
to refusal to play with the toy or crying on awakening (Table V.4). There was a 
significant correlation between the volume of flumazenil- administered and the eye 
opening time (p<0.001) and the self-identification time (p<0.02). Multivariate 
analysis revealed no relationships of statistical significance. 
V RECOVERY 141 
DISCUSSION 
This study demonstrates that flumazenil effectively reverses the residual 
hypnotic effect of midazolam induction of anaesthesia in children. All aspects of 
arousal assessment during the first 2 hr postoperatively demonstrated flumazenil 
administration to be significantly superior to the placebo. The mean dose of 
flumazenil required to reverse the effects of midazolam was 0.024 mg kg'. The dose 
of flumazenil reported to awaken adult patients in whom midazolam was used to 
induce anaesthesia is approximately 0.5 mg (Wolff, 1988; Nilsson et al, 1988; Alon et 
al, 1987). In our children the dose administered ranged from 0.5 to 1.0 mg, and 55% 
of the flumazenil group were given a maximum dose of 1.0 mg before awakening. 
Despite the relatively large dose per kilogram of midazolam (0.5 mg kg') used to 
induce our children, reversal was achieved with a dose of flumazenil similar to that 
given to adults. However there was only a weakly significant relationship between 
body weight and the flumazenil dose required for awakening (p<0.04) and this 
showed no correlation with age. 
The onset and mode of action of midazolam depends in part on the 
relationship between the benzodiazepine receptor and the gamma-amino-butyric acid 
(GABA) receptor complex (Haefely, 1988). It has been demonstrated that the rate of 
chloride uptake by cultured neurons following midazolam administration is dose 
dependent (Thompson et al, 1988). The onset of anaesthesia with midazolam is faster 
in children (Salonen, 1987) and this may be due to a greater free midazolam 
concentration around the benzodiazepine receptor or a stronger affinity of midazolam 
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for the benzodiazepine receptor. Flumazenil reversal of benzodiazepine effects 
depends on the number of receptors occupied at the time of flumazenil administration 
(Haefely, 1988). It is postulated that the hypnotic effects of benzodiazepines occur 
with 60-90% receptor occupancy and anxiolytic properties at 20-30% receptor 
occupancy (Amrein and Hetzel, 1990). High doses of midazolam are therefore 
necessary for hypnosis but low doses of flumazenil convert the adult from the 
hypnotic to the sedated state (Amrein and Hetzel, 1990). It is surprising that there was 
no demonstrable relationship between the midazolam induction and flumazenil 
reversal dose. The variable response to midazolam and dose requirement of 
flumazenil in relation to body weight in children requires further investigation. 
Children may differ from adults in their pharmacokinetic profile, plasma protein 
binding, receptor occupancy rate, chloride channel opening frequency and the amount 
of GABA present at the GABA receptor (Thompson et a1,1988). 
This study shows that mean eye-opening and identification time was 
approximately three times as fast in the flumazenil group compared to the placebo 
group. One child in the flumazenil group did not awaken for 30 min after flumazenil 
administration and behaved in a manner identical to the placebo group. This may have 
been caused by an undue sensitivity to midazolam, resistance to flumazenil, unusual 
pharmacokinetic profile of these drugs or the unlikely event of there not being any 
active drug in that particular ampoule of blinded solution. The remaining flumazenil 
treated children awoke within 18 min of administration while the placebo treated 
group demonstrated a wide variation in awakening times from 20 to 77 min. The 
modified Steward coma scales at 5 and 10 minutes were statistically and clinically 
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superior in the flumazenil treated children. These children demonstrated a rapid 
regaining of consciousness and airway control compared to the placebo group who 
required vigilant observation for a long period of time. 
The observer assessed both the rate and quality of reversal (Table V.2). One 
child awoke after flumazenil adMinstration and remained uncommunicative in a 
dissociated state for about three minutes. The child then began to cry and appeared 
normal. All other flumazenil treated children awoke faster and were more 
co-operative, more rapidly calmed if distressed and if they went back to sleep they 
were easily aroused. Resedation after midazolam reversal in our children did not 
present the same problem as in adults (Whitwam, 1990). This may be because they 
were given a single intravenous dose of midazolam, their lack of concomitant disease 
and the absence of synergistic drugs (excluding halothane) for supplementation of 
anaesthesia. Interestingly, Geller and colleagues found that although flumazenil did 
not actually reverse halothane anaesthesia, it had a definite effect on hastening 
recovery as well as making it more pleasant (Geller et al, 1988). The reversal of the 
midazolam-induced deep hypnosis by careful titration of flumazenil appears to leave 
the anxiolytic properties of midazolam intact (Amrein et al, 1988). The placebo group 
in this study had a higher toy participation refusal rate, were irritable on awakening 
and were still somnolent after eye-opening. 
Vomiting, tremor and involuntary movements reported in adults after 
flumazenil administration (Haefely, 1988), were not seen in any of our children. The 
low incidence of vomiting may be explained by the brief duration of anaesthesia for 
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peripheral surgery in children, the midazolam premedication and a caudal epidural 
being preferred to narcotics for the provision of analgesia. 
The post-box toy completion time ratio provided a sensitive psychomotor 
assessment, a measure of the speed of recovery from anaesthetic agents and took into 
account the practice effect associated with performing a complex motor task. During 
the first 2 hr postoperatively the flumazenil group performed significantly faster when 
compared to the placebo treated children. This is in accord with previous clinical 
experience in adults (Raeder et al, 1988; Geller et al, 1988) and the pharmacokinetic 
profiles of midazolam and flumazenil (Hunkeler, 1988; Gerecke, 1983). At 4 hr the 
mean toy completion ratios were identical between the two patient groups and their 
performance was less than twice their preoperative fastest completion time. Despite 
the large dose of midazolam given at premedication and induction of anaesthesia, both 
the flumazenil treated and placebo treated children demonstrated a degree of recovery 
from anaesthesia which would allow them to be safely discharged home four hours 
postoperatively. 
The mean change in cardio-respiratory parameters from pre-reversal 
administration were small and similar in both groups of patients. The only statistically 
significant finding was a minimal increase in systolic blood pressure after flumazenil 
administration corresponding to the normal awakening, a similar finding to Geller and 
colleagues in adults (Geller et al, 1986). 
Flumazenil provides safe reversal of the residual sedative effects of midazolam 
induced hypnosis in children. Of particular benefit is the rapid return of consciousness 
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and upper airway control during early recovery and the preservation of the anxiolytic 
properties of midazolam anaesthesia. To provide a more complete understanding of 
the place of midazolam in clinical paediatric anaesthetic practice, a comparison of 
recovery following anaesthesia induced with other commonly used agents is 
_ 
necessary. 
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RECOVERY FOLLOWING INDUCTION OF ANAESTHESIA 
WITH MIDAZOLAM, PROPOFOL OR THIOPENTONE 
Paediatric surgery is being increasingly performed on a day-stay basis because 
of rising hospital costs. Ambulatory care also reduces displacement anxiety in the 
child and decreases exposure to nosocomial infection (Kapur, 1992). Circumcision is 
a suitable procedure for ambulatory surgery because the procedure is of short 
operative duration, has a low incidence of complications and postoperative pain relief 
can be easily and reliably provided (Hannallah and Epstein, 1991). Circumcision 
patients form a suitable subgroup for assessment of induction agents because the 
procedure permits delivery of a standard anaesthetic technique of relatively constant 
duration. Furthermore, the control of intra and postoperative pain with caudal 
anaesthesia allows assessment of anaesthetic recovery without pain confounding the 
data (Runcie et al, 1993). 
Recovery after anaesthesia is multidimensional (Zuurmond et al, 1989). Of 
particular interest in ambulatory care is the immediate recovery of protective reflexes 
following surgery and a later return to "street fitness" prior to discharge from the 
ward. A variety of tests of psychomotor performance, cognition and memory have 
been used to assess recovery in adults (Cashman and Power, 1989) but patient 
compliance makes assessment of psychomotor recovery difficult in children. The aim 
of this study was to evaluate two tests of recovery and describe any relative 
advantages following induction with either thiopentone, propofol or midazolam, in 
children undergoing circumcision. 
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MATERIALS AND METHODS 
Thirty ASA grade I Chinese children, aged 4-12 yr, undergoing circumcision 
for treatment of phimosis were investigated. The study was approved by the Faculty 
of Medicine Ethics Committee (The University of Hong Kong) and written informed 
consent obtained from the parents. Children were excluded from the study if they 
failed to conform with the criteria as described in Chapter II. The day prior to 
surgery, each child was familiarised with a post-box toy (PBT) and the completion 
time of his best seven attempts recorded (Jones et al, 1991). The children also 
underwent a Wechsler intelligence scale (WISC-R) coding performance assessment, 
matched for race (The Hong Kong Wechsler Intelligence Scale for Children, 1981). 
Long term memory recall was assessed by a simplified Williams test (Williams, 
1968), whereby the children were shown a simple picture of a school scene for 30 s 
and asked to name and remember five depicted objects. The following morning before 
premedicant administration, the child was asked to recall the objects from the picture 
shown to him the previous evening and scored according to his degree of success. 
On the day of surgery, EMLA emulsion cream 2 g (lignocaine 25 mg g"' and 
prilocaine 25 mg g1 ) was applied to the cubital fossa of the non-dominant arm 2 hr 
before premedication with midazolam 0.5 mg kg - ' (maximum dose 15 mg) and 
atropine 0.02 mg kg"' by mouth. On administration of the premedicant, a 23-gauge 
cannula was inserted into a vein underlying the EMLA-pretreated area. Prior to 
transfer to the operating suite the child was again shown another simple picture of a 
family scene for 30 sec and asked to name and remember five depicted objects. On 
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arrival in the operating suite, all children were assessed by the same attendant 
anaesthetist as agitated or crying, aware and apparently anxiety free, drowsy, or asleep 
but responsive to command (Jones et al, 1990). The awake children were then asked if 
they felt frightened and if so, to specify the cause of their anxiety. Routine monitoring 
devices included an electrocardiograph, intermittent non-invasive arterial pressure 
recorder and pulse oximeter (Datex, Cardiocap CM-104). The children were randomly 
allocated to receive either propofol 2.5 mg kg" 1 (Aun et al 1992; Patel et al 1988), 
midazolam 0.5 mg kg"' (Salonen et al, 1987) or thiopentone 4.0 mg kg"' (Sorbo et al, 
1984) intravenously over 30 sec. Thereafter, anaesthesia was maintained with the 
patient breathing spontaneously 67% nitrous oxide and 1% halothane in oxygen via a 
Mapleson F (< 25kg) or a Mapleson A (>25 kg) breathing system. A caudal injection 
of 0.25% bupivacaine 0.5 ml kg"' was administered to all children. 
The duration of anaesthesia and cardio-respiratory data during surgery and 
recovery were recorded. The time to spontaneous eye opening and self-identification 
were recorded by an anaesthetist blinded to the agent used for induction of 
anaesthesia. The child's co-operation, mood and sedative level were recorded were 
recorded on awakening using a structured observation score (Krane et al, 1987) and 
the modified Steward coma score (Robertson et al, 1977), and a 1 ml blood sample 
taken. The blood samples were collected into tubes containing lithium-heparin 
(Sarstedt LH/5) for measurement of the plasma or whole blood concentration of the 
induction agent. As soon as the child became co-operative he was encouraged to 
complete the post-box toy in the quickest possible time and the WISC-R coding 
performance was scored. At each of the blood collection times the child was offered 
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the post-box toy and his fastest completion time at a single attempt recorded. The 
child was also asked to complete the WISC-R coding test within 2 min and scored 
according to his performance. The raw WISC-R data was then scaled to produce score 
equivalents adjusted for the child's age. The child's best, preoperative, unmedicated 
performance was divided by the child's postmedication performance at each 
assessment point for both the PBT and WISC-R, and the data expressed as the post 
box toy completion ratio (PBTR) and WISC-R scale ratio. The child was offered the 
toy and coding test at 60, 120 ,180 and 240 min after awakening and a 1 ml blood 
sample was taken immediately after completion of each psychomotor assessment. 
Four hours after awakening the child was asked to recall 5 objects from the picture 
shown to him immediately preoperatively and scored according to his degree of 
success. Each assessment of psychomotor function was performed by the same 
investigator on all occasions in all patients. 
Whole blood propofol concentrations, midazolam and thiopentione plasma 
concentrations were determined employing an HPLC technique as described in 
Chapter II. 
Statistical significance (p < 0.05) was determined for the three induction agent 
groups for demographic and awakening data by analysis of variance using the 
Newman-Keuls test for post-hoc comparisons. Pearson product moment correlation 
was used to determine any relationship between postoperative awakening and duration 
of anaesthesia, PBT and WISC-R ratios, and, drug concentration and psychomotor 
test. A significant difference between the coma scores at each postoperative 
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assessment for the three induction agents was determined using the Kruskal-Wallis 
statistic and chi-square analysis (with Yates' correction) was used to analyse the 
mood data. Memory recall before and after induction in the same individuals was 
analysed using Wilcoxon signed-rank test. Data computation was performed using the 
computer interactive statistical program CSS:StatisticaTM (Complete Statistical 
System, 1991). 
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RESULTS 
There was no significant difference between the midazolam, propofol, and 
thiopentone groups when comparing patient characteristics, anaesthetic duration and 
psychomotor assessment by WISC-R or post box toy (PBT) on the evening before 
surgery or after midazolam premedication (Table V.6). One child presented to the 
operating suite asleep and the remainder were awake and apparently anxiety free. No 
child required any post operative analgesic supplementation. 
TABLE V.6 Demographic data, anaesthetic duration and preinduction assessment 
in the three induction agent groups. Data are mean (SD) [range]. 
Midazolam 
(n = 10) 
Propofol 
(n = 10) 
Thiopentone 
(n = 10) 
p 
value 
Statistical 
test 
Age (yr) 7.2(2.5)[4-11] 7.4(2.0)[5-11] 7.4(2.3)[5-12] 0.97 general 
anova 
Weight (kg) 21.4(4.5)[15-27] 23.9(5.3)[16-33] 23.7(7.4)[17-17] 0.57 
Anaesthetic 
duration (min) 
35.5(6.0)[27-48] 29.9(4.6)[25-39] 32.5(7.6)[21-47] 0.15 general 
anova 
Preoperative 
state 
asleep/drowsy 0 1 0 
awake 10 9 10 
crying 0 0 0 
Testing the association between anaesthetic duration and the time to 
self-identification in all patients revealed a correlation coefficient of 0.17 (Table V.7). 
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TABLE V.7 Postoperative awakening and psychomotor performance data in the 
three induction agent groups. Data are mean (SD) [range]. * r value = 
correlation coefficient for the relationship between postoperative 
self-identification time and the duration of anaesthesia for each 
induction agent. 
Midazolam 
(n = 10) 
Propofol 
(n = 10) 
Thiopentone 
(n = 10) 
p value Statistical test 
Eye opening 
time (min) 
31.8(10.8)[21-57] 21.9(7.6)[10-33] 25.2(7.0)[16-36] 0.05 General anova 
Identification 
time (min) 
36.3(10.0)[24-57] 22.9(8.1)[10-34] 27.0(7.7)[16-40] 0.01 General anova 
Newman-Keuls 
Postoperative 
PBTR 
Awake 0.2(0.2)[0.1-0.6] 0.4(0.2)[0.1-0.8] 0.4(0.2)[0.2-1.0] 0.03 General anova 
60 0.5(0.3)[0.1-0.9] 0.8(0.2)[0.3-1.2] 0.6(0.2)[0.3-0.8] 0.18 Newman-Keuls 
120 0.8(0.2)[0.5-1.1] 0.7(0.2)[0.5-1.2] 0.8(0.2)[0.6-1.2] 0.34 
180 0.9(0.2)[0.4-1.1] 0.9(0.2)[0.6-1.3] 0.8(0.1)[0.6-0.9] 0.83 
240 0.9(0.2)[0.7-1.4] 0.9(0.2)[0.6-1.1] 0.9(0.2)[0.6-1.2] 0.63 
Postoperative 
WISC-R 
scale R 
Awake 0.1(0.1)[0.1-0.2] 0.5(0.4)[0.1-1.0] 0.4(0.2)[0.1-0.7] 0.02 General anova 
60 0.6(0.3)[0.1-1.0] 0.7(0.4)[0.1-1.0] 0.6(0.4)[0.1-1.0] 0.44 Newman-Keuls 
120 0.9(0.2)[0.3-1.0] 0.9(0.4)[0.1-1.2] 1.0(0.2)[0.7-1.5] 0.60 
180 1.0(0.1)[0.8-1.1] 1.0(0.2)[0.7-1.3] 1.1(0.2)[0.9-1.6] 0.50 
240 1.0(0.1)[0.8-1.1] 1.1(0.1)[0.9-1.3] 1.1(0.2)[0.9-1.6] 0.32 
*r value 0.36 0.22 0.56 Pearson product 
moment 
correlation 
The midazolam group of children took a significantly longer time to identify 
themselves compared to both the propofol (p=0.005) and thiopentone groups 
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(p=0.02), however there was no difference between the groups in the time to eye 
opening (p=0.05). The propofol group were able to identify themselves 13 minutes 
faster than the midazolam group. On awakening, both PBT and WISC-R ratios were 
significantly lower in the midazolam group compared to propofol (p=0.03 and 0.01) 
and thiopentone groups (p=0.01 and 0.02). However, after 1 hr, there was no 
statistical difference between the groups with either method of assessment. Most 
children had recovered to 80% of their best recorded performance four hours after 
awakening, irrespective of the induction agent administered (Figure V.3). 
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FIGURE V.3 Postoperative drug concentrations of the induction agents midazolam, thiopentone and propofol and hourly assessments of 
psychomotor recovery using the PBT and WISC-R ratios. (n=10). 
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The Pearson product moment correlation testing the association between PBT and 
WISC-R ratios for al psychometric data was 0.7 (Figure V.4). 
-1.25 	 -1 	 -0.75 	 -0.5 	 -0.25 	 0 	 0.25 	 0.5 
log PBT ratio 
FIGURE V.4 Pearson product moment correlation testing the association between 
PBT and WISC-R ratios for al psychometric data. (n=30). 
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FIGURE V.5 Pearson product moment correlation testing the association between 
serum midazolam concentration and PBT ratio. (n=10). 
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FIGURE V.6 Pearson product moment correlation testing the association between 
serum midazolam concentration and WISC-R ratio. (n=10). 
The correlation coefficients between PBT and serum midazolam (Figure V.5), 
thiopentone and blood propofol concentrations were 0.67, 0.38 and 0.37 respectively. 
WISC-R testing and serum drug concentrations showed correlation coefficients for 
midazolam (Figure V.6), propofol and thiopentone of 0.78, 0.63 and 0.52 
respectively. 
Mood score, incidence of sleep and coma score analysis showed no significant 
differences between the three drug groups, however memory recal after anaesthesia 
was significantly beter than after natural, unmedicated sleep, although the 
performance error rates in al groups were smal (Table V.8). The mean number of 
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errors in preoperative overnight memory recall for all three groups of children was 
2.0(1.6)[1-6], that of postoperative errors was 1.2(0.6)[1-4]. Thiopentone group 
showed significant less number of recall errors postoperatively (p=0.02). In the 
propofol and midazolam groups, there was no statistical significant difference in the 
number of preoperative and postoperative memory recall errors (p=0.27 and 0.14 
respectively). 
TABLE V.8 Mood, sedation and memory data for the three induction agent 
groups. Data are mean (SD) [range  
Midazolam 
(n = 10) 
Propofol 
(n = 10) 
Thiopentone 
(n = 10) 
p value Statistical 
analysis 
Co-operation 
refused 1 0 0 Chi-square 
willing 9 10 10 0.36 analysis 
Sleep assessment 
aleep 4 3 2 Chi-square 
awake 6 7 8 0.71 analysis 
Mood score 
1-3 = happy 7 9 8 Chi-square 
4, 5= unhappy 3 1 2 0.61 analysis 
Postoperative 
Coma Score t 
Awake 5.9(1.2)[4-8] 6.1(1.3)[4-8] 6.2(1.9)[3-9] 0.9 
7.4(1.2)[5-9] 8.1(1.2)[6-9] 6.9(2.4)[3-9] 0.42 
120 min 8.6(1.0)[6-9] 8.5(1.1)[6-9] 9.0(0.0)[9-9] 0.33 Kruskal-Wallis 
180 min 9.0(0.0)[9-9] 8.9(0.3)[8-9] 9.0(0.0){9-9] 0.37 statistic 
240 min 8.8(0.6)[7-9] 9.0(0.0)[9-9] 9.0(0.0)[9-9] 0.37 
No. of recall Kruskal-Wallis 
errors overnight 2.2(2.0)[1-6] 1.4(0.7)[1-3] 2.3(1.8)[1-6] 0.43 statistic 
No. of recall Kruskal-Wallis 
errors post- 
operatively 
1.2(0.4)[1-2] 1.3(1.0){1-4] 1.1(0.3)[1-2] 0..80 statistic 
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DISCUSSION 
The time taken for the child to identify himself was independent of the 
duration of anaesthesia and predominantly influenced by the induction agent 
administered, although identification after thiopentone administration was more 
closely associated with anaesthetic duration than midazolam or propofol. Children 
awoke more quickly after propofol compared to thiopentone and midazolam however 
this only reached statistical significance when self identification time was compared 
between the three groups and not the time of eye opening (p=0.05). This illustrates the 
greater sensitivity of cognitive awareness compared to the more simple physical tests 
of awakening which presumably require greater patient numbers to demonstrate 
significance and prevent a type II statistical error. Furthermore, time to eye opening is 
not related to time of attaining hospital discharge criteria in children following 
anaesthesia with sevoflurane (Sarner et al, 1995). 
Psychomotor performance on awakening was worst in the midazolam group 
but 1 hour later there was no statistical difference between the groups, and by 4 hours 
all groups were virtually identical in performance with both tests. Psychomotor 
improvement paralleled drug redistribution and metabolism but some children were 
able to perform at unmedicated levels after 1 hour, despite significant induction agent 
blood levels. The narrower range of awakening drug concentrations in patients 
induced with midazolam may be associated with greater predictability of recovery, 
whereas like other workers, this study demonstrated that the awakening blood 
concentrations of thiopentone and propofol varied widely (Kay et al, 1985). The more 
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gradual decline of midazolam levels produces more somnolent patients in the early 
postoperative phase, which under, some circumstances may be advantageous. All 
patients could be discharged 3 hours after awakening having achieved 90% of their 
unmedicated psychomotor performance, confirming the work of Runcie and 
colleagues (Runcie et al, 1993). 
The association between serum midazolam levels and PBTR and WISC-R 
ratio was stronger than both propofol and thiopentone in the postoperative period, 
inferring a closer relationship between blood levels and cerebral effect and therefore a 
more predictable pattern of postoperative awakening in children induced with 
midazolam. Coma score and mood assessment lacked both specificity and sensitivity 
in recovery assessment and were not helpful in differentiating between the induction 
agents. This was disappointing as previous work discussed in Chapter IV had shown 
that children receiving midazolam and flumazenil appeared calmer and more 
compliant in accord with the anxiolytic properties of the drug and serum levels (Geller 
et al, 1988). 
Despite the specific effect of benzodiazepines on recall and recognition 
components of memory which rely on personal experiences within specific contexts 
(Ghoneim and Mewaldt, 1990), memory recall of a picture card viewed 2 hours after 
oral administration of midazolam and anaesthesia, was better than memory recall after 
unmedicated, natural sleep. This finding is probably not clinically meaningful as the 
sample groups were small, the error rate in one child could have a disproportionate 
influence on the group as a whole and like Twersky and colleagues we found a higher 
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number of false positive recall responses in children less than six years (Twersky et al, 
1993). It is inappropriate to covary emeory scores for age and false positive 'guess' 
responses because of the small uncontrolled (no placebo) sample groups, the 
descriptive nature of this part of the study and the lack of age based norms. 
Furthermore the serum midazolam levels were not in the adult amnesic range 2 hours 
after oral administration and the children may have experienced heightened awareness 
in the unfamiliar operating theatre environment (File and Lister, 1982). 
This study has demonstrated the suitability of the post box toy ratio for 
measurement of psychomotor performance in children because of its simplicity and 
ease of use in the clinical environment, although it suffers the limitations of 
familiarity as do other tests of this type. Rapid recovery of cognitive function in the 
recovery room is best achieved with propofol but 4 hours after awakening all children 
were equally suitable for discharge irrespective of the induction agent administered. 
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Midazolam possesses many of the properties of an ideal anaesthetic agent but 
introduction of the drug into paediatric anaesthetic practice requires an evaluation of 
its suitability in children. The objectives of this thesis were 
• to investigate the effects of midazolam on psychomotor function and oxygen 
desaturation when administered as a premedicant in children 
• to describe the pharmacokinetic disposition of rnidazolam, flumazenil and 
propofol in children 
• to investigate the induction pharmacodynamics and psychomotor recovery 
following administration of midazolam in elective paediatric anaesthetic 
practice, and compare these data with midazolam antagonised with flumazenil, 
propofol and thiopentone. 
Premedication 
The incidence of oxygen desaturation episodes during the 2 hours immediately 
before induction of anaesthesia, following administration of midazolam 0.5 mg kg - ' 
orally, was low and of minimal clinical significance (Jones et al, 1993b). Neither the 
time spent desaturated, the degree of desaturation or the frequency of desaturation 
episodes was significantly different from normal, unmedicated sleep. Furthermore, the 
incidence of desaturation after midazolam was not significantly different to that found 
after administration of another commonly prescribed premedicant, pethidine. The 
possibility exits for concluding that midazolam has no effect on oxygen saturation, 
when in reality it does. In drawing conclusions, the small sample size and data 
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variability described in this thesis risk Type II error and should be born in mind when 
interpreting data where no difference was demonstarted with a beta error of < 0.05. 
However, computerised aquisition of large volumes of data may result in 
unmanageable data sets. For example, with respect to the oxygen saturation data, a 
sample size of 1100 per group would be required to give a probability of 0.8 of 
rejecting the null hypothesis of equal means if the alternative holds (Dallal, 1990). 
Orally administered midazolam in this dose was associated with no dangerous 
effects in the small samples investigated and is effective without the unwanted effects 
associated with higher dosage that have been reported by other workers (McMillan et 
al, 1992). The peak desaturation episode incidence did not coincide with expected 
peak serum concentrations of midazolam suggesting that any depressant effect on 
ventilation was independent of serum levels. This is the only study reported to date 
which has attempted to filter out artefactual desaturation data associated with probe 
movement and calls into question the findings of other studies which have drawn 
conclusions directly from raw data (de Santos et al, 1991, Roelofse and de-V-Joubert, 
1990). 
Oral midazolam resulted in peak serum levels 60 minutes after administration 
however other workers have' described peak sedation at 30 minutes following the 
same oral dose of midazolam (Weldon et al, 1992) and the maximum decline in 
psychomotor performance also occurred at 30 minutes in this study. The improved 
psychomotor performance at 60 minutes may be due to a "test-retest' practice effect, 
despite increasing serum concentrations of midazolam. An alternative explanation 
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may be that the rate of increase of midazolam concentration rather than its absolute 
value, has a maximal agonist effect on the benzodiazepine receptor-modulated 
chloride channels, resulting in a coincident maximal decline in psychomotor 
performance. The benzodiazepine/GABA receptor complex requires a minimum 
amount of GABA to be present for a benzodiazepine to be effective (Thompson et al, 
1988), and the basal state of the receptors in these children is unknown. The incidence 
of sleep was uniformly distributed throughout the two hour assessment period and 
was unrelated to serum drug levels. The majority of children presented to the 
operating room awake, with a quiet and cooperative mood, and on specific 
questioning, 66% of the children denied feeling frightened. The measured serum 
midazolam levels at 2 hr remained in the anxiolytic range described for adults 
(Dundee et al, 1984) and the assessed mood of the children described in this thesis, 
reinforces the superiority of the drug to placebo (Parnis et al, 1992). Preinduction 
serum midazolam concentrations were below those associated with anterograde 
amnesia, and retrograde amnesia was not demonstrated. 
Induction 
Midazolam is the only hypnotic induction agent that has a specific antagonist. 
The disposition of midazolam in children has been studied by a number of workers 
(Salonen et al, 1987; Payne et al, 1989; Rey et al, 1991) but the contemporaneous 
disposition of flumazenil in children has not previously been reported. In contrast to 
other workers (Tolia et al, 1991; Salonen et al, 1987; Payne et al, 1989), clearance of 
midazolam from the plasma was best described by a tri-exponential function because 
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of an increased sampling rate during the early redistribution phase and better 
definition of the elimination phase. Differences in pharmacokinetic data can be 
explained by the different fat distribution in Chinese children, the differing anaesthetic 
techniques and the age related variation in metabolism of benzodiazepines (Greenblatt 
et al, 1984). 
Flumazenil pharmacokinetic data were suitably interpreted by 
non-compartmental analysis because of the combined bolus and infusion 
administration regimen used to reverse midazolam. The steady state volume of 
distribution of flumazenil was about half that reported in adults, clearance values were 
similar and the terminal half-life was about 35 minutes (Klotz et al, 1984). The small 
volume of distribution and high clearance of flumazenil resulted in a terminal half-life 
which was one third that of midazolam. These findings provide some insight into the 
resedation controversy (Ashton, 1985). Resedation was presumably due to the residual 
mild sedative effects of midazolam being relatively unopposed by flumazenil. The 
decline in serum flumazenil concentration was paralleled by a concomitant decline in 
serum midazolam concentration, resulting in the children being easily aroused from 
sleep. 
The clinical efficacy of flumazenil in rapidly antagonising the sedative effects 
of midazolam induction in children had not been previously reported. The flumazenil 
treated children were significantly more orientated, co-operative and demonstrated 
better comprehension when compared to the placebo group. The children in this study 
were both premedicated and induced with midazolam, and all but one child awoke 
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within 21 minutes of the termination of anaesthesia. This compares very favourably 
with the children in the propofol pharmacokinetic study. The benzodiazepine receptor 
is a positive modulatory subunit of the gamma-amino-butyric acid (GABA) receptor 
complex (Amrein and Hetzel, 1990). Flumazenil antagonism of benzodiazepine 
effects depends in part, on thenumber of receptors occupied at the time of flumazenil 
administration and also the amount of GABA present at the GABA receptor (Haefely, 
1988). Neither these receptor models nor the reciprocal dose dependent effects of 
midazolam and flumazenil fully explain the variable dose response to midazolam and 
the variable dose requirement of flumazenil in relation to body weight in children, and 
this requires further investigation. Recommendations to use an antagonist with a 
shorter half-life than a parent compound must be made with reservation, especially 
when the response to the agents is variable. 
Propofol is the latest intravenous induction agent to be introduced into clinical 
practice and its reported rapid postoperative recovery prompted a comparison with a 
midazolam induction technique antagonised by flumazenil. However, 
pharmacokinetic data for propofol were incomplete in children and a meaningful 
comparison required that propofol first be investigated in a similar study population. 
The blood clearance of propofol was best described by a tri-exponential function. The 
large total body clearance and relatively small volume of distribution for a highly 
lipophilic drug resulted in a relatively fast elimination of propofol from the blood in 
children which was constrained by the slow return of propofol to the blood from the 
deep compartment. Differences from other propofol pharmacokinetic studies may be 
attributable to the different anaesthetic techniques employed, different types of 
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surgical procedure, the different sample collection times and the small patient 
populations examined (Valtonen et al, 1989; Saint-Maurice et al, 1989). The higher 
clearance and smaller steady state volume of distribution results in a T y: which was 
half, and a Ty,13 which was 66% that of propofol. Children in the pharmacokinetic 
study of propofol awoke within 30 minutes of the termination of anaesthesia but 
unfortunately these data were confounded by the long half-life of the premedicant 
trimeprazine. Furthermore, compartmental kinetic analysis, although standard 
practice, has limited direct clinical application because of the between subject 
variability for many of the parameters. 
A number of authors have compared the induction characteristics of propofol 
and thiopentone but there have been no comparative studies with midazolam in 
children (Runcie et al, 1993; Mirakhur, 1988). Propofol caused the greatest and most 
protracted fall in blood pressure after an induction dose of 2.5 mg kg -1 administered 
over 30 seconds into an antecubital vein. Thiopentone 4.0 mg kg-1 caused the least 
haemodynamic perturbation and midazolam 0.5 mg kg' was associated with a 
maximum decrease of 20% below baseline mean arterial pressure. Exclusion criteria 
for this study were designed to provide a homogeneous patient sample who would 
permit comparison of the induction agent effect on haemodynamics, independent of 
patient pathology. The relatively slow sampling rate of the Cardiocap could not 
display the acute haemodynamic changes seen with the noninvasive continuous 
monitoring of the Finapres during the early induction phase. Although the Finapres 
demonstrates a wide variability in discrete values, it accurately reflects changes in 
pressure (Jones et al, 1992b). Thiopentone provided smooth induction conditions in 
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nearly all children, with an occasional brief period of apnoea being the only side 
effect. Propofol induction was associated with pain and semi-purposeful arm 
movement in 50% of patients, while the end point of midazolam induction was less 
distinct than with the other two agents. 
Recovery 
Recovery after anaesthesia is multidimensional (Zuurmond et al, 1989). Of 
particular interest in ambulatory care in children is the immediate recovery of 
protective reflexes following surgery and the later return to "street fitness" prior to 
discharge from the ward. Sophisticated tests of psychomotor recovery are not practical 
in children and a simple, practical, repeatable assessment of suitability for discharge 
would be useful. Work in this thesis showed the post box toy ratio to be equally as 
sensitive and specific as the Wechsler intelligence scale ratio-R (matched for race), for 
the assessment of psychomotor recovery, however the latter assessment was more 
difficult to perform, particularly in younger children. The residual influence of 
anaesthesia diminished discrimination between the physical and cognitive 
components of each test, resulting in an improvement in their correlation. 
Psychomotor performance on awakening was worst in patients induced with 
midazolam but not antagonised by flumazenil. At one hour postoperatively there was 
no statistical difference in psychomotor performance between midazolam, propofol 
and thiopentone induced children and at 4 hours all children were equally suitable for 
discharge irrespective of the induction agent administered. Awakening was fastest in 
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the midazolam children given flumazenil and was equal in quality to the propofol 
group. 
This thesis confirms the hypothesis that midazolam is a suitable and effective 
premedicant in elective paediatric anaesthetic practice but its acceptance could be 
improved if the taste of the drug was more efficiently disguised. As an intravenous 
induction agent, the hypnotic onset of action of midazolam reaches a peak 2-3 minutes 
after administration in children, unlike propofol and thiopentone which produce 
hypnosis in one arm-brain circulation time. This relatively slow induction time and 
indefinite end point limit the application of midazolam as the sole-agent for induction 
of anaesthesia, however recent work in adults has demonstrated the synergistic effects 
of pretreatment with midazolam prior to induction with another agent (Tverskoy et al, 
1988; Short and Chui, 1991). The place of coinduction and induction agent synergism 
in children, requires further investigation. There are inherent risks in using an 
antagonist with a shorter half-life than the parent compound and therefore patient 
observation must be continued for an appropriate duration. 
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CONCLUSIONS 
1. Midazolam, in a dosage of 0.5 mg kg - ', is a satisfactory oral premedicant in 
children less than 30 kg. 
2. Oral administration of 0.5 mg kg - ' midazolam in the children studied did not 
result in increased incidence of episodic arterial oxygen desaturation above 
that accompanying normal, unmedicated sleep. 
3. Oral administration of 0.5 mg kg' midazolam as a premedicant in children is 
not associated with a delay in postoperative recovery or discharge from the 
ward. 
4. Midazolam has a faster clearance and shorter elimination half-life than 
propofol in healthy Chinese children. 
5. Mild resedation occurs following antagonism of an induction dose of 
midazolam with flumazenil in healthy children because the terminal half-life 
of flumazenil is one third that of midazolam. 
6. In recommended clinical doses, propofol induction is associated with 
hypotension which is more severe in degree and duration compared to 
midazolam and thiopentone, in healthy children undergoing minor surgery. 
7. Midazolam antagonised with flumazenil produced a rapid immediate recovery 
of consciousness, equivalent in quality to propofol. 
8. Two hours postoperatively there was no significant difference in psychomotor 
performance, irrespective of which induction agent was administered and all 
patients were assessed as "street-fit" for discharge from the ward at four hours. 
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9. The post box toy ratio was not only as effective as the Wechsler intelligence 
scale ratio in assessing postoperative psychomotor function, but was more 
easily performed in children.. 
10. Accurate interpretation of pulse oximetry profiles require prior exclusion of 
• 
artefactual data. 
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,!1" 	 ,7 Tr; ;•;. 	 .:17; 	 ;-j 	 "i";- 
INFORNED CONSENT FOR CIRCUMCISION PATIENTS AT DCH 
= g 	 t 	 1F1 g ry nane is Dr. Jones. 1 an a Senior Lecturer in Anaesthesia at the Hong Yong University. 
••• cr. - 	 I 	 EE 	 — • -• 	 • !; • - 	 • 	 z.7 	 .72 - 	 24 A\ X 	• 4 ‘4 	= 	 ( = , 
We would like to measure by repeated blod sanpling through a venous canula which is left 
! 	 • -.1 
."11 	 14 4!".1 
in place for 24 hours, the rate of clearance fro n the blod of one of the drugs which is 
used to anaesthetise your child. A total of 7 Is of Blood only will he taken. There is 
only mininal chance of side effects or infection occuring. . 
=- 	 1J 
I shal be present at al the anaesthetics adninistered. Your child wij be nonitored with = tg f: 	 r 1\ 3• • 
sophisticated nonitoring equipment throughout the operation to ensure that al precautions 
have ben caried out. 
: 	 , 	 = 
CONSENT 
	 hereby consent for my child 	  —to be placed in 
	
Jy 	 - e= 	:7 ••-• = 
the trial described above and fuly understand the procedure. I also understand that 
FE 	 i= 	 :f; t: 	 tT-41 7i2 1'7,7; q • . 
this trial wil he conducted with al the Precaution and safety that would be aplied 
77 F; 77 	 Z.1.4 iF 
to any other procedure, and I nay chose to withdraw my child fron the trial at any tine, 
without afecting the usual treatnent, 
r 77 	 Ti 	 2 
SIGNED THIS 	 DAY OF 195 	 nUCHESS OP YENT HOSPITAL Parent Signature 	  
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APPENDIX B 212 
INFORMED CONSENT FOR CIRCUMCISION PATIENTS AT DCH 
I! g  
My name is Dr. Jones, I al a Senior Lecturer in Anaesthesia at the Hong Xong University. 
1; I 	 g 	fi g 	M 1' 	'JP 	ti "fi 1 	 t 	g 
We would like to measure the efectivenes of a nel4 drug used to wake children up after 
7.1~ J z 5E 4 	 1' YL., 	 R 1 	 P 	 gi 
anaesthesia. At the end of the operation, your child wil be given either saline 
g 4; 2! 	7/4K 
intravenously or the new drug, and the time taken to complete a simple gase measured, 
g g f! 	 It g 	 * A 0 fi t4 ti 	 g 
I shal be present at al the anaesthetics adsinistered. Your child wil'be'monitored with 
El sophisticated monitoring equipment throughout the operation to ensure that al precautions 
have ben caried out. 
19 .6 
CONSENT 
.7Z. 44. 61 	 AA 04 
i. h 	 c.) T 
	 hereby consent for ny child 	  ,,to be placed in 
1.7T g -p•1 
the trial described above and fuly understand the procedure. I also understand that 
f. 	 4 t '01 5,2 	 .1‘ 	 t). F A ft 	 r-7 
this trial wil be conducted with al the precaution and safety that would be aplied 
F ti1i 7t: I 
to any other procedure, and I may chose to withdraw 4y child from the trial at any tine, 
without afecting the usual treatnent, 
E 
:•?s .1%( r".:7 	 ct.1. A , jr. 0 	9, 	t ;1 r 
SIGNED THIS 	 DAY OF 198 AT DUCHES OF ENT HOSPITAL Parent Signature 
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APPENDIX C 
Psychometric data 
Cl - C6 	 Conscious state & mood 	 215 
C7 - C19 	 Psychomotor assessment 	 221 
Patient 
number 
Body 
weight 
(kg) 
Age 
(yr) 
Duration 
of 
anaesthesia 
(min) 
Time to eye 
opening after 
flumazenil 
(sec) 
Time to self 
identification 
after flumazenil 
(sec) 
Dose of 
flumazenil 
administered 
(mg) 
APPENDIX C 
Mood on 
awakening 
(**) 
1 18.7 6 31 240 360 0.62 D 
2 16.0 5 33 120 240 0.46 D 
3 20.0 6 39 120 240 0.60 D 
4 20.0 6 35 240 300 0.60 C 
5 32.0 8.5 43 240 300 0.82 B 
6 38.5 9 40 180 180 0.75 C 
7 14.0 5 31 180 420 0.56 B 
8 24.0 7 58 300 360 0.56 D 
9 20.0 8 31 150 270 0.53 C 
10 17.0 5 31 180 180 0.35 D 
11 25.0 7.5 29 60 120 0.42 B 
12 19.0 5 48 240 300 0.58 D 
mean 22.0 6.5 37.4 ' 187.5 272.5 0.60 
SD 6.7 1.4 8.4 65.0 82.6 0.10 
min 14.0 5.0 29.0 60 120 0.40 
max 38.5 9.0 58.0 300 420 0.80 
APPENDIX C 1: Anaesthetic and awakening data from Jones et at (1993). 
(**) A: laughing, euphoric B: happy, contented, playful C: calm, drowsy, asleep D: crying but calmed, irritable 
E: severe pain, screaming, inconsolable 
215 
Patient 
number 
Age 
(yr) 
Weight 
(kg) 
Premed 
efect 
(*) 
Loss of 
eye-lash 
reflex 
(sec) 
Anaes. 
duration 
(min) 
Time to 
eye open 
(min) 
Time to 
giving 
name 
(min) 
Dose of 
drug 
(ml) 
Oserved 
efect (**) 
Tolerance 
of 
injection (***) 
Coma 
score at 
5 min 
APPENDIX C 
Coma 
score at 
10 min 
1 7.5 25.0 2 85 37 4 6 6.3 1 1 4 8 
4 5.5 18.0 2 14 30 6 30 6.8 1 1 4 8 
7 3.5 17.0 2 79 41 15 52 7.2 3 2 4 4 
8 8.5 22.0 2 84 80 9 11 10.0 2 2 3 7 
9 9.0 25.0 2 33 31 8 12 10.0 2 1 5 8 
10 6.0 15.1 2 49 23 14 35 10.0 3 3 4 4 
14 4.5 17.3 2 123 39 6 6 5.0 1 1 7 8 
16 11.5 28.5 2 72 47 2 6 7.5 1 1 7 9 
18 11.0 30.5 2 18 38 5 8 7.0 1 1 6 9 
20 11.0 27.0 2 106 32 5 9 8.0 1 1 9 9 
23 4.5 17.5 2 90 17 9 11 10.0 2 1 3 9 
24 10.0 25.5 2 32 25 7 9 9.0 2 2 2 8 
25 9.0 25.0 2 83 63 15 18 10.0 3 1 4 4 
26 4.5 17.8 2 120 24 9 17 10.0 2 1 4 9 
29 11.0 28.0 1 52 33 16 16 10.0 3 1 2 9 
31 4.5 18.5 1 64 43 10 12 10.0 2 1 8 9 
33 4.0 13.5 2 71 25 32 36 10.0 4 1 3 3 
34 6.5 20.0 2 61 28 13 14 10.0 3 1 3 5 
38 5.0 14.3 2 117 32 7 8 6.0 2 2 5 9 
39 6.0 17.8 2 32 31 16 26 10.0 3 3 2 9 
APPENDIX C 2: Patient and anaesthetic data from the flumazenil group in Jones et al (1991). 
(*) 	 : 1 = agitated and crying, 2 = aware, apparently anxiety free,- 3 = drowsy, 4 = asleep, responds to commands (**)(***) : 1 = excelent, 2 = good, 3 = moderate, 4 = poor 
Coma score refer Chapter II, page 21 
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Patient 
number 
Age 
(yr) 
weight 
(kg) 
Premed 
efect 
(*) 
Loss of 
eye-lash 
reflex 
(sec) 
Anaes. 
duration 
(min) 
Time to 
eye open 
(min) 
Time to 
giving 
name 
(min) 
Dose of 
drug 
(m1) 
Observed 
efect (**) 
Tolerance 
of 
injection (***) 
Coma 
score at 
5 min 
APPENDIX C 
Coma 
score at 
10 min 
2 3.0 17.5 2 87 27 31 31 10 4 1 3 3 
3 8.0 23.0 2 17 25 47 47 10 4 1 1 1 
5 6.0 16.5 2 52 46 33 39 10 4 1 2 2 
6 7.0 23.0 2 43 33 23 49 10 4 1 1 1 
11 5.8 18.-0 2 20 27 76 77 10 4 1 1 1 
12 5.5 19.0 2 40 26 28 27 10 4 1 2 2 
13 5.5 18.5 2 40 25 57 61 10 4 1 2 2 
15 12.5 44.0 2 21 29 21 22 10 4 1 2 2 
17 3.8 17.0 2 118 43 25 32 10 4 1 2 2 
19 8.0 24.5 2 94 69 23 43 10 4 1 0 0 
21 4.5 18.5 2 24 38 22 31 10 4 1 2 2 
22 11.5 30.5 2 88 26 32 34 10 4 1 3 3 
27 5.6 29.0 2 27 35 30 33 10 4 1 1 2 
28 8.0 26.0 2 110 45 30 30 10 4 1 1 1 
30 6.8 19.7 4 60 22 47 63 10 4 1 2 2 
32 7.0 21.5 2 26 19 31 60 10 4 1 1 2 
35 10.5 34.0 2 72 30 46 54 10 4 1 1 3 
36 5.5 15.5 2 72 25 38 43 10 4 1 1 1 
37 9.0 20.5 2 51 28 66 67 10 4 1 4 4 
40 5.0 18.0 4 20 33 53 59 10 4 1 2 2 
APPENDIX C 3: 	 Patient and anaesthetic data in the placebo group from Jones et al (1991). 
(*) 	 : 1 = agitated and crying, 2 = aware, apparently anxiety free, 3 = drowsy; 4 = asleep, responds to commands 
(**)(***) : 1 = excelent, 2 = good, 3 = moderate, 4 = poor 
Coma score refer Chapter II, page 21 
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APPENDIX C 218 
Coma Scale Mood Score 
Patient time (min) time 	 (min) number 2 5 30 60 120 240 18 hr 2 5 10 60 120 240 
1 4 8 8 8 9 9 9 
1 	 e
n e
n e
n e
n e
n e
n en . e
n e
n e
n e
n e
n e
n e
n e
n e
n e
n e
n e
n en 
4 4 4 8 9 9 9 9 
7 2 4 4 5 9 9 9 
8 2 3 7 9 9 8 9 
9 2 5 8 8 8 9 9 
10 1 4 4 5 5 8 9 
14 1 7 8 8 8 9 9 
16 5 7 8 9 9 9 9 
18 1 6 6 8 7 9 9 
20 5 9 9 9 9 9 9 
23 1 3 9 9 7 9 9 Ch en 
24 2 2 8 8 6 6 6 
25 4 4 4 6 6 9 9 
26 0 4 9 9 9 9 9 
29 0 2 3 9 8 9 9 
31 1 8 9 9 9 9 9 
33 2 3 3 8 9 9 9 
34 2 2 5 9 9 9 9 
38 1 5 9 9 9 9 9 
39 0 0 9 9 9 9 9 
APPENDIX C 4: Coma and mood scores folowing flumazenil administration from Jones et al (1991). 
Coma and mood scale refer Chapter II, page 21. 
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Coma Scale Mood Score 
Patient time (min) time _ 	(min) 
number 2 5 30 60 120 240 18 hr 2 5 10 60 120 240 
2 0 2 2 7 9 9 9 	
1  
e
n e
n e
n e
n c
n e
n en
 e
n r
n e
n e
n e
n e
n e
n e
n e
n e
n e
n e
n en 
3 1 4 4 4 6 9 9 
5 1 1 1 1 8 9 9 
6 1 1 3 4 4 8 9 
11 1 1 2 2 2 9 9 
12 1 2 2 3 3 9 9 	. 
13 1 1 1 1 5 4 9 
15 1 1 2 2 1 6 7 
17 1 3 3 5 8 5 9 
19 0 0 0 6 6 9 9 
21 0 2 2 9 9 9 9 en 
22 0 2 2 4 9 9 9 
27 2 2 2 9 9 9 9 
28 2 2 2 6 9 9 9 
30 0 1 1 1 6 9 9 
32 1 1 1 1 1 8 8 
35 2 2 2 2 7 9 9 
36 1 1 1 2 9 9 9 
37 3 3 3 3 3 7 7 
40 2 2 2 3. 9 8 9 
APPENDIX C 5: Coma scale and mood scores folowing placebo administration from Jones et al (1991). 
Coma and mood scale refer Chapter II, page 21. 
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Mood Score Coma Score 
Patient 
number 
Preoperative time (min) 
30 	 60 	 90 120 
Postoperative time (min) 
awake 	60 	 120 	 180 	 240 
Preoperative time (min) 
30 	 60 	 90 	 120 
Postoperative time (min) 
awake 	 60 	 120 	 180 	 240 
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0.
) 
CT
  
0
0
 0
0 
.
0 -
4 
C
T 
UI
 
0
0 
O
N 
4=•
•  
ON 
 
O
N 
-.4
  
00
  V
I  
\
 Ui 
 
(
A 4
).  
CT 
 
VI
  0
0  
-
4  
ON
  -
4  
LA
 C
T 
.0
 0
)
 t
.1'
t  
00
  .
0  
.
0 -
4 .
0 -
4
 
.
0 -
.4
 V
D 
-
4
 CT
 L
A .
0 -
4
0
0 
.
0 -
4-
4
-
4 -
4  
00
  
,C)
 V
D 
.
0
 V
D 
.
0
 .0
  C
T  
.0
  
V
D 
.
0 
.0
 -
4 .
0 C
T 
.
0 .
0 .
0 
.0
 .
0 .
0 '
C
OO
 V
D 
v
;
 
.
0 .
0 .
0 V
D 
.
0 .
0 .
0
 .
0 '
C
OO 
V;
 V
D 
 s
C)  
.0
 .
0 
.
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V
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V
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 V
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V
D 
.0
  
.0
 .
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0 .
0 .
0 .
0  .
0 
V
D .
0 .
0  
.0
 .
0  
.
0 
.
0 .
0 .
0 .
0 .
0  
40
  .
0  
.
0  
.
0  
.
0  
--I
  
7 2 2 2 2 
9 2 2 3 3 
11 2 3 3 3 
12 2 2 2 2 
14 2 2 2 2 
19 3 3 3 2 
20 2 3 3 2 
23 3 3 2 2 
26 3 3 3 3 
2 2 2 2 3 
5 2 3 3 3 
6 3 3 3 3 
13 2 2 2 2 
16 2 2 2 2 
17 2 2 2 2 0,1 ON 
18 2 3 3 3 
22 3 3 3 3 
25 4 3 3 4 
30 3 4 4 4 
1 2 3 3 3 
3 2 2 3 3 
8 2 2 2 2 
10 3 2 2 2 
15 2 2 2 2 
21 3 3 3 3 
24 3 3 3 3 
27 3 3 3 3 
28 3 3 2 3 
29 3 3 2 2 
APPENDIX C 6: 	 Preoperative and postoperative mood score and coma scale data from Jones et al (1993 c & d). 
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Patient 
number 
Age 
(yr) 
Unmedicated preoperative post box toy completion attempts (sec) 
1st rd 37d 4 th 5th 6th 7th fastest 
completion time 
1 6 34 31 23 34 37 26 26 23 
2 5 34 63 30 24 25 24 20 20 
3 6 22 22 20 15 18 21 18 15 
4 6 16 24 15 19 19 16 13 13 
5 8.5 17 15 16 15 11 14 11 11 
6 9 33 18 17 20 17 22 15 15 
7 5 19 20 23 23 22 23 20 19 
8 7 25 27 26 17 23 26 19 17 
9 8 29 21 17 16 22 18 13 13 
10 5 115 31 27 21 44 33 28 21 
11 7.5 25 21 23 22 13 16 18 13 
12 5 38 28 33 24 23 20 27 20 
APPENDIX C 7: Unmedicated preoperative post box toy completion time learning curve data om Jones et al (1993). 
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Patient 
number 
Pre-op 
Fastest 
CT 
(sec) 
Post operation 
First awake 10 min 20 min 30 min 60 min 120 min 180 min 240 min 
Time 
(min) 
CT 
(sec) 
PBT 
ratio 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PET 
ratio 
CT 
(sec) 
PBT 
ratio 
1 23 10 70 3.04 40 1.74 R R R R 
2 20 20 65 3.25 R A A R 37 1.85 
3 15 10 30 2.00 35 2.33 R A 30 2.00 28 1.87 
4 13 20 25 1.92 34 2.62 41 3.15 R R 38 2.92 
5 11 10 35 3.18 22 2.00 20 1.82 20 1.82 14 1.27 17 1.55 
6 15 10 90 6.00 55 3.67 40 2.67 32 2.13 18 1.20 19 1.27 
7 19 10 48 2.53 40 2.11 A 40 2.11 R 25 1.32 
8 17 R R R R R R R R 
9 13 10 42 3.13 31 2.31 54 4.03 A R 28 2.09 
10 21 R R R 120 5.71 A 124 5.90 48 2.29 30 1.43 
11 13 10 78 6.00 41 3.15 28 2.15 25 1.92 20 1.54 18 1.38 
12 20 R R R R R R 36 1.80 21 1.05 
mean 16.7 48.3 3.70 2.59 34.8 2.90 16.6 2.30 21.9 2.30 15.1 1.40 23.7 1.50 
SD 3.7 26.1 1.51 1.51 31.1 1.20 19.9 1.30 35.3 • 1.80 16.3 0.70 10.1 0.70 
n 9 7 2 9 5 5 6 10 
min 11 25 2.00 1.92 22 1.74 20 1.82 20 1.82 14 1.20 17 1.05 
max 23 90 _ 6.00 3.25 _ 	120 5.71 54 4.03 	, • 124 5.90 48 2.29 38 2.92 
- 
APPENDIX C 8: 	 Psychomotor data from Jones et al (1993). Post box toy completion time and completion time ratios. 
PBT = post box toy, CT = completion time, A = asleep, R = refused the toy. 
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Patient 
number 
Age 
(yr) 
Unmedicated preoperative post box toy completion atempts (sec) 
1st 2'd 3rd 4th 5th 6th 7th fastest 
completion time 
1 7.5 16 14 17 14 17 14 13 13 
4 5.5 32 37 28 24 27 27 25 24 
7 3.5 52 50 55 63 29 51 43 29 
8 8.5 29 24 18 18 14 16 15 14 
9 9 13 17 16 18 16 16 14 13 
10 6 35 34 35 29 27 28 31 27 
14 4.5 40 33 31 38 23 27 34 23 
16 11.5 18 15 13 14 14 14 12 12 
18 11 14 26 17 12 15 12 14 12 
20 11 18 18 10 12 20 9 13 9 
23 4.5 58 42 29 42 22 20 22 20 
24 10 20 15 14 14 13 13 11 11 
25 9 18 15 10 9 9 8 11 8 
26 4.5 40 36 30 35 29 25 29 25 
29 11 24 17 18 17 20 18 15 15 
31 4.5 45 47 39 27 27 31 28 27 
33 4 53 70 52 78 55 60 53 52 
34 6.5 40 28 37 23 21 29 19 19 
38 5 88 71 44 51 47 37 34 34 
39 6 17 19 21 18 24 - 	18 21 17 
APPENDIX C 9: 	 Unmedicated preoperative post box toy completion time learning curve data for the flumazenil group from 
Jones et al (1991). 
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Patient 
number 
Pre-op 
Fastest 
CT 
(sec) 
Post-operation 
10 min 30 min 60 min 120 min 240 min 18 hr 
CT 
(sec) 
PBT 
Ratio 
CT 
(sec) 
PBT 
Ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
1 13 36 2.79 28 2.17 20 1.55 19 1.47 18 1.40 13 1.01 
4 24 97 4.04 83 3.46 95 3.96 33 1.37 22 0.92 
7 29 66 2.28 63 2.17 58 2.00 57 1.97 
8 14 69 4.93 22 1.57 25 1.79 22 1.57 18 1.29 18 1.29 
9 13 45 3.46 24 1.85 19 1.46 17 1.31 25 1.92 15 1.15 
10 27 15 0.56 19 0.70 
14 23 56 2.43 54 2.35 32 1.39 37 1.61 33 1.43 31 1.35 
16 12 37 3.08 20 1.67 21 1.75 21 1.75 15 1.25 12 1.00 
18 12 47 3.92 20 1.67 21 1.75 27 2.25 17 1.42 17 1.42 
20 9 28 3.11 18 2.00 25 2.78 16 1.78 15 1.67 7 0.78 
23 20 50 2.50 27 1.35 32 1.60 35 1.75 20 1.00 19 0.95 
24 11 34 3.09 28 2.55 27 2.45 27 2.45 33 3.00 15 1.36 
25 47 5.87 30 3.75 26 3.25 14 1.75 
26 25 50 2.0 29 1.16 34 1.36 
29 15 46 3.07 27 1.73 34 2.27 30 2.0 31 2.07 18 1.20 
31 27 43 1.59 30 1.11 
33 52 154 2.96 48 0.92 55 1.06 184 2.00 
34 19 44 2.32 39 2.05 33 1.74 24 1.26 40 2.11 44 2.32 
38 34 71 2.09 58 1.71 112 3.29 47 1.38 60 1.76 38 1.12 
39 17 60 3.53 58 3.41 40 2.35 42 2.47 23 1.35 
APPENDIX C 10: Post box toy completion time and completion time ratio in the flumazenil group from Jones et al (1991). 
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Patient 
number 
Age 
(yr) 
Unmedicated preoperative post box toy completion atempts (sec) 
1" 2" 3rd 4th 5th 6" 7th fastest 
completion time 
2 3 227 57 50 58 55 43 56 43 
3 8 25 21 16 20 15 19 17 15 
5 6 46 46 56 46 46 38 31 31 
6 7 102 51 114 21 36 19 24 19 
11 5.5 37 23 26 46 32 30 23 23 
12 5.5 28 22 22 16 21 16 13 13 
13 5.5 60 35 31 40 50 29 29 29 
15 12 26 14 18 18 14 10 9 9 
17 4 44 41 31 51 30 29 31 29 
19 8 18 45 28 21 23 20 19 18 
21 4.5 119 49 47 40 35 41 24 24 
22 11.5 27 17 18 15 13 14 14 13 
27 5.5 47 57 27 30 28 24 21 21 
28 8 11 15 13 18 12 15 13 11 
30 7 28 24 28 24 23 15 15 15 
32 7 24 21 16 14 14 13 13 13 
35 10.5 19 16 13 11 10 11 12 10 
36 5.5 44 30 27 31 26 19 20 19 
37 9 22 18 19 15 15 13 13 13 
40 5 21 24 24 23 50 26 20 20 
APPENDIX C 11: 	 Unmedicated preoperative post box toy completion time learning curve data for the placebo group from 
Jones et al (1991). 
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Patient 
number 
Pre-op 
Fastest 
CT 
(sec) 
Post-operation 
10 min 30 min 60 min 120 min 240 min 18 hr 
CT 
(sec) 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
2 43 36 0.84 
3 15 123 8.20 28 1.87 31 2.07 14 0.93 
5 31 125 4.03 48 1.55 45 1.45 26 0.84 
6 19 30 1.58 29 1.53 
11 23 176 7.65 45 1.96 27 1.17 28 1.22 
12 13 32 2.46 20 1.54 20 1.54 15 1.15 
13 29 27 0.93 18 0.62 
15 9 20 2.22 25 2.78 16 1.78 
17 29 32 1.10 41 1.41 
19 18 42 2.33 25 1.39 24 1.33 
21 24 192 8.00 60 2.50 80 3.33 40 1.67 
22 13 185 8.08 18 1.38 15 1.15 15 1.15 
27 21 508 24.19 111 5.29 50 2.38 29 1.38 30 1.43 
28 11 59 5.36 17 1.55 14 1.27 18 1.64 
30 15 84 5.60 29 1.93 16 1.07 
32 13 50 3.85 23 1.77 26 2.00 15 1.15 
35 10 45 4.5 24 2.40 19 1.90 15 1.50 
36 19 250 13.16 90 4.74 30 1.58 22 1.16 
37 13 194 14.92 55 4.23 25 1.92 19 1.46 
40 20 215 10.75 37 1.85 33 1.65 
APPENDIX C 12: Post box toy completion time and completion time ratio in the placebo group from Jones et al (1991). 
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Patient 
number 
Age 
(yr) 
Unmedicated preoperative post box toy completion attempts (sec) 
1st 2ed 3rd 4th 5th 61h 7th fastest 
completion 
time 
1 6 28 38 48 25 25 27 22 22 
2 8.5 25 18 22 19 18 16 14 14 
3 10 16 13 14 14 14 13 11 11 
4 5 23 21 25 23 25 22 26 21 
5 11 15 16 14 13 12 12 15 12 
6 9 18 18 15 13 17 18 16 13 
7 9 19 23 21 15 17 18 21 15 	. 
8 7 25 21 18 20 22 18 16 16 
9 5 42 32 29 28 21 22 25 21 
10 6 41 24 23 25 22 23 20 ' 20 
11 8 15 13 13 14 19 12 16 12 
12 4 76 38 35 41 32 39 25 25 
13 6 22 19 20 20 19 16 17 16 
14 6 59 53 21 18 23 22 20 18 
15 12 16 14 15 14 13 14 14 13 
16 6 39 24 27 25 27 28 24 24 
17 5 37 38 79 36 23 20 25 20 
18 6 59 39 21 26 21 21 20 20 
19 9 20 18 18 14 20 16 15 14 
20 10 15 13 13 13 14 12 13 12 
21 5 39 32 35 30 28 23 23 23 
22 9 20 18 14 15 17 15 15 14 
23 11 23 23 20 19 17 19 15 15 
24 8 19 17 13 15 15 16 13 13 
25 8 24 18 16 15 14 13 13 13 
26 4 66 61 37 48 79 63 57 37 
27 8.5 26 22 19 18 19 17 16 16 
28 5 33 34 30 29 30 36 38 29 
29 6 38 34 30 23 21 25 22 21 
30 5 61 23 26 22 34 25 22 22 
APPENDIX C 13: Unmedicated preoperative post box toy completion time 
learning curve data for the midazolam, propofol and 
thiopentone groups from Jones et al (1993 c & d). 
APPENDIX C 228 
Patient 
number 
, 
Age Fastest 
(yr) 	 CT 
Preoperative data after premedication Postoperative performance 
30 min 60 min 90 min 120 min Awakening 60 min 120 min 180 min 240 min 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(see) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
4 5 21 39 0.54 28 0.75 22 0.96 25 0.84 38 0.55 24 0.88 26 0.81 24 0.88 26 0.81 
7 9 15 19 0.79 16 0.94 14 1.10 20 0.75 R A 19 0.79 17 0.88 16 0.94 
9 5 21 58 0.38 45 0.47 47 0.45 44 0.48 R 180 0.12 29 0.72 24 0.88 23 0.91 
11 8 12 15 0.80 15 0.80 17 0.71 14 0.86 R 24 0.50 16 0.75 12 1.00 14 0.86 
12 4 25 84 0.30 49 0.51 46 0.54 27 0.93 A A R 40 0.63 35 • 0.71 
14 6 18 28 0.64 23 0.78 24 0.75 21 0.86 171 0.11 24 0.75 30 0.60 18 1.00 19 0.95 
19 9 14 17 0.82 17 0.82 19 0.74 19 0.74 121 0.12 46 0.30 16 0.88 15 0.93 15 0.93 
20 10 12 13 0.92 19 0.63 20 .0.60 96 0.13 29 0.41 24 0.50 27 0.44 16 0.75 
23 11 15 25 0.60 20 0.75 17 0.88 14 1.10 55 0.27 22 0.68 14 1.10 16 0.94 11 1.36 
26 4 37 62 0.60 78 0.47 49 0.76 40 0.93 R A A 35 1.10 37 1.00 
mean 7.2 19 35.8 0.64 31 (169 28.3 0.76 24.4 0.80 99.2 0.23 49.8 0.52 21.8 0.77 22.8 0.86 21.2 0.92 
SD 2.5 7.2 24 0.19 20.4 0.16 14.6 0.19 10.2 0.17 53.1 0.19 57.9 0.27 6.3 0.17 9.1 0.19 8.9 0.18 
n 10 10 10 10 10 10 9 9 10 10 5 5 7 7 8 8 10 10 10 10 
min 4 12 13 0.30 15 0.47 14 0.45 14 0.48 38 0.11 22 . 	0.12 14 0.50 12 0.44 11 0.71 
max 11 37 84 0.92 78 0.94 _ 	49 1.10 44 1.10 171 0.55 180 0.88 30 1.10 40 1.1 37 1.36 
APPENDIX C 14: Post box completion time and completion time ratios in the midazolam group from Jones et al (1993 c & d). 
PBT = post box toy, CT = completion time, A = asleep, R = refused the toy. 
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Patient 
number 
Age Fastest 
(yr) 	 CT 
(sec) 
Preoperative data after premedication Postoperative performance 
30 min 60 min 90 min 120 min Awakening 60 min 120 min 180 min 240 min 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
2 8.5 14 25 0.56 19 0.74 22 0.64 19 0.74 44 0.32 25 0.56 31 0.45 21 0.67 18 0.78 
5 11 12 15 0.80 19 0.63 15 0.80 18 0.67 80 0.15 17 0.71 18 0.67 15 0.8 13 0.92 
6 9 13 36 0.36 23 0.57 18 0.72 18 0.72 R 19 0.68 22 0.59 17 0.77 18 0.72 
13 6 16 26 0.62 25 0.64 22 0.73 21 0.76 36 0.44 17 0.94 24 0.67 20 0.80 18 0.89 
16 6 24 26 0.92 29 0.83 29 0.83 32 0.75 65 0.37 35 0.69 20 1.20 19 1.26 22 1.10 
17 5 20 29 0.69 39 0.51 32 0.63 34 0.59 38 0.53 27 0.74 28 0.71 23 0.87 28 0.71 
18 6 20 24 0.83 22 0.91 23 0.87 35 0.57 40 0.50 24 0.83 22 0.91 24 0.83 19 1.10 
22 9 14 20 0.70 22 0.64 23 0.61 18 0.78 122 0.12 42 0.33 28 0.50 24 0.58 22 0.64 
25 8 13 28 0.46 22 0.59 17 0.77 21 0.62 17 0.77 11 1.18 R 10 1.30 13 1.00 
30 5 22 31 0.71 30 0.73 31 0.71 25 0.88 40 0.55 25 0.88 26 0.85 23 0.96 23 0.96 
mean 7.4 16.8 26 0.67 25 0.68 23.2 0.73 24.1 0.71 53.6 0.42 24.2 0.76 24.3 0.73 19.6 0.88 19.4 0.88 
SD 2.0 4.3 5.8 0.17 6.2 0.12 5.9 0.09 7.0 0.10 31.4 0.20 9.1 0.23 4.2 0.23 4.5 0.23 4.6 0.16 
n 10 10 10 10 10 10 10 10 10 10 9 9 10 10 9 9 10 10 10 10 
min 5 12 15 0.36 19 0.51 15 0.61 18 0.57 17 0.12 11 . 0.33 18 0.45 10 0.58 13 0.64 
max 11 24 36 0.92 _ 	39 0.91 32 0.87 35 0.88 122 0.77 42 1.18 31 1.2 _ 	24 1.30 28 1.10 
APPENDIX C 15: 	 Post box toy completion time and completion time ratios in the propofol group from Jones et at (1993 c & d). 
PBT = post box toy, CT = completion time, R = refused the toy. 
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Patient 
number (yr) 
Age fastest 
Preoperative data after premedication Postoperative performance 
CT 30 min 60 min 90 min 120 min Awakening 60 min 120 min 180 min 240 min (sec) CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
CT 
(sec) 
PBT 
ratio 
1 6 22 42 0.52 48 0.46 41 0.54 43 0.51 62 0.36 A 36 0.61 24 0.92 31 0.71 
3 10 11 14 0.79 14 0.79 15 0.73 15 0.73 31 0.36 20 0.55 17 0.65 14 0.79 18 0.61 
8 7 16 21 0.76 22 0.73 22 0.73 27 0.59 33 0.49 20 0.80 22 0.73 19 0.84 22 0.73 
10 6 20 63 0.32 32 0.63 31 0.65 24 0.83 R 30 0.67 23 0.87 35 0.57 40 0.67 
15 12 13 19 0.68 17 0.77 13 1.00 16 0.81 66 0.20 25 0.52 13 1.00 15 0.87 13 1.00 
21 5 23 A A 53 0.43 45 0.51 78 0.30 70 0.33 27 0.85 26 0.89 27 0.85 
24 8 13 16 0.81 14 0.93 15 0.87 16 0.81 33 0.39 30 0.43 15 0.87 15 0.87 15 0.87 
27 8.5 16 23 0.70 45 0.36 29 0.55 23 0.70 34 0.47 A 20 0.80 27 0.59 17 0.94 
28 5 29 30 0.97 ' 33 0.88 34 0.85 30 0.97 A 42 0.69 34 0.85 25 1.16 
29 6 21 27 0.78 24 0.88 22 0.96 19 1.11 49 0.43 27 0.78 17 1.24 26 0.81 20 1.05 
mean 7.35 18.4 28.3 0.70 27.7 0.71 27.5 0.73 25.3 0.73 46.2 0.44 31.7 0.58 23.2 , 	0.83 23.5 0.80 21.8 0.86 
SD 2.3 5.6 15.5 0.19 12.7 0.20 12.8 0.19 11.4 0.19 18.2 0.22 17.4 0.18 9.4 0.19 7.6 0.12 6.3 0.18 
n 10 10 9 9 9 9 10 10 9 9 9 9 7 7 10 10 10 10 10 10 
min 5 11 14 0.32 14 0.36 13 0.43 15 0.51 30 0.20 20 0.33 13 0.61 14 0.57 13 0.61 
max 12 29 63 0.97 48 0.93 53 1 45 1.10 78 0.97 _ 	70 Q.80 42 1.24 35 0.92 31 1.16 
APPENDIX C 16: Post box toy completion time and completion time ratios in the thiopentone group from Jones et al (1993 c & d). 
PBT = post box toy, CT = completion time, A = asleep, R = refused the toy. 
APPENDIX C 231 
Patient 
number 
Age 
(yr.m 
day) 
Highest 
code 
score 
Preoperative WISC-R performance after premedication Postoperative WISC-R coding performance 
30 min 60 min 90 min 120 min Awake 60 min 120 min 180 min 240 min 
score scale score scale score scale score scale score scale score scale score scale score scale score scale 
4 5.4,24 48 42 18 47 19 45 18 45 18 .471. -
- — 
-- 	
e
n —, 
— 
—, 
cr.
 c
4 p
4 a
4 < 
vt) •zr "1-'  '
t  
c4 
38 16 48 19 49 19 45 18 
7 9.0,15 85 63 17 64 18 46 11 49 12 R 1 29 5 52 14 68 18 
9 5.9,18 49 45 18 48 19 47 18 46 18 25 10 45 18 46 18 49 19 
11 8.0,5 85 71 19 65 19 74 19 81 19 69 19 80 19 85 19 78 19 
12 4.9,23 20 14 17 24 31 A R 38 32 
14 6.2,21 48 46 18 46 18 48 .18 47 18 46 18 49 19 50 19 50, 19 
19 9.2,13 74 48 12 65 18 53 14 61 17 23 4 52 14 77 19 77 19 
20 9.11,8 74 84 19 61 15 86 19 46 10 66 17 59 15 78 19 
23 11.5,4 75 38 5 67 14 71 15 71 15 41 6 67 14 80 18 66 13 
26 4.5,15 45 15 15 18 17 A A 19 R 
mean 57.6 46.6 15.8 49.5 17.5 47.3 16.1 53.4 17.0 9.6 1.6 41.1 10.5 54.5 15.6 59.6 17.6 60.3 18.0 
SD 19.5 22.2 4.9 19.4 1.9 18.4 2.9 21.6 2.4 4.8 1.2 15.4 6.7 15.8 4.8 16.9 2.0 16.8 2.1 
n 10 10 8 10 8 9 7 10 8 5 8 .7 8 8 8 10 8 9 8 
min 20 14 5 15 14 18 11 17 12 4 1 23 1 29 5 38 14 32 13 
max 85 _ 	84 19 67 19 74 19 86 19 15 4 _ 	69 , 19 80 19 85 19 87 19 
APPENDIX C 17: Perioperative Wechsler inteligence scale coding performance in the midazolam group from Jones et al (1993 c &d) 
A = asleep, R = refused the toy. 
APPENDIX C 232 
Patient 
number 
Age 
(yr.m. 
day) 
Highest 
code 
score 
Preoperative WISC-R performance after premedication Postoperative WISC-R coding performance 
30 min 60 min 90 min 120 min Awake 60 min 120 min 180 min 240 min 
score scale score scale score scale score scale score scale score scale score scale score scale score scal 
2 8.6,17 50 46 13 53 16 60 18 52 16 31 7 41 11 58 17 '66 19 71 19 
5 11.0,25 73 84 19 49 9 73 16 75 17 13 1 68 15 89 19 87 19 88 19 
6 9.2,19 60 39 9 46 11 56 15 54 15 R 1 59 16 67 18 56 15 70 19 
13 6.3,14 50 48 18 49 19 50 19 50 19 48 18 50 19 50 19 50 19 50 19 
16 6.1,13 49 49 19 47 18 48 18 49 19 30 11 46 18 50 19 50 19 49 19 
17 5.7,1 47 42 18 45 18 46 18 46 18 30 3 44 18 47 19 46 18 47 19 
18 6.2,1 50 48 18 48 18 48 18 47 18 45 17 46 18 49 19 48 18 44 17 
22 9.0,15 50 47 12 34 7 37 8 32 6 3 1 15 1 29 5 40 9 50 13 
25 8.2,10 55 14 1 20 4 47 14 9 1 51 16 R 1 R 1 82 19 65 19 
30 5.2,16 30 18 8 23 10 25 11 21 9 15 6 25 11 34 15 33 14 30 13 
mean 51.4 43.5 13.5 41.4 13.0 49.0 15.5 43.5 13.8 29.6 8.1 43.8 12.8 52.6 15.1 55.8 17.0 56.4 17.( 
SD 10.8 19.1 6.1 11.6 5.4 12.8 3.6 18.5 6.3 16.7 6.9 16.0 6.8 17.8 6.6 17.5 3.4 16.8 2.5 
n 10 10 10 10 10 10 10 10 10 9 10 9 10 9 10 10 10 10 10 
min 30 14 1 20 4 25 8 9 1 3 1 15 1 29 1 33 9 30 13 
max 73 84 19 53 19 73 19 75 19 51 18 _ 	68 19 89 19 87 19 	_ 88 19 
APPENDIX C 18: Perioperative Wechsler inteligence scale coding performance in the propofol group from Jones et al (1993 c & d). 
R = refused the toy. 
APPENDIX C 233 
Patient 
number 
Age 
(yr.m. 
day) 
Highest 
code 
score 
Preoperative WISC-R performance after premedication Postoperative WISC-R coding performance 
30 min 60 min 90 min 120 min Awake 60 min 120 min 180 min 240 min 
score scale score scale score scale score scale score scale score scale score scale score scale score scale 
1 6.5,3 32 27 9 31 11 32 11 34 12 8 2 R 1 44 16 49 18 49 18 
3 8.8,9 75 88 19 75 19 52 15 69 19 41 10 44 11 69 19 93 19 93 19 
8 7.0,10 50 50 50 50 50 41 49 49 50 50 
10 5.7,1 48 48 19 46 18 48 19 48 19 33 14 45 18 46 18 50 19 49 19 
15 12.8,12 78 52 8 62 10 68 12 75 14 29 4 77 14 73 13 85 17 81 16 
21 4.11,2 41 A 1 A 1 25 11 44 19 14 6 26 12 49 19 49 19 49 19 
24 7.10,11 52 32 9 44 14 44 14 48 15 14 2 35 10 40 12 51 16 51 16 
27 8.8,8 48 52 15 10 1 18 3 33 7 18 3 A 1 43 11 43 1 54 15 
28 5.3,19 47 49 19 48 19 47 19 1 22 10 A 1 48 19 49 19 50 19 
29 5.7,14 48 45 18 48 19 50 19 49 19 28 12 47 19 49 19 47 19 48 19 
mean 51.9 49.2 13.0 46.0 12.4 43.4 13.7 50.0 13.9 24.8 7.0 46.1 9.7 51.0 16.2 56.6 17.4 57.4 17.8 
SD 14.2 17.1 6.5 18.2 7.4 14.6 5.2 14.0 6.4 11.5 4.6 15.8 7.1 11.0 3.4 17.3 2.7 15.9 1.6 
n 10 10 9 10 9 10 9 9 8 10 9 7 9 10 9 10 9 10 9 
min 32 27 1 10 1 18 3 33 7 8 2 26 1 40 11 43 11 48 15 
max 78 88 19 75 19 68 19 75 19 41 14 77. 19 73 19 93 19 _ 	93 19 
APPENDIX C 19: Perioperative Wechsler inteligence scale coding performance in the thiopentone group from Jones et at (1993 c &d) 
A = asleep, R = refuse the toy. 
APPENDIX D 234 
APPENDIX D 
Pharmaco dynamic data 
D1 - D8 	 Oximetric 	 235 
D9 - D27 	 Cardiorespiratory 	 243 
APPENDIX D 235 
Preoperative night - RAW data, F 102 0.21 
Time in saturation range (% total time) Number of episodes (>15 sec) in saturation range 
Satmaster 
Pt. No. sex age weight time mean lowest 90-95 85-90 80-85 75-80 <75 90-95 85-90 80-85 75-80 <75 
premed (yr) (kg) discounted Sp02 SpO, (%) (%) (%) (%) (%) (%) (%) (0/0) (0/0) (0/0) 
(P/M) (hr,min,sec) (%) (0/0) 
1 M M 6 15 0:03:33 99 79 3:51(1) 1:51(0) 0:46(0) 0:11(0) - 21 6 5 1 - 
2 M F 4 16 0:07:56 100 90 2:37(0) 0:05(0) - - - 14 1 - - - 
3M F 1.5 11.5 0:20:43 99 69 1:55(0) 0:42(0) 0:10(0) 1:16(0) 0:13(0) 8 3 2 4 2 
4 M M 5 20 4:29:54 98 93 3:33(1) - - - - 7 - - - - 
5 M M 7 17.5 0:07:51 96 61 3:19(1) 0:47(0) 3:35(1) 20:00(3) 46:22(7) 16 5 5 13 49 
6 M M 2.5 14.5 0:02:47 97 63 79:17(13) 5:39(1) 2:30(0) 0.08(0) 0.07(0) 179 15 10 3 3 
7 M M 4.5 15 0:01:23 97 73 74:00(9) 43:29(5) 26:50(3) 2:43(0) 0.09(0) 132 96 69 21 1 
8 M F 10 18 4:43:48 98 92 10:47(2) - - - - 47 - - - - 
9M M 2.5 16 0:00:18 98 91 4:31(1) - - - - 12 - - - - 
10 M M 2.5 16.5 2:58:31 99 88 6:18(1) 0:25(0) - - - 25 2 - - - 
1 P M 5.5 16 0:01:29 99 85 5:38(1) 2:06(0) 0.16(0) - - 22 4 2 - - 
2P F 2.5 10.5 0:10:19 99 92 2:46(0) - - - - 16 - - - - 
3 P M 3.5 15 0:02:54 99 85 3:45(1) 0:39(0) 0:26(0) - - 17 2 I - - 
4 P M 1.8 10.8 0:05:23 99 96 - - - - - - - - - - 
5 P F 5.5 20 0:05:09 98 84 10:41(2) 1:02(0) 0:13(0) - - 46 6 1 - - 
6 P F 7.5 30 0:05:09 99 88 5:45(1) 0:19(0) - - - 25 4 - - - 
7 P M 2.7 14.5 0:16:35 100 94 0:26(0) - - - - 1 - - - - 
8P M 3 13.3 0:00:15 99 88 2:46(0) 0:19(0) - - - 10 1 - - - 
9 P M 2.5 14 3:22:35 97 73 54:59(6) 18:04(2) 12:16(1) 4:44(1) 0:42(0) 126 65 35 13 4 
10 P M 3.5 19 1:09:54 98 37 21:55(3) 6:43(1) 5:33(1) 1:58(0) 14:30(2) 93 33 19 13 25 
APPENDIX D 1: Patient details and preoperative raw oximetric data from Jones et al (1993b). 
M = midazolam premedication P = pethidine premedication. 
APPENDIX D 236 
Preoperative night - EVALUATED data, F 102 0.21 
Time in saturation range (% total time) Number of episodes (>15 sec) in saturation range 
Operator total 
Pt. No. time valid mean lowest 90-95 85-90 80-85 75-80 <75 90-95 85-90 80-85 75-80 <75 
premed discounted time SpO, SpO, (%) (0/0) ( % ) (%) (0/0) (%) (0/0) (%) (%) (%) 
(P/M) (hr,min,sec) (hr,min,sec) (%) (Y0) 
1 M 0:05:12 10:44:23 99 85 1:09(0) 0.23(0) 0.07(0) - - 1 1 - - - 
2M 0:01:42 8:50:36 100 92 0:51(0) - - - - 1 - - - - 
3 M 0:00:55 10:49:19 99 92 1:37(0) - - - - 3 - - - - 
4M 4:22:56 9:53:57 98 94 5:48(1) - - - - 7 - - - - 
5M 1:19:26 9:21:12 99 95 0:43(0) - - - - - - - - - 
6M 1:12:50 8:47:57 98 94 33:01(6) - - - - 22 - - - - 
7 M 2:56:26 10:23:47 99 93 6:03(1) - - - 10 - - - - 
8M 0:06:10 8:27:54 98 92 8:10(2) - - - - 8 - - - - 
9 M 0:06:05 9:48:50 98 94 2:09(0) - - - - 2 - - - - 
10 M 0:04:38 9:04:46 99 88 3:26(1) 0:25(0) - - - 6 - - - - 
1 P 0:06:44 12:07:32 99 92 3:37(0) - - - - 5 - - - - 
2 P 0:00:54 10:16:45 99 93 1:25(0) - - - - 1 - - - 
3 P 0:05:22 11:30:56 99 91 2:23(0) - - - 5 - - - - 
4 P 0:30:00 9:01:01 99 96 - - - - - - - - - - 
5P 0:11:44 10:11:11 98 94 2:25(0) - - - - 2 - - - - 
6 P 0:07:40 11:04:33 99 94 0:39(0) - - - - 1 - - - - 
7 P 0:00:52 10:24:53 100 94 0:28(0) - - - • _ 1 - - - - 
8P '0:02:18 10:47:17 99 93 0:56(0) - - - - 1 - - - 
9 P 1:26:50 14:13:24 98 73 19:26(2) 3:25(0) 1:29(0) 0:15(0) - 17 7 4 - - 
10 P 1:22:42 11:36:23 99 91 0:55(0) - - ,. 
- 1 - - - 
APPENDIX D 2: Preoperative oximetric data are after template evaluation from Jones et al (1993b). 
APPENDIX D 237 
Post premedication - RAW data, F102 0.21 
Time in saturation range (% total time) Number of episodes (>15 sec) in saturation range 
Satmaster 
Pt. No. time mean lowest 90-95 85-90 80-85 75-80 <75 90-95 85-90 80-85 75-80 <75 
premed discounted Sp02 SpO, (ok) (%) (%) (%) (%) (%) (%) (%) (%) (%) 
(P/M) (hr,min,sec) (0/0) (Y0) , 
1 M 0:00:00 99 92 1:41(1) - - - - 4 - - - - 
2M 0:00:14 100 94 0:12(0) - - - - 1 - - - - 
3M 0:15:53 97 64 4:31(4) 1:10(1) 3:45(4) 2:36(3) 1:00(1) 17 4 4 9 10 
4M 0:00:04 100 96 - - - - - - - - - - 
5 M 0:07:53 95 62 27:05(23) 15:21(13) 4:09(4) 1:20(1) 0:27(0) 61 43 19 8 3 
6M 0:02:49 97 82 14:58(12) 4:28(4) 1:21(1) - - 39 8 5 
7M 0:01:25 98 91 4:15(4) - - - - 22 - - - - 
8M 0:00:00 97 84 7:57(1) 1:15(1) 0.08(0) - - 22 6 2 - - 
9M 0:02:00 98 91 1:08(1) - - - - 3 - - - - 
10 M 0:00:25 99 95 0:04(0) - - - - 1 - - - - 
1 P 0:00:00 99 94 2:32(4) - - - - 8 - - - 
2 P 0:00:00 100 96 0:56(1) - - - - 2 - - - _
3 P 0:00:00 99 93 0:13(0) - - - - 2 - - - - 
4 P 0:02:00 99 97 - - - - - - - - - 
5 P 0:00:00 98 95 0:20(0) - - - - 4 - - - - 
6P 0:02:41 99 90 1:44(2) 0:02(0) - - - 6 . 1 - - - 
7P 0:00:07 100 96 - - - - - - - - - - 
8 13 0:00:00 98 94 0:25(0) - - - - 3 - - - - 
9 P 0:00:00 98 77 1:54(3) 0:47(1) 0:06(0) - - 4 3 2 - - 
10 P 0:03:16 96 69 13:26(19) 6:00(8) 3:22(5) 1:41(2) 	_. 0:16(0) 48 26 13 8 4 
APPENDIX D 3: Post premedication raw oximetric data from Jones et al (1993b). 
APPENDIX D 238 
Post premedication - EVALUATED data, F102 0.21 
Time in saturation range (% total time) Number of episodes (>15 sec) in saturation range 
Pt. No. 
premed 
(P/M) 
Operator 
time 
discounted 
(hr,min,sec) 
total 
valid 
time 
(hr,min,sec) 
mean 
SpO, 
(%) 
lowest 
SpO, 
(%) 
90-95 
(%) 
85-90 
(%) 
80-85 
(%) 
75-80 
(%) 
<75 
(%) 
90-95 
(%) 
85-90 
CYO 
80-85 
(oh) 
75-80 
(0/0) 
<75 
(0/) 
1 M 
2 M 
3M 
4 M 
5M 
6M 
7M 
8 M 
9M 
10 M 
1 P 
2P 
3 P 
4 P 
5 P 
6 P 
7 P 
8 P 
9P 
10 P 
0:01:48 
0:00:20 
0:12:28 
0:00:00 
0:47:27 
0:21:04 
0:05:18 
0:07:24 
0:00:00 
0:00:00 
1:06:02 
0:13:06 
0:00:28 
0:30:00 
0:01:03 
0:02:49 
,0:00:00 
• 0:00:14 
0:01:38 
0:35:03 
1:55:16 
1:52:58 
1:29:28 
2:14:27 
1:11:01 
1:46:23 
1:36:27 
1:52:03 
2:10:50 
1:50:57 
1:01:54 
1:23:45 
1:30:14 
1:51:07 
1:19:48 
1:22:28 
1:27:33 
1:27:13 
0:56:23 
0:37:33 
99 
100 
99 
100 
98 
98 
99 
97 	. 
98 
99 
97 
99 
99 
99 
98 
99 
100 
98 
98 
99 
95 
96 
92 
96 
87 
91 
95 
92 
91 
95 
92 
94 
95 
97 
95 
96 
96 
95 
85 
91 
0:02(0) 
- 
1:11(1) 
- 
9:55(14) 
6:34(6) 
1:00(1) 
3:34(3) 
1:08(1) 
004(0) 
2:29(4) 
0:56(1) 
0:05(0) 
- 
0:07(0) 
- 
- 
0:14(0) 
1:08(2) 
3:21(9) 
- 
- 
- 
- 
1:15(2) 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0:16(0) 
- 
-
- 
- 
- 
- 
- 
- 
- 
-
-
-
-
_ 
-
- 
- 
- 
0:02(0) 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
-' 
- 
- 
- 
- 
- 
1 
- 
11 
7 
- 
4 
1 
- 
3 
1 
- 
- 
- 
- 
- 
- 
2 
5 
- 
- 
- 
- 
2 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
. 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
APPENDIX D 4: Post premedication oximetric data after templated evaluation from Jones et al (1993b). 
APPENDIX D 239 
Recovery room - RAW data, F102 0.28 - 0.35 
Time in saturation range (% total time) Number of episodes (>15 sec) in saturation range 
Satmaster 
Pt. No. time mean lowest 90-95 85-90 80-85 75-80 <75 90-95 85-90 80-85 75-80 <75 
premed discounted SpOz SpO, (%) (0/0) (0/0) (0/) (%) (%) (%) (0/0) (0/0) (yo) 
(P/M) (hr,min,sec) (%) (%) 
1 M 0:00:29 99 82 0:26(1) 2:26(6) 0:28(1) - - 
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2 M 0:00:00 100 99 - - - - - 
3 M 0:00:00 100 98 - - - - - 
4 M 0:00:00 100 99 - - - - - 
5 M 0:01:14 100 93 0:31(2) - - - - 
6 M 0:00:07 96 82 2:29(25) 0:48(8) 0:06(1) - - 
7 M 0:00:00 99 90 1:31(8) 0:03(0) - - - 
8 M 0:00:00 96 82 8:00(40) 0:10(1) 0:50(4) - - 
9M 0:00:00 99 91 1:10(6) 0:05(0) - - - 
IOM 0:01:13 100 88 0:11(1) 0:06(0) 0:06(0) 0:07(0) - 
1 P 0:00:00 99 80 0:19(1) 0:09(1) 0:15(1) 0:13(1) - 
2 P 0:00:00 100 98 - - -  - - 
3 P 0:00:00 98 92 1:44(5) - -  - - 
4 P 0:00:00 98 91 0:28(8) - -  - - 
5P 0:00:00 99 89 1:16(7) 0:07(1) - - - 
6P 0:01:09 100 100 - - -  - - 
7 P 0:00:00 100 97 - - -  - - 
8 P 0:00:00 100 99 - - -  - - 
9 P 0:00:00 98 88 0:27(3) 0:29(3) - - - 
10 P 0:00:21 100 94 _ 	0:21(2) - -  - - 
APPENDIX D 5: Recovery room raw oximetric data from Jones et al (199313). 
APPENDIX D 240 
Recovery room - EVALUATED data, F 102 0.28 - 0.35 
Time in saturation range (% total time) Number of episodes (>15 sec) in saturation range 
Operator total 
Pt. No. time valid mean lowest 90-95 85-90 80-85 75-80 <75 90-95 85-90 80-85 75-80 <75 
premed discounted time SpO, Sp02 (0/0 ) (yo) (%) (%) (%) (%) (%) (%) (%) rho 
(P/M) (hr,min,sec) (hr,min,sec) (%) (0/0) 
1 M 0:00:10 0:37:51 99 80 0:18(1) 2:26(6) 0:49(2) 0:01(0) - 1 2 1 -  
2 M 0:00:00 0:11:54 100 99 - - - - - - - - - 
3 M 0:00:00 0:41:31 100 98 - - - - - - - - - - 
4M 0:00:00 0:14:14 100 99 - - - - - - - - - - 
5 M 0:03:52 0:29:52 100 98 - - - - - - - - - 
6 M 0:03:58 0:06:06 97 82 0:12(3) - 0:02(1) - - - - - - -  
7 M 0:02:32 0:15:26 99 96 - - - - - - - - - - 
8 M 0:02:56 0:16:57 97 85 6:39(39) - 0:01(0) - 2 - - - - 
9 M 0:32:57 0:17:45 99 95 0:50(5) - - - - 1 - - - - 
10 M 0:25:31 0:23:05 100 97 - - - -' - - - - - - 
1 P 0:00:00 0:21:50 99 80 0:19(1) 0:09(1) 0:15(1) 0:13(1) - 1 1 1 1 -  
2 P 0:00:00 0:05:17 100 98 - - - - - - - - - - 
3P 0:02:15 0:30:31 98 92 0:25(1) - - - - - - - - - 
4 P 0:01:00 0:04:32 99 97 - - - - - - - - - - 
5P 0:01:40 0:16:48 99 95 0:09(1) - - - - - - - - - 
6 P 0:09:07 0:09:31 100 98 - - - - - - - - - - 
7 P 0:12:34 0:20:30 100 100 - - - - -. - - - - - 
8 P 0:00:00 0:21:05 100 99 - - - - - - - - - - 
9 P 0:00:58 0:12:54 99 96 - - - - - - - - - - 
10 P 0:00:49 0:21:59 100 97 - - - - - - - - - - 
APPENDIX D 6: Recovery room oximetric data after template evaluation from Jones et al (1993b). 
APPENDIX D 241 
Post operative ward - RAW data, F102 0.21 
Time in saturation range (% total time) Number of episodes (>15 sec) in saturation range 
Pt. No. 
premed 
(P/M) 
Satmaster 
time 
discounted 
(hr,min,sec) 
mean 
Sp02 
(%) 
lowest 
SpO, 
(%) 
90-95 (0/0) 85-90 (%) 
80-85 
(%) 
75-80 
(%) 
<75 
(A) 
90-95 
(%) 
85-90 
(%) 
80-85 
(%) 
75-80 
(%) 
<75 
(%) 
1 M 
2M 
3M 
4M 
5M 
6M 
7 M 
8 M 
9 M 
10 M 
1 P 
2P 
3P 
4P 
5 P 
6 P 
7P 
8 P 
9P 
10 P 
0:00:05 
0:04:35 
0:00:05 
0:00:11 
0:00:45 
0:42:06 
0:00:00 
0:00:00 
0:00:00 
0:00:00 
0:00:58 
0:22:17 
0:01:14 
0:07:54 
0:00:00 
0:05:46 
0:00:04 
0:00:00 
0:00:00 
0:11:06 
99 
99 
98 
99 
99 
97 
98 
97 
98 
98 
98 
99 
98 
100 
98 
99 
99 
99 
98 
98 
97 
85 
79 
87 
88 
81 
92 
89 
95 
88 
78 
92 
93 
88 
96 
84 
80 
84 
90 
72 
-
8:26(2) 
24:54(4) 
6:11(1) 
2:26(1) 
28:19(12) 
6:03(2) 
13:05(4) 
0:25(0) 
2:35(1) 
11:31(3) 
1:17(0) 
5:51(2) 
15:57(3) 
- 
55:32(15) 
1:19(0) 
7:07(1) 
1:11(0) 
_ 	8:25(2) 
- 
1:19(0) 
2:54(1) 
1:28(0) 
0:12(0) 
4:44(2) 
- 
0:41(0) 
- 
0:08(0) 
1:10(0) 
- 
- 
4:09(1) 
- 
20:29(4) 
0:12(0) 
0:37(0) 
0:03(0) 
1:17(1) 
- 
0:02(0) 
0:17(0) 
- 
- 
1:43(1) 
- 
- 
- 
- 
0:19(0) 
- 
- 
2:18(0) 
- 
6:24(1) 
0:06(0) 
0:05(0) 
- 
0:38(0) 
- 
- 
0:12(0) 
-
-
-
- 
-
- 
- 
0:07(0) 
- 
- 
0:30(0) 
- 
0:41(0) 
0:06(0) 
- 
- 
0:19(0) 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0:09(0) 
- 
- 
- 
0:07(0) 
- 
31 
57 
18 
12 
14 
14 
38 
3 
12 
44 
8 
18 
54 
- 
168 
6 
20 
4 
25 
- 
4 
11 
1 
1 
2 
- 
4 
- 
1 
7 
- 
- 
18 
- 
52 
2 
5 
1 
2 
- 
- 
1 
- 
- 
- 
- 
- 
- 
- 
1 
- 
- 
5 
- 
22 
1 
1 
- 
1 
- 
- 
1 
- 
- 
- 
- 
- 
- 
- 
1 
- 
- 
4 
- 
3 
1 
- 
- 
1 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
. 
1 
- 
I 
APPENDIX D 7: General postoperative ward raw oximetric data from Jones et al (1993b). 
APPENDIX D 242 
Post operative ward - EVALUATED data, F 102 0.21 
Time in saturation range (% total time) Number of episodes (>15 sec) in saturation range 
Pt. No. 
premed 
(P/M) 
Operator 
time 
discounted 
(hr,min,sec) 
total 
valid 
time 
(hr,min,sec) 
mean 
SpO, 
(zio) 
lowest 
Sp02 
(%) 
90-95 
(%) 
85-90 
(%) 
80-85 
(%) 
75-80 
(0/0 ) 
<75 
(0/0) 
90-95 
(%) 
85-90 
(%) 
80-85 
(%) 
75-80 
(%) 
<75 
(%) 
1 M 
2 M 
3M 
4M 
5 M 
6 M 
7 M 
8 M 
9 M 
10 M 
1 P 
2 P 
3P 
4 P 
5P 
6 P 
7 P 
8P 
9 P 
10 P 
0:01:42 
0:05:02 
0:13:14 
0:06:08 
0:08:04 
0:36:30 
0:18:16 
0:00:34 
0:00:00 
0:00:00 
0:10:08 
0:00:52 
0:04:36 
0:30:46 
0:00:00 
1:27:12 
0:01:44 
. 0:03:12 
0:00:52 
0:12:54 
8:34:06 
5:39:38 
9:12:20 
6:51:01 
7:15:48 
3:24:17 
3:48:39 
5:10:40 
7:17:28 
7:59:34 
5:34:18 
6:45:42 
7:12:13 
7:35:29 
7:51:10 
6:26:00 
7:16:48 
8:51:32 
5:23:54 
7:33:06 
99 
100 
98 
99 
99 
98 
98 
97 
98 
98 
98 
99 
98 
100 
98 
98 
99 
99 
98 
98 
97 
87 
79 
91 
95 
87 
95 
89 
95 
88 
90 
93 
93 
94 
96 
90 
95 
84 
95 
94 
- 
3:20(1) 
12:30(2) 
1:37(0) 
0:22(0) 
5:33(3) 
0:19(0) 
12:35(4) 
0:25(0) 
2:35(1) 
6:16(2) 
0:53(0) 
3:39(1) 
1:50(0) 
- 
15:43(4) 
0:20(0) 
5:07(1) 
0:24(0) 
2:10(0) 
- 
0:52(0) 
2:13(0) 
- 
- 
0:12(0) 
- 
0:41(0) 
- 
0:08(0) 
0:29(0) 
- 
- 
- 
- 
0:08(0) 
- 
0:11(0) 
- 
- 
- 
- 
0:17(0) 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0:05(0) 
- 
- 
- 
- 
0:12(0) 
-
-
-
- 
- 
-
-
-
-
-
- 
-
-
-
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
' - 
- 
- 
- 
5 
17 
2 
- 
6 
- 
16 
- 
3 
5 
1 
4 
2 
- 
15 
- 
8 
1 
2 
_ 
1 
4 
- 
- 
- 
- 
- 
- 
- 
1 
- 
- 
- 
- 
- 
1 
- 
- 
- 
1 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
APPENDIX D 8: General ward oximetric data after template evaluation from Jones et al (1993b). 
APPENDIX D 243 
Heart rate (beats min1) after midazolam induction (min) 
Patient Body Mood on 
number weight Age arrival in 0 2 4 6 8 10 15 20 30 
(kg) (yr) theatre (*) 
1 18.70 6.0 77 106 111 116 114 113 115 113 104 
2 16.00 5.0 154 110 126 107 108 110 108 107 101 
3 20.00 6.0 92 107 138 129 120 120 147 141 122 
4 20.00 6.0 99 117 129 122 128 132 132 99 88 
5 32.00 8.5 90 93 148 130 100 96 99 102 79 
6 38.50 9.0 124 93 134 112 108 111 104 113 92 
7 14.00 5.0 122 131 156 125 110 108 129 104 101 
8 24.00 7.0 97 120 113 107 102 96 84 76 79 
9 20.00 8.0 113 110 115 113 107 108 105 105 104 
10 17.00 5.0 109 94 88 79 81 72 77 75 88 
11 25.00 7.5 81 94 109 100 98 101 105 78 87 
12 19.00 5.0 79 112 119 118 111 109 112 101 101 
APPENDIX D : Heart rate data after midazolam induction from Jones et al (1993). 
(*) 	 A: agitated, crying B: aware, apparently anxiety free C: drowsy D: asleep, responds to commands 
APPENDIX D 244 
Systolic Blood Pressure (mm Hg) after induction (min) 	 Diastolic Blood Pressure (mm Hg) after induction (min) 
Patient 
number 0 2 4 6 8 10 15 20 30 0 2 4 6 8 10 15 20 30 
1 109 102 115 99 98 76 109 107 101 47 57 48 37 36 48 43 39 39 
2 127 141 109 100 96 110 102 70 95 80 100 72 57 57 68 57 59 54 
3 105 111 146 117 109 104 127 136 121 62 57 70 54 54 50 58 59 58 
4 103 91 108 99 87 88 108 109 96 68 54 69 56 60 62 95 69 68 
5 60 94 168 117 98 92 107 116 95 46 43 86 55 41 45 38 63 37 
6 105 148 126 109 92 68 97 115 97 64 104 53 47 48 51 53 68 51 
7 107 94 117 115 94 93 102 96 91 52 41 77 49 46 46 53 44 50 
8 105 128 120 101 93 78 87 81 86 53 77 55 45 45 52 47 44 42 
9 82 112 121 111 106 103 119 106 104 47 72 61 49 47 48 57 55 45 
10 96 98 90 88 85 81 88 83 87 61 70 57 53 49 40 51 48 52 
11 119 150 125 103 88 91 111 90 117 64 78 74 51 46 61 66 65 78 
12 120 115 126 110 101 93 102 99 99 58 52 72 48 40 42 48 41 44 
APPENDIX D 10: Systolic and diastolic blood pressure data folowing midazolam induction from Jones et al (1993). 
APPENDIX D 245 
Heart rate data (beats min"' ) after flumazenil (min) 	 Respiratory rate data (breaths mm') after flumazenil (min) 
Patient 
number 0 4 6 8 10 15 20 30 0 2 4 6 8 10 15 20 	 30 
1 81 113 113 108 93 90 72 75 82 24 24 24 24 24 20 20 
2 97 114 114 124 106 78 92 92 26 25 25 25 25 25 25 
3 105 110 98 14 24 
4 88 104 90 65 68 66 33 25 25 20 
5 94 70 75 83 78 20 25 25 25 
6 92 94 75 74 83 111 100 92 11 20 20 20 22 22 20 
7 68 105 78 82 79 72 12 22 20 15 
8 79 79 79 79 79 79 82 79 77 9 9 9 9 9 18 18 
9 111 111 111 101 92 83 80 86 79 24 24 26 26 26 26 26 
10 108 104 104 133 24 24 24 24 24 
11 72 83 71 83 74 85 105 78 107 9 15 15 15 
12 75 55 65 86 60 65 67 67 67 14 14 14 24 24 24 
APPENDIX D 11: Heart rate and respiratory rate data during recovery room administration of flumazenil from Jones et at (1993). 
APPENDIX D 246 
Systolic blood pressure (mm Hg) after flumazenil (min) Diastolic blood pressure (mm Hg) after flumazenil (min) Mean change from baseline values 
Patient heart systolic resp. 
number 0 2 4 6 8 10 15 20 30 0 2 4 6 8 10 15 20 30 rate press. rate 
1 92 103 120 126 106 112 106 114 99 36 46 64 50 54 60 54 80 52 32 11 0.0 
2 104 96 96 96 94 94 106 106 61 61 49 49 45 45 46 47 17 -8 -1 
3 119 136 136 61 75 62 5 17 10 
4 96 149 132 112 120 107 68 79 51 61 71 55 16 53 -8 
5 106 113 125 100 118 78 62 81 79 73 -24 7 5 
6 114 128 128 115 111 120 117 117 51 62 56 78 62 69 94 68 2 14 9 
7 91 89 91 91 129 127 132 114 50 42 52 50 64 54 46 57 37 38 10 
8 86 90 101 42 49 48 3 4 9 
9 111 111 108 106 109 106 122 123 54 49 49 45 43 43 53 60 -10 -3 2 
10 94 98 98 111 56 40 48 74 -4 4 0 
11 123 129 131 114 128 116 107 136 95 56 64 59 52 56 71 67 47 63 11 6 6 
12 114 114 114 109 117 112 125 43 47 43 66 47 44 45 11 -5 10 
APPENDIX D 12: Blood pressure data following flumazenil administration from Jones et al (1993). 
APPENDIX D 247 
Systolic blood pressure (mm Hg) during induction (min) Diastolic blood pressure (mm Hg) during induction (min) Heart rate (beats min -I) during induction (min) 
Patient pre- pre- pre- 
number induction 1 2 5 15 30 induction 1 2 5 15 30 induction 1 2 5 15 30 
1 102 110 94 86 102 94 77 68 60 59 65 55 107 104 106 122 109 100 
4 110 104 94 81 95 81 64 58 60 60 83 118 95 99 99 103 
_ 
7 142 108 130 98 119 124 89 77 80 69 67 65 111 123 124 87 99 107 
8 114 110 95 101 101 102 87 57 54 64 61 55 114 95 92 105 91 98 
9 107 97 87 92 93 91 79 65 49 51 54 56 127 107 104 113 95 100 
10 89 88 83 89 99 66 58 52 59 66 103 115 118 132 125 
14 105 102 93 87 88 87 60 72 55 54 55 52 107 126 109 112 106 106 
16 110 108 107 95 91 72 78 70 54 61 81 90 112 89 87 
18 121 110 96 84 104 95 77 72 50 43 57 55 131 124 109 101 122 106 
20 111 111 106 85 94 90 88 88 71 57 59 49 106 124 115 104 108 104 
23 100 110 98 89 98 71 82 60 53 60 95 118 115 87 109 
24 96 92 92 73 106 72 65 65 49 68 98 114 123 95 125 
25 130 121 84 89 113 104 89 74 82 35 60 92 65 74 77 56 124 115 
26 111 109 102 92 90 65 65 67 60 60 79 84 93 104 95 
29 116 111 105 77 100 96 56 65 50 38 49 49 125 123 122 74 84 88 
31 119 119 99 67 93 94 65 64 56 37 49 . 47 176 107 121 93 100 103 
33 124 94 125 92 88 85 61 91 50 47 , 148 134 141 116 120 
34 109 96 99 94 108 112 81 67 70 56 67 69 92 114 100 90 102 108 
38 156 117 106 107 95 104 82 55 61 55 - 41 41 140 194 138 142 120 133 
39 101 102 100 116 102 100 51 68 58 70 - 55 58 91 94 119 120 102 113 
APPENDIX D 13: Induction haemodynamic data in the flumazenil group from Jones et at (1991). 
APPENDIX D 248 
Respiratory rate (breaths mm') during induction (min) End tidal carbon dioxide (mm Hg) during induction Maximum change in paramters 
during induction 
Patient pre- pre- mean 
number induction 1 2 5 15 30 induction 1 2 5 15 30 RR SBP HR ETCO, 
1 35 26 26 35 31 27 49 44 53 56 0 8 15 50 
4 30 34 32 35 30 60 60 65 63 57 5 -29 35 62 
7 28 44 44 57 55 60 50 49 59 56 32 -44 12 54 
8 34 29 41 47 53 44 42 46 52 51 19 -19 23 48 
9 32 32 41 42 39 48 50 48 54 37 -20 -27 47 
10 29 58 49 43 47 66 10 29 52 
14 20 28 32 35 32 47 47 54 56 18 19 51 
16 24 18 20 20 44 46 48 20 19 31 47 
18 24 32 29 29 36 35 47 52 54 53 70 12 -37 30 46 
20 19 36 28 48 59 58 26 18 55 
23 28 >60 >60 >60 >60 45 32 60 32 10 23 46 
24 24 40 42 57 54 50 57 33 10 27 54 
25 37 38 40 52 63 68 46 59 61 
26 39 46 34 45 49 49 21 25 48 
29 28 24 31 30 34 30 42 52 , 56 6 -20 -51 45 
31 39 39 24 35 37 46 46 46 51 49 -83 48 
33 43 21 39 38 39 47 1 -32 41 
34 24 32 37 35 31 47 53 58 55 13 3 22 53 
38 36 29 33 46 49 47 .37 43 46 13 -61 54 46 
39 24 23 42 64 49 43 44 44 39 48 . 63 -40 15 -72 44 
APPENDIX D 14: Induction respiratory data in the flumazenil group from Jones et al (1991). 
RR = respiratory rate (breaths min-'); SBP = systolic blood pressure (mm Hg); HR = heart rate (beats 	 ); ETCO3= end-tidal carbon dioxide tension (mm hg) 
APPENDIX D 249 
Respiratory rate (breaths min-I) after flumazenil (min) Heart rate (beats min') after flumazenil (min) Maximum change in parameters 
after flumazenil 
Patient pre- pre- 
number flumazenil 2 5 10 30 60 flumazenil 2 5 10 30 60 RR SBP HR 
1 20 16 18 18 93 77 104 90 83 -4 20 11 
4 97 92 94 107 98 100 23 10 
7 105 83 147 101 85 90 24 42 
8 86 66 75 60 84 82 20 4 
9 97 84 78 84 75 73 15 -25 
10 138 125 120 94 113 120 7 -44 
14 22 24 22 81 65 97 96 97 74 4 66 
16 24 24 22 72 65 64 70 64 60 20 8 
18 18 24 24 24 24 94 113 113 102 108 108 25 16 
20 18 20 20 24 24 20 94 111 78 78 86 102 2 22 17 
23 102 89 81 125 104 100 11 21 
24 36 30 93 79 84 86 84 88 13 14 
25 111 136 136 122 96 92 -7 25 
26 92 68 150 72 108 13 58 
29 28 24 20 82 65 65 64 94 80 -3 -17 
31 98 88 61 35 -37 
33 19 19 19 24 18 22 113 113 98 94 98 102 0 0 -5 
34 24 20 20 24 20 18 97 82 73 100 89 90 -4 7 -24 
38 24 24 24 121 122 122 163 0 -11 0 
39 32 108 88 83 -9 -25 
APPENDIX D 15: Patient cardio-respiratory data folowing flumazenil administration from Jones et at (1991). 
RR = respiratory rate (breaths min') 	 SBP = systolic blood pressure (mm Hg) HR = heart rate (beats min') 
APPENDIX D 250 
Systolic blood pressure (mm Hg) after tlumazenil (min) Diastolic blood pressure (mm Hg) after flumazenil (min) 
Patient pre- pre- 
number flumazenil 2 5 10 30 60 flumazenil 2 5 10 30 60 
1 88 82 108 99 101 81 59 57 54 59 
4 98 94 99 107 121 110 65 65 76 82 84 80 
7 122 138 146 146 135 120 59 63 81 87 73 70 
8 103 108 123 114 110 110 65 67 90 69 70 70 
9 95 90 96 106 100 103 54 52 63 63 58 54 
10 88 84 95 92 85 90 51 56 68 76 68 70 
14 81 74 85 96 96 98 52 35 47 58 58 41 
16 110 111 130 124 116 100 73 82 73 92 82 60 
18 87 93 112 113 120 120 44 54 52 76 90 90 
20 87 109 94 94 108 110 51 71 59 59 62 72 
23 93 82 88 101 110 110 43 46 50 59 70 70 
24 95 82 86 106 110 104 49 47 58 76 86 76 
25 101 104 94 III 44 48 60 
26 96 95 109 107 100 54 54 71 69 70 
29 82 79 79 74 100 110 43 35 35 38 56 60 
31 81 90 125 48 47 83 
33 83 83 83 81 79 35 35 38 32 41 
34 102 101 109 130 113 99 58 58 58 88 77 78 
38 91 88 88 82 41 41 41 68 
39 100 91 96 49 47 - 	49 
APPENDIX D 16: Haemodynamic data after flumazenil administration from Jones et al (1991). 
Systolic blood pressure (mm Hg) during induction (min) Diastolic blood pressure (mm Hg) during induction (min) 
APPENDIX D 251 
Heart rate (beats mm') during induction (min) 
Patient 
number 
pre- 
iinduction 1 2 5 15 30 
pre- 
induction 1 2 5 15 30 
pre- 
induction 1 2 5 15 30 
2 93 108 95 83 98 41 41 40 35 41 133 133 133 129 123 
3 108 105 95 94 116 60 60 45 41 48 97 104 91 117 133 
5 115 134 126 120 122 93 67 113 90 97 62 48 121 116 147 149 116 126 
6 100 92 89 79 109 107 65 67 60 36 66 , 53 96 118 120 124 111 116 
11 97 91 83 72 87 58 61 55 44 58 101 93 103 92 109 
12 102 109 129 71 96 65 79 98 37 60 93 86 100 91 97 
13 108 100 98 73 91 68 64 69 43 59 98 101 113 98 104 
15 112 112 87 82 99 87 56 48 44 46 49 47 89 88 84 86 82 72 
17 102 109 101 91 92 91 77 77 57 50 65 59 136 148 110 122 125 130 
19 105 105 105 105 98 101 79 79 79 79 58 64 110 150 140 102 120 116 
21 104 90 90 90 90 93 66 65 54 54 58 52 114 103 130 III 124 141 
22 113 - 127 121 121 103 68 66 70 70 67 80 96 89 78 81 
27 115 112 95 94 98 94 76 74 59 55 46 46 109 105 108 96 105 101 
28 104 110 103 98 95 100 69 71 64 53 48 45 97 121 124 103 105 107 
30 93 94 90 84 95 57 65 53 55 60 . 94 90 98 117 115 
32 106 111 105 94 91 63 71 72 53 41 89 113 103 97 103 
35 129 109 106 103 114 75 73 49 49 63 107 149 108 121 139 
36 100 98 105 93 96 65 72 64 56 53 85 102 119 89 108 
37 104 90 85 99 96 57 37 40 52_ 56 100 84 74 94 99 
40 130 122 113 82 111 113 91 80 47 49 69 63 141 137 141 126 125 129 
APPENDIX D 17: Induction haemodynamic data in the placebo group from Jones et at (1991). 
APPENDIX D 252 
Respiratory rate (breaths miff') during induction (min) End-tidal carbon dioxide tension (mm Hg) during induction (min) Maximum change in parameters 
during induction 
Patient pre- pre- mean 
number induction 1 2 5 15 30 induction 1 2 5 15 30 RR SBP HR ETCOz 
2 48 41 43 57 50 59 15 -10 55 
3 24 32 28 28 40 48 50 52 50 16 8 36 50 
5 28 33 33 43 41 49 47 48 69 72 19 28 59 
6 30 39 35 37 48 47 40 40 39 63 64 18 7 28 49 
11 24 32 44 53 49 50 54 63 29 -25 8 56 
12 29 38 40 55 57 64 27 4 59 
13 24 22 32 44 44 45 50 61 35 15 50 
15 24 28 34 41 51 42 49 51 27 30 17 47 
17 30 39 48 44 42 43 48 54 59 18 7 12 51 
19 20 55 55 60 49 45 57 40 40 50 
21 24 29 33 34 45 45 58 63 73 21 -14 17 60 
22 24 30 30 48 51 53 52 24 10 16 52 
27 24 30 36 35 32 51 47 51 54 12 21 13 51 
28 42 35 32 32 52 56 70 66 6 27 61 
30 27 40 35 45 . 44 64 2 23 51 
32 28 26 26 54 . 	57 -2 5 24 56 
35 28 30 38 40 46 49 51 12 -26 42 49 
36 28 31 35 48 39 41 47 20 5 34 42 
37 32 27 28 28 35 41 45 46 55 3 19 -26 45 
40 28 37 43 42 40 32 37 39 47 55 52 15 -48 -16 46 
APPENDIX D 18: Induction respiratory data in the placebo group from Jones et at (1991). 
RR = respiratory rate (breaths min-I); SBP = systolic blood pressure (mm Hg); HR = heart rate (beats 	 ); ETCO2= end-tidal carbon dioxide tension(mm Hg) 
Respiratory rate (breaths min') after placebo (min) Heart rate (beats min') after placebo (min) 
APPENDIX D 
Maximum change in parameters after 
placebo administration 
Patient 
number 
pre- 
placebo 2 5 10 30 60 
pre- 
placebo 2 5 10 30 60 RR SBP HR 
2 35 36 40 115 111 110 108 102 4 -13 
3 32 34 34 28 101 92 91 88 87 2 -11 -14 
5 129 115 111 108 96 117 13 -45 
6 117 125 93 85 78 80 31 -43 
11 101 97 101 100 80 81 4 -4 
12 92 101 89 86 87 68 11 9 
13 101 96 87 76 68 62 -7 -14 
15 28 28 28 28 26 24 63 66 65 74 83 78 0 6 3 
17 32 22 26 24 24 125 115 147 101 101 124 24 22 
19 36 36 36 26 26 24 122 122 122 120 120 108 0 V 0 
21 24 24 24 28 28 117 117 117 104 147 120 0 0 
22 28 24 24 24 24 24 73 79 79 70 72 70 -4 3 6 
27 24 24 22 102 93 91 91 127 97 -4 -11 
28 24 24 24 24 94 90 74 117 78 0 2 -4 
30 26 20 115 104 98 91 75 75 -4 17 
32 26 26 24 93 87 90 78 76 77 0 -10 -6 
35 20 20 20 24 24 22 105 105 97 96 88 75 0 -9 -8 
36 113 117 113 110 100 -1 4 
37 24 24 22 24 94 94 96 84 82 58 -7 2 
40 129 120 128 120 102 4 -9 
APPENDIX D 19: Cardio-respiratory data after placebo administration from Jones et al (1991). 
RR = respiratory rate (breaths min") 	 SBP = systolic blood pressure (mm Hg) HR = heart rate (beats 	 ) 
253 
APPENDIX D 254 
Systolic blood pressure (mm Hg) after placebo (min) 	 Diastolic blood pressure (mm Hg) after placebo (min) 
Patient 
number 
pre- 
placebo 2 5 10 30 60 
pre- 
placebo 2 5 10 30 60 
2 77 80 81 79 80 32 30 44 43 50 
3 87 83 78 80 76 48 35 39 42 41 
5 93 87 87 87 86 104 53 44 44 46 48 70 
6 86 117 105 103 103 95 35 47 51 49 53 64 
11 68 66 72 73 71 70 33 30 39 38 36 37 
12 93 98 104 83 109 88 48 59 59 61 66 44 
12 82 79 75 67 75 55 47 42 39 41 37 45 
15 93 95 99 98 101 88 43 47 43 41 49 42 
17 89 87 113 109 98 100 62 47 58 62 59 60 
19 81 82 81 85 125 120 31 33 35 35 71 76 
21 92 92 97 53 90 51 51 62 46 50 
22 93 96 96 90 110 110 40 42 42 46 60 70 
27 87 81 83 83 142 112 51 42 41 41 63 72 
28 85 87 104 100 106 43 46 49 51 43 
30 85 81 85 88 84 85 49 40 47 53 46 50 
32 81 77 81 86 85 112 31 33 . 	35 58 33 69 
35 101 101 92 99 85 117 51 51 49 46 43 68 
36 83 82 82 76 82 38 39 37 41 42 
37 88 88 81 87 84 85 47 .; 	47 54 55 58 58 
40 98 102 98 102 102 44 45 45 45 45 
APPENDIX D 20: Haemodynamic data during placebo administration from Jones et at (1991). 
APPENDIX D 255 
Patient Induction Time after induction (min) Maximum change 
number agent 0 1 2 3 4 5 6 7 8 9 10 in first 6 min 
4 128 109 106 105 106 106 90 110 115 115 121 -38 
7 105 115 107 85 89 92 II I 114 106 106 -20 
9 123 115 109 97 97 92 99 100 95 93 93 -31 
11 105 105 105 66 89 91 89 89 89 92 95 -39 
12 108 105 98 89 87 81 72 95 97 92 -27 
14 103 108 113 96 78 87 87 107 98 105 105 -25 
19 110 88 87 87 83 81 103 -29 
20 118 104 95 93 85 78 90 108 97 101 114 -40 
23 110 116 106 93 95 112 98 94 96 103 95 -17 
26 95 88 95 110 93 90 97 91 111 123 105 15 
2 105 132 108 101 91 84 86 92 88 86 95 27 
5 119 88 83 82 82 84 90 93 88 87 84 -37 
6 127 90 88 91 89 85 92 91 81 82 -42 
13 94 99 93 82 84 92 76 87 91 93 97 -25 
16 104 86 78 71 68 83 84 86 84 -36 
17 94 81 80 75 74 79 89 88 89 91 -20 
18 103 103 93 78 78 78 85 85 -25 
22 104 77 68 75 84 79 79 88 100 88 92 -36 
25 99 90 86 83 84 85 86 89 98 96 -16 
30 114 115 98 81 82 89 67 86 94 93 106 -47 
1 94 109 111 120 108 103 105 103 92 90 92 26 
3 99 99 99 86 74 93 83 82 84 84 -25 
8 119 112 106 102 95 95 104 116 103 100 99 -24 
10 133 107 129 120 88 85 108 114 119 119 120 -48 
15_ 142 137 116 103 86 101 107 89 125 -56 
21 113 100 97 100 96 69 85 91 91 85 95 -44 
24 108 87 86 72 76 79 79 79 89 -36 
27 115 116 106 103 101 99 100 101 88 102 99 -16 
28 103 107 98 95 84 91 74 73 79 122 91 -29 
29 136 109 93 84 85 84 84 77 77 88 86 -52 
APPENDIX D 21: Systolic blood pressure data (mm Hg) measured using the Cardiocap CM104 Tm during induction of anaesthesia 
with midazolam (M), propofol (P) and thiopentone (T) from Jones et at (1993d). 
APPENDIX D 
Patient 	 Induction 
number 	 agent 0 1 2 3 
Time 
4 
after 
5 
induction 
6 
(min) 
7 8 9 10 
Maximum change in 
first 6 min 
4 90 60 56 57 57 56 46 63 65 62 71 -44 
7 84 75 62 49 52 56 80 71 65 65 -35 
9 79 63 67 57 52 63 63 58 57 53 54 -27 
11 66 75 62 36 58 48 53 48 51 51 55 -30 
12 75 62 64 53 53 46 44 56 61 56 -29 
14 49 45 45 37 39 39 39 46 36 42 42 -12 
19 54 49 43 48 34 36 63 -20 
20 74 57 56 51 49 37 56 61 57 63 75 -37 
23 66 84 73 61 59 74 65 60 65 61 60 18 
26 36 45 47 55 45 45 40 44 46 55 43 19 
2 60 80 70 58 46 46 47 51 48 44 51 20 
5 61 57 47 49 50 52 60 59 56 54 51 -14 
6 73 42 37 36 38 37 42 37 36 37 -37 
13 55 45 42 40 39 38 53 42 43 39 43 -17 
16 70 41 38 41 37 48 48 47 48 -33 
17 55 45 42 43 38 46 54 40 52 52 -17 
18 63 63 49 45 45 45 45 45 -18 
22 56 46 46 43 43 44 44 59 57 56 58 -13 
25 59 51 46 44 48 44 47 49 56 56 -15 
30 67 61 51 42 45 49 39 58 56 54 69 -28 
1 55 61 60 80 65 56 64 62 49 51 53 25 
3 59 60 65 55 39 48 50 47 48 51 -20 
8 81 72 67 61 54 55 93 100 62 60 61 -27 
10 78 41 72 63 45 38 58 52 54 52 57 -40 
15 58 52 47 37 47 43 50 50 42 -21 
21 62 54 56 47 41 39 45 41 46 38 45 -23 
24 68 47 53 44 37 40 40 40 48 -28 
27 73 72 64 56 54 55 76 ..58 55 52 59 -19 
28 76 56 49 48 51 42 38 37 41 90 48 -38 
29 68 61 55 47 42 45 44 46 47 34 50 -26 
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APPENDIX D 22: Diastolic blood pressure data (mm Hg) measured using the Cardiocap CM104Tm during induction of anaesthesia with 
midazolam (M), propofol (P) and thiopentone (T) from Jones et al (1993d). 
APPENDIX D 
Patient 	 Induction 
number 	 agent 0 1 2 3 
Time 
4 
after 
5 
induction 
6 
(min) 
7 8 9 10 
Maximum change in 
first 6 min 
4 105 76 71 73 74 74 62 81 83 81 90 -43 
7 90 85 75 60 62 63 93 84 77 77 -30 
9 94 80 81 70 67 73 75 72 70 66 67 -27 
11 79 85 76 46 68 62 65 62 64 65 68 -33 
12 85 75 75 65 63 57 51 68 	, 74 68 -28 
14 66 65 67 51 51 53 53 63 58 62 62 -15 
19 68 60 55 57 49 50 63 -19 
20 84 70 66 63 63 63 69 82 70 76 86 -21 
23 77 96 83 71 70 86 75 71 72 70 71 19 
26 56 58 63 76 60 59 58 56 70 73 63 20 
2 76 96 78 71 60 58 58 63 61 58 65 20 
5 83 64 59 58 59 60 70 71 -64 63 61 -25 
6 85 54 53 54 54 52 56 55 50 51 -33 
13 67 62 58 53 53 55 61 56 58 56 60 -14 
16 78 58 53 50 49 61 61 61 61 -29 
17 66 55 54 53 50 56 66 56 50 64 -16 
18 76 78 76 51 50 51 52 61 -26 
22 71 53 51 50 54 53 53 65 69 64 67 -21 
25 69 61 56 55 57 58 57 61 68 67 -14 
30 78 77 66 52 55 63 47 67 67 66 79 -31 
1 66 73 76 90 79 70 78 74 61 64 64 24 
3 71 73 77 66 50 58 62 59 60 62 -21 
8 95 85 80 74 69 69 68 71 77 74 74 -27 
10 96 63 91 82 59 54 75 73 76 74 78 -42 
15 85 81 69 61 59 64 68 62 74 -26 
21 73 65 65 62 57 48 58 55 	. 58 57 59 -25 
24 77 58 63 50 47 55 53 53 60 -30 
27 87 88 77 73 70 66 86 .- 71 59. 68 70 -21 
28 84 68 59 59 61 54 49 45 51 102 56 -36 
29 83 80 65 56 55 56 58 55 57 52 59 -28 
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APPENDIX D 23: Mean blood pressure data (mm Hg) measured using the Cardiocap CM104Tm during induction of anaesthesia 
with midazolam (M), propofol (P) and thiopentone (T) from Jones et al (1993d). 
APPENDIX D 
Patient 	 Induction 
number 	 agent 0 1 2 3 
Time 
4 
after 
5 
induction 
6 
(min) 
7 8 9 10 
Maximum change in 
first 	6 min 
4 123 112 90 95 94 95 93 110 111 109 117 -33 
7 94 124 94 74 104 92 113 120 106 106 30 
9 114 106 108 107 125 114 98 95 93 93 94 -16 
11 130 130 127 116 129 125 118 113 114 112 118 -14 
12 88 89 119 116 122 104 89 114 106 105 34 
14 105 129 107 105 99 107 109 109 113 110 107 24 
19 73 83 79 79 77 81 94 10 
20 112 114 107 111 115 114 152 134 123 120 153 40 
23 81 122 126 120 119 109 136 133 127 117 114 55 
26 89 105 128 131 103 105 104 107 112 137 139 42 
2 78 98 106 108 97 81 95 85 91 86 96 30 
5 129 120 123 125 125 126 129 139 129 127 124 -9 
6 108 90 89 91 87 86 86 86 83 86 88 -22 
13 91 94 94 87 85 88 87 97 93 95 93 -6 
16 112 113 111 107 108 104 104 105 103 -5 
17 87 92 94 95 96 98 95 95 94 95 11 
18 113 124 108 101 100 99 92 97 -21 
22 93 87 89 81 78 69 81 85 84 78 89 -24 
25 75 96 89 87 82 85 85 94 85 81 21 
30 107 141 116 108 101 99 100 96 97 93 117 34 
1 135 128 121 148 135 119 113 115 117 104 104 -22 
3 89 117 119 109 95 93 92 94 97 98 99 30 
8 103 129 130 125 122 119 97 103 91 94 97 27 
10 96 131 133 100 93 81 83 86 91 93 93 37 
15 120 113 108 102 98 95 89 96 95 95 -31 
21 83 105 103 105 98 91 86 82 84 89 91 22 
24 91 99 97 89 84 78 73 78 80 -13 
27 110 129 113 99 86 82 83 _78 83 83 81 -28 
28 106 113 119 121 115 109 99 87 88. 92 92 15 
29 166 140 111 97 89 93 98 121 101 118 106 -77 
APPENDIX D 24: Heart rate data (beats min') measured using the Cardiocap CM104Tm during induction of anaesthesia 
with midazolam (M), propofol (P) and thiopentone (T) from Jones et at (1993d). 
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APPENDIX D 259 
Finapres Haemodynamic Data - Midazolam Group - (n = 8) 
SYSTOLIC 
BLOOD PRESSURE 
(mmHg) 
DIASTOLIC 
BLOOD PRESSURE 
(mmHg) 
MEAN 
BLOOD PRESSURE 
(mmHg) 
HEART 
RATE 
(beats min') 
TIME 
(sec) 
average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range 
-120 102 40 35 - 164 72 25 29-113 85 29 31-133 92 20 67 - 123 
-110 101 41 34 - 167 69 27 29-117 81 32 30 -134 100 20 70-128 
-100 105 29 71-148 72 20 52 -111 86 24 62 -131 98 19 70 - 134 
-90 109 32 62-169 74 22 53 -122 88 26 54 -141 97 17 67 - 126 
-80 106 33 62 - 168 74 22 55 -122 86 26 54 -141 96 18 64 - 128 
-70 113 33 74 - 180 78 21 56-125 91 26 64-146 98 17 69 - 124 
-60 114 27 87 - 168 81 17 55 -114 94 20 68-137 102 14 78-126 
-50 113 28 85 - 166 80 17 59 - 114 94 20 70-131 101 13 83- 121 
-40 117 26 89 - 169 82 18 54-118 94 22 69 -139 103 15 85- 133 
-30 116 27 90 - 171 81 18 55-117 95 21 69-139 100 16 76 - 125 
-20 116 26 92 - 165 79 18 55-115 95 21 70-137 99 16 72 - 125 
-10 118 24 93 - 164 82 17 61 -116 96 20 70 -137 105 15 86 - 131 
0 115 19 89 - 146 83 16 60-113 97 17 74 -130 99 18 73 - I'29 
10 116 28 84 - 170 83 20 60-122 96 21 70 -138 102 12 84 - 115 
20 120 39 63 - 192 82 27 38 -124 95 30 ' 48-150 101 21 72-141 
30 104 23 63 - 132 73 21 38 - 94 88 23 47-114 101 17 76-132 
40 106 24 61 - 130 72 20 36 - 95 87 23 46-118 101 11 87-117 
50 100 24 53 - 128 68 18 33-88 82 22 38-101 99 16 79-127 
60 100 24 56-124 68 19 33 - 88 81 21 42 -106 102 22 65 - 140 
70 106 32 55 - 162 72 23 33- 110 84 25 41 - 121 93 70 - 107 
80 101 21 57 - 122 71 19 34 - 92 80 18. 42 -101 97 27 63 - 148 
90 98 20 57 - 117 68 18 32-84 81 20 41-101 102 21 70 - 133 
100 95 22 52 - 116 67 21 30 - 94 77 21 38 ;102 96 19 70 - 133 
110 97 21 57 - 123 68 19 34 - 93 78 20 40-107 102 21 74- 129 
120 102 12 83 - 115 73 14 53-94 85 16 64-112 108 24 67 - 140 
130 100 14 81 - 127 70 13 52 - 94 83 14 64 -111 108 21 75- 142 
APPENDIX D 260 
SYSTOLIC 
BLOOD PRESSURE 
(mmHg) 
DIASTOLIC 
BLOOD PRESSURE 
(mmHg) 
MEAN 
BLOOD PRESSURE 
(mmHg) 
HEART 
RATE 
(beats min") 
TIME 
(sec) 
average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range 	 _ average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range 
140 102 16 82-134 72 14 54-102 84 15 66-117 108 25 60-143, 
150 100 14 82-125 71 12 52-94 83 12 66-107 110 23 70-142 
160 98 11 80-113 70 10 54-83 82 12 67-104 112 23 75-143 
170 96 12 80-113 69 11 50-83 80 10 63-93 112 21 85-144 
180 95 12 76-113 68 12 48-84 79 11 59-93 110 19 86-145 
190 96 17 74-131 70 17 47-101 80 17 56-115 108 19 91-145 
200 98 19 72-135 70 17 46-100 81 17 55-113 110 17 96-143 
210 100 24 71-153 74 23 46-120 85 24 55-136 112 19 90-142 
220 98 21 69-142 73 19 46-110 82 21 54-127 110 24 65-139 
230 94 14 68-112 70 13 47-90 80 13 54-96 114 15 96-137 
240 96 20 72-139 71 19 48-114 81 17 58-117 115 19 95-141 
250 94 18 72-128 69 16 48-101 79 14 57-107 112 20 86-145 
260 96 25 70-152 71 22 46-120 82 25 55-139 109 19 82-138 
270 98 29 68-163 72 24 44-126 83 28 54-147 110 16 92-136 
280 99 27 66-158 72 21 42-116 82 23 51-132 110 18 84-132 
290 98 26 65-154 72 20 42-115 83 23 50-131 111 16 88-132 
300 97 23 63-143 71 19 41-108 82 21 49-124 109 17 88-133 
310 96 29 62-160 71 23 41-121 81 24 49-134 107 19 76-136 
320 95 29 63-158 70 22 42-120 81 27 49-141 107 18 77-134 
330 95 32 62-165 71 27 41-132 81 29 49-146 108 20 75-132 
340 93 34 61-167 68 28 40-132 80 31 48-151 106 17 80-133 
350 91 33 53-160 68 30 35-134 75 27 41-130 98 16 70-127 
360 93 23 63-140 70 21 41-114 81 _r 23 49-131 108 17 82-129 
370 96 32 64-170 70 26 42-130 82 29 51-149 105 18 74 - 125 
380 97 33 63-169 72 26 42-128 83 29 50-147 103 18 74-126 
390 97 32 65-166 72 25 44-127 83 29 52-146 100 18 68-122 
400 97 31 65 - 165 72 26 43-128 82 28 52-144 105 18 75 - 127 
APPENDIX D 261 
SYSTOLIC 
BLOOD PRESSURE 
(mmHg) 
DIASTOLIC 
BLOOD PRESSURE - 
(mmHg) 
MEAN 
BLOOD PRESSURE 
(mmHg) 
HEART 
RATE 
(beats tale) 
TIME 
(sec) 
average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range 
410 98 31 66 - 157 74 23 43-119 85 27 51 -136 103 20 71 - 125 
420 99 33 61 - 160 74 25 43 -121 86 29 51 -140 102 20 65 - 127 
430 98 32 59 - 155 73 23 43-115 84 27 52 -133 104 20 67 - 133 
440 97 32 58 - 153 72 23 43-113 83 28 52 -133 - 103 22 66 - 136 
450 99 33 60 - 157 74 24 44-117 85 28 53 -136 105 21 70 - 138 
460 99 31 62 - 155 74 24 44-117 84 27 54 -134 106 22 69- 138 
470 99 32 60 - 156 74 23 49-118 84 27 54 -135 108 19 72 - 136 
480 101 33 62 - 163 75 25 51 -125 86 29 57-143 108 19 73 - 136 
490 101 31 64 - 161 75 24 53 -123 87 28 58 -142 108 19 72 - 135 
500 101 31 66 - 161 75 23 55 -124 86 27 60-141 109 19 72- 135 
510 103 33 66 - 169 76 25 53-130 88 29 60 -148 107 • 20 70 - 135 
520 101 33 60- 167 75 26 48 -128 86 - 	 29 54 -147 107 20 69- 134 
530 91 17 64 - 110 65 11 51 - 79 77 13 58 - 93 105 21 69 - 133 
540 104 38 64 - 183 75 30 51 -141 84 25 58 -136 105 19 69 - 132 
550 99 33 61 - 165 73 25 49-124 85 28 56 -142 107 21 69- 134 
560 99 31 62 - 160 71 24 46 -119 83 27 54-138 107 20 72 - 133 
570 100 31 67 - 164 73 24 49 -123 85 27. 58 -142 108 21 70 - 132 
580 100 29 69 - 161 72 22 51 -119 85 25 60 -138 107 21 69 - 132 
590 102 28 71 - 158 73 21 52-115 86 24 p2-135 107 20 67 - 132 
600 102 29 71 -159 72 21 52-116 85 25 62 -136 108 21 67 - 133 
610 102 29 71 - 159 73 21 52-115 85 24 60 -134 108 21 68 - 133 
620 102 27 72 - 153 73 20 52 -111 85 22 63 -128 110 22 69 - 134 
630 102 27 74 - 156 73 20 53-112 86 J 	 23 64 -131 109 21 70 - 132 
640 101 26 73 - 153 72 20 53-110 85 23 63 -130 108 21 69 - 133 
650 101 25 73 - 149 72 19 52 -108 85 21 64125 110 22 71 - 133 
660 102 27 75 - 155 73 21 52 -113. 86 23 63 -131 110 22 71 - 134 
670 102 28 75 - 157 73 22 51 -116 86 24 63 -134 111 24 70 - 136 
APPENDIX D 262 
SYSTOLIC 
BLOOD PRESSURE 
(mmHg) 
DIASTOLIC 
BLOOD PRESSURE 
(mmHg) 
MEAN 
BLOOD PRESSURE 
(mmHg) 
HEART 
RATE 
(beats mi n t) 
TIME 
(sec) 
average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range 
680 102 29 71 - 158 73 23 50-116 86 25 63 -135 112 25 71 - 137 
690 103 30 72 - 160 73 23 50-117 86 26 61 -136 112 22 76 - 138 
700 103 27 75 - 156 74 21 50 -113 86 23 61 -131 114 20 85 - 138 
710 102 24 75 - 147 74 20 50-113 86 22 61 -129 110 20 80 - 136 
720 104 27 75 - 156 74 21 49-115 87 23 61 -133 112 19 84 - 136 
730 105 27 75 - 156 74 20 49-112 87 22 61 -129 113 18 87 - 133 
740 105 26 75 - 155 74 19 49-111 88 22 60 -130 111 17 88 - 132 
750 103 25 75 - 151 73 18 49 -107 86 21 61 -126 112 17 95 - 135 
760 103 26 77 - 154 73 19 51 -110 86 22 63 -128 112 16 91 - 133 
770 103 25 74 - 151 73 19 51 -110 86 21 63 -127 114 13 99 - 133 
780 104 25 79 - 155 75 19 53-114 88 22 65 -132 113 14 95 - 133 
790 105 26 80 - 158 74 21 54-117 88 22 67 -135 113 14 95 - 133 
800 103 27 76 - 158 74 20 55 -116 86 23 65 -133 114 12 102 - 133 
810 104 28 77 - 162 74 22 55 -121 87 25 66 -139 113 15 92 - 132 
820 104 28 77 - 162 74 22 54 -120 88 24 66 -138 112 17 82 - 132 
830 105 28 82 - 164 74 23 52 -121 88 25 65 -140 111 16 86 - 132 
840 104 27 81 - 162 73 22 52-119 87 25 65 -139 113 13 100 - 132 
APPENDIX D 25: Haemodynamic data measured using the Finapres TM during induction of anaesthesia with 
midazolam from Jones et al (1993d) 
APPENDIX D 263 
Finapres Haemodynamic Data - Propofol Group - (n = 9) 
SYSTOLIC 
BLOOD PRESSURE, 
(mmHg) 
DIASTOLIC 
BLOOD PRESSURE 
(mmHg) 
MEAN 
BLOOD PRESSURE 
(mmHg) 
HEART 
RATE 
(beats min') 
TIME 
(sec) 
average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range average data standard 
deviation 
range average 
data 
standard 
deviation 
range 
-120 114 44 47-169 61 32 23-105 78 37 26 -125 99 15 86-116 
-110 119 37 71-174 61 34 27 -108 81 36 40 -132 92 12 78-108 
-100 113 44 47 -168 58 37 16-107 75 42 26 -129 93 14 72-111 
-90 118 29 83-171 60 30 27 -105 78 34 31 -129 93 17 65-114 
-80 110 41 46-172 59 33 18-106 76 37 29 -129 98 20 69-128 
-70 120 29 89-170 64 28 18-102 83 30 37-127 94 11 76 -105 
-60 109 28 59-145 54 26 20 - 82 72 26 34-101 94 10 78 -105 
-50 107 33 50 -150 54 28 16 - 89 71 31 26-109 94 14 78-110 
-40 110 29 60-148 58 27 22 - 85 75 27 39-105 91 9 80-i06 
-30 108 36 41 -149 56 29 14 - 86 74 31 26-107 93 15 76-110 
-20 121 16 96-139 66 20 35 - 85 83 20 53 -105 99 16 78 -122 
-10 123 12 107 -139 69 18 34 - 85 87 18 54-107 99 20 80 -135 
115 21 80-145 74 22 38 -108 91 25 59 -139 101 38 12 -133 
10 103 26 70 -140 66 27 28 -107 82 28 49-125 108 30 46-143 
20 96 36 56-i64 61 33 24 -129 74 34 28-138 109 15 96 -140 
30 95 36 47 -165 59 27 13 -107 72 31 24 -131 109 17 91 -133 
40 94 35 42 -163 57 26 9-97 70 29 17-119 103 10 85-120 
50 94 	' 35 42-146 58 27 9-91 71 29 17 -107 102 7 93-114 
60 93 32 49 -137 55 24 18-80 69 27 30-99 99 10 86-114 
70 88 31 39 -134 55 23 16 - 84 66 26 28 -103 98 10 82-116 
80 84 33 39-131 56 27 16 - 88 66 29 ' 22 - 99 104 10 86 -117 
90 94 32 46 -136 61 28 15 -100 74 30 27 -110 104 14 82 -122 
100 88 27 43 -129 55 23 16 - 86 67 24 26 - 94 103 14 87 -137 
110 87 25 43 -128 52 24 14 - 85 65 24 25 - 96 105 16 86-139 
120 91 29 42 -140 54 25 13 - 97 68 27 25-116 104 15 88 -135 
APPENDIX D 264 
SYSTOLIC 
BLOOD PRESSURE 
(mmHg) 
DIASTOLIC 
BLOOD PRESSURE 
(mmHg) 
MEAN 
BLOOD PRESSURE 
(mmHg) 
HEART 
RATE 
(beats min') 
TIME 
(sec) 
average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range average data standard 
deviation 
range average 
data 
standard 
deviation 
range 
130 90 28 42 -137 53 23 12 - 87 67 25 24-107 100 9 90-118 
140 82 30 41-135 50 23 11 - 84 62 27 21-106 96 8 88 -109 
150 89 25 40 -125 53 22 9-80  66 24 19 - 99 98 10 85-112 
160 87 24 40 -120 51 20 11 - 74 64 23 20 - 94 97 8 88 -107 
170 87 24 38 -118 51 20 8-74  63 22 18 - 91 97 8 87 -108 
180 85 24 39-119 50 20 8-73  63 22 19 - 92 97 9 84 -109 
190 82 24 38-113 48 22 5-70  60 24 16 - 87 95 9 84-105 
200 • 82 22 34 -107 49 19 7-65  60 21 16 - 81 95 9 84-108 
210 80 22 31 -102 48 20 5-63  60 21 14 - 78 95 9 81 -109 
220 80 19 38 -100 47 20 6-66  59 20 17 - 77 95 8 82-102 
230 79 18 39 - 98 46 19 7-66  58 19 19 - 76 94 7 82 -100 
240 79 18 40-100 47 19 7-65  58 19 20 - 76 94 7 81 -101 
250 78 20 39 -101 47 21 4-66  58 21 17 - 76 93 8 79-101 
260 72 24 34 -101 43 23 4-68  53 23 16 - 77 90 10 73 -100 
270 77 19 39 -100 44 23 3-68  56 22 16 - 79 93 7 79-101 
280 75 18 41 -101 43 23 4-67  56 21 20 - 78 93 8 78 -102 
290 75 18 41 -102 43 22 4-67  55 21 20 - 78 92 9 77-104 
300 76 16 52-101 46 17 20 - 68 57 18 26 - 78 91 10 69-104 
310 77 16 50 -101 46 19 16 - 70 57 18 30 - 80 91 10 72 -105 
320 79 16 51 -102 48 20 14 - 68 60 19 30 - 80 93 II 75-107 
330 80 16 52 -104 48 21 13 - 68 60 19 28 - 80 93 9 76-102 
340 77 17 43 -103 49 19 19 - 66 60 19 27 - 79 93 9 77 -102 
350 75 19 33 -104 48 17 20 - 67 58 ' 	17 	. 25 - 79 80 28 10 - 97 
360 73 21 28 - 97 49 19 15 - 67 60 18 22 - 79 91 II 74-110 
370 79 20 35 -101 54 14 27 - 68 64 17 28 - 81 89 19 44-102 
380 80 19 41 -102 55 16 27 - 70 65 17 32 - 83 97 II 85-119 
390 83 22 34-103 57 16 28 - 74 67 19 27 - 84 97 14 82-130 
APPENDIX D 265 
SYSTOLIC 
BLOOD PRESSURE 
(mmHg) 
DIASTOLIC 
BLOOD PRESSURE 
(mmHg) 
MEAN 
BLOOD PRESSURE 
(mmHg) 
HEART 
RATE 
(beats min') 
TIME 
(sec) 
average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range average data standard 
deviation 
range average 
data 
standard 
deviation 
range 
400 85 19 45 -108 59 14 39 - 77 69 16 41-89 98 11 82-119 
410 86 22 44-117 59 17 37 - 89 70 19 40-101 96 15 78 -126 
420 88 22 44 -122 60 17 38 - 89 71 19 40-103 97 15 78-121 
430 88 22 44-122 60 17 38 - 91 71 19 40-103 98 14 78-126 
440 92 24 44-i22 62 17 38 - 89 73 19 40-104 98 12 78-116 
450 91 20 62-117 62 16 39 - 84 74 18 46 - 98 90 27 24-113 
460 93 18 67-116 64 16 41-89 76 17 51-101 97 8 85 -111 
470 91 16 66-114 62 13 42 - 83 74 15 53 - 96 94 11 74-115 
480 91 19 59-118 59 19 29-89 70 23 26-103 99 8 85 -108 
490 92 18 67-117 60 17 40-87 73 17 52-100 96 8 84-109 
500 92 17 66-116 60 17 37-85 72 - 18 44 - 98 98 9 82-110 
510 96 13 79-117 62 15 40 - 83 75 16 55 - 96 99 8 85 -109 
520 95 12 78-113 61 14 41 - 81 75 14 56 - 94 99 7 87 -109 
530 95 13 73-112 61 15 36-83 75 15 53 - 97 100 7 86 -111 
540 96 14 72 -111 63 15 34-81 77 15 50-95 98 7 91 -112 
550 94 14 74-110 61 16 34-82 74 16 50-95 99 12 74-114 
560 94 13 75 -109 60 15 36-79 74 15 53 - 92 96 12 74-115 
570 94 14 74 -108 60 15 34 - 79 74 15 52 - 92 96 11 74-116 
580 93 15 70-109 60 16 34-80 74 16 4t - 92 99 9 86-113 
590 94 13 75 -108 61 14 36-78 75 14 53 - 91 100 7 90 -111 
600 97 13 73 -109 63 15 33 - 80 77 14 51 - 94 99 9 85-111 
610 96 13 72-108 60 14 31-74 73 13 49-89 102 II 88-115 
620 93 12 71 -107 58 14 31-73 72 13 	• 49-88 101 11 83-117 
630 92 12 72-107 58 14 31-73 72 14 48-88 102 12 84-117 
640 92 12 71-107 57 13 31-73 71 13 48-88 102 II 85-116 
650 92 12 73 -107 57 13 32-73 71 13 49 - 88 100 12 79-112 
660 91 12 73 -107 57 12 33 - 73 71 13 49 - 88 100 II 81-113 
APPENDIX D 266 
SYSTOLIC 
BLOOD PRESSURE 
(mmHg) 
DIASTOLIC 
BLOOD PRESSURE 
(mmHg) 
MEAN 
BLOOD PRESSURE 
(mmHg) 
HEART 
RATE 
(beats min') 
TIME average standard range average standard range average data standard range average standard range 
(sec) data deviation data deviation deviation data deviation 
670 89 17 64-115 58 16 32 - 84 70 16 49 - 95 100 13 82-118 
680 96 15 71-119 61 18 32 - 90 75 17 48-103 107 11 94-128 
690 96 16 71-123 61 19 31 - 94 75 18 48-107 109 12 95-132 
700 97 18 71-129 63 19 31 - 95 77 19 48 -111 110 10 100-129 
710 97 18 71-127 63 20 31 - 95 77 19 48-109 110 12 98-130 
720 100 18 72-126 65 19 32 - 92 80 19 49-109 112 10 99-122 
730 94 19 67-123 62 17 36 - 88 75 19 50-104 108 12 92-125 
740 97 17 74-124 62 17 36 - 87 76 17 52-104 108 10 97-126 
750 95 18 75 -121 62 18 37 - 85 75 19 51 -101 107 12 92-126 
760 95 18 73-120 61 17 36 - 83 75 17 52 - 98 108 11 97-126 
770 94 16 73-117 61 15 36 - 80 74 16 51 - 97 108 9 97-122 
780 95 15 75-118 62 ' 	14 41 - 82 76 15 56 - 98 107 5 99-112 
790 92 16 72-115 62 11 46 - 79 73 16 53 - 95 108 9 96-118 
800 97 13 82-115 63 11 47 - 79 76 12 61 - 94 108 9 96-119 
810 96 12 83-113 63 10 48 - 79 76 11 63 - 94 110 8 101 -122 
820 94 15 83-116 63 14 48 - 82 76 15 63 - 98 115 6 107-119 
830 95 14 84-115 63 14 47 - 80 76 14 62 - 96 113 7 105-121 
840 95 14 84 -III 62 15 46 - 76 76 15 62 - 92 _ 	 107 8 98-114 
APPENDIX D 26: Haemodynamic data measured using the FinapresTM during induction of anaesthesia with 
propofol from Jones et al (1993d) 
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Finapres Haemodynamic Data - Thiopentone Group - (n = 8) 
SYSTOLIC 
BLOOD PRESSURE 
(mmHg) 
DIASTOLIC 
BLOOD PRESSURE 
(mmHg) 
MEAN 
BLOOD PRESSURE 
(mmHg) 
HEART 
RATE 
(beats min') 
TIME 
(sec) 
average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range average data standard 
deviation 
range average 
data 
standard 
deviation 
range 
-120 105 15 78-127 70 18 42-98 83 15 58-105 100 16 88-131 
-110 110 23 76-149 75 17 47 - 99 85 18 56-115 103 20 72-134 
-100 101 13 77-119 67 16 49 - 87 81 15 59-102 99 13 78-118 
-90 102 18 75 -127 69 19 45 - 98 81 17 59 -105 101 17 80-132 
-80 109 21 73 -140 74 19 46 -101 88 19 57-115 104 16 84 -135 
-70 103 21 64-129 68 23 36 - 96 81 22 48 -109 101 17 84 -131 
-60 110 16 86-133 73 19 49 - 99 86 19 62-111 103 18 85-137 
-50 108 19 72-136 73 20 43 -104 85 16 55 -101 99 18 79 -132 
-40 109 20 77-141 73 19 43 - 99 87 18 58-115 103 20 01.140 
-30 111 24 69-149 74 22 40 -103 88 21 53 -120 103 20 70-132 
-20 108 23 	. 68-145 72 21 39-103 86 19 55-114 99 21 75-138 
-10 105 19 69 -130 71 17 42 - 89 85 15 58 -104 100 17 81 -132 
105 18 74 -127 69 17 42 - 87 83 13 64 - 97 105 12 83-117 
10 104 13 84-123 71 14 47 - 92 83 15 64-107 113 II 93-130 
20 96 9 82-110 64 10 46 - 79 77 10 60 - 93 112 12 96-129 
30 97 12 82-116 68 15 48 - 87 82 14 	. 63 - 98 117 14 100-135 
40 106 19 78 -131 74 18 45-96 87 19 61-114 113 13 92-127 
50 105 21 78-140 74 20 41 -106 89 26 5,7 -140 111 15 91-132 
60 99 18 70 -125 69 16 45 - 85 83 16 59-102 113 ii 98-130 
70 95 25 68 -140 64 20 42-98 78 20 55-115 110 16 91-137 
80 84 34 37-132 57 25 16 - 86 67 31 13 -102 101 15 80 -121 
90 93 27 58 -143 63 22 36-100 73 _: 	21 	' 46 -110 109 15 89 -133 
100 94 29 52-151 63 24 31 -108 75 24 .- 45 -122 107 16 85 -135 
110 92 28 54-146 62 . 23 33 -105 73 23 43-116 107 15 85 -132 
120 93 29 58 -149 63 24 35 -107 74 25 44-122 106 15 84 -128 
130 93 26 57-142 63 22 35 -102 75 22 46-115 105 14 87 -123 
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SYSTOLIC 
BLOOD PRESSURE 
(mmHg) 
DIASTOLIC 
BLOOD PRESSURE 
(mmHg) 
MEAN 
BLOOD PRESSURE 
(mmHg) 
HEART 
RATE 
(beats min') 
Tim 
(see) 
average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range average data standard 
deviation 
range average 
data 
standard 
deviation 
range 
140 90 23 58-13! 61 20 34 - 95 72 21 44-107 103 17 77-124 
150 88 24 54-130 59 21 31 - 94 69 23 34-105 103 16 82-123 
160 87 23 54-125 58 21 32 - 91 69 20 42-101 103 15 85-123 
170 87 22 53-123 58 20 32 - 89 69 19 42 - 98 103 15 85-122 
180 86 21 53-120 57 20 31 - 88 69 19 42 - 97 102 16 82-121 
190 86 22 59-125 58 21 32 - 93 69 21 42-104 101 16 82-120 
200 85 21 58-12! 57 20 35 - 89 68 20 43-101 99 19 70-124 
210 85 23 59-127 58 21 36-96 68 21 47-107 102 17 84-129 
220 85 22 60-123 57 19 36 - 90 68 20 47-103 102 15 85-121 
230 86 24 59-131 58 23 35-104 68 21 47-108 103 18 85-134 
240 87 27 60-144 59 25 36-114 70 27 47-129 104 21 87-147 
250 87 29 61-148 59 27 37 -117 70 28 48 -133 104 22 87-148 
260 86 27 62-142 58 24 37108 68 23 49-115 102 23 84-149 
270 84 22 62-127 57 22 36-10! 68 22 48-113 101 22 82-146 
280 84 22 61-124 58 21 36 - 99 69 22 48-115 100 22 83-146 
290 84 24 60-132 57 22 36-100 67 22 47-11! 100 22 82-144 
300 83 22 60-126 56 20 36 - 95 66 20 	. 47-108 99 20 80-139 
310 82 21 61-125 55 19 37-93 65 19 48-104 98 19 78-134 
320 83 20 61-121 56 18 39 - 91 66 18 51-102 98 19 74-131 
330 85 20 63-121 58 17 39 - 90 67 17 50-100 96 18 72-125 
340 85 18 65-116 59 14 42-87 69 15 53-98 96 16 78-122 
350 84 18 65-114 57 15 42 - 86 67 16 49 - 96 96 16 78-124 
360 84 17 65-112 58 14 43-84 68 14- 55-94 95 14 79-120 
370 84 17 63-111 58 14 44 - 84 68 14 54 - 94 93 14 77-117 
380 82 19 59-112 57 16 42 - 84 66 16 48-93 92 17 71-115 
390 83 18 59-109 58 15 42 - 81 68 	. 16 51 - 92 94 17 73-123 
400 84 18 64-110 58 18 40 - 87 69 16 56 - 97 94 15 77-118 
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SYSTOLIC 
BLOOD PRESSURE 
(mmHg) 
DIASTOLIC 
BLOOD PRESSURE 
(mmHg) 
MEAN 
BLOOD PRESSURE 
(mmHg) 
HEART 
RATE 
(beats tame) 
TIME 
(sec) 
average 
data 
standard 
deviation 
range average 
data 
standard 
deviation 
range average data standard 
deviation 
range average 
data 
standard 
deviation 
range 
410 84 20 60-114 57 18 35 - 86 68 19 46-100 94 14 70-t14 
420 83 19 62-110 57, 16 40 - 81 67 17 48 - 93 94 18 70-125 	, 
430 85 19 60-114 59 15 44 - 82 69 16 52 - 95 95 20 63 -127 
440 86 20 61 -115 60 17 40 - 88 71 18 51 - 98 98 20 67 -124 
450 88 19 64-115 61 17 37 - 89 72 17 53 -100 97 21 71 -124 
460 86 20 61-115 61 16 41 - 87 71 17 51 - 99 96 17 69-118 
470 86 19 60 -111 60 16 39 - 84 71 17 50 - 96 95 15 72-114 
480 86 18 60-111 61 15 39 - 84 71 16 52 - 95 95 15 68-114 
490 86 17 58 -108 60 15 37 - 84 71 15 52 - 95 96 13 76-116 
500 86 18 57 -107 60 15 42 - 83 71 16 46 - 94 95 12 80-114 
510 88 16 65 -105 63 13 41 - 81 74 14 53 - 92 96 13 82-113 
520 89 15 67 -105 63 12 43 - 82 74 13 54 - 92 96 12 82-115 
530 89 15 68-105 63 12 45 - 82 74 12 56 - 92 95 13 , 78-115 
540 89 16 63 -107 62 16 36 - 86 71 20 32 - 95 95 14 78-119 
550 92 14. 74 -109 64 13 46 - 84 75 13 58 - 96 94 12 79 -111 
560 91 14 74-109 64 12 48 - 83 76 12 62 - 96 90 12 71 -104 
570 91 14 72-107 65 10 54 - 81 75 13 56 - 93 93 12 76-106 
580 91 14 72-107 64 II 48 - 80 75 12 62 - 93 94 II 75-103 
590 92 13 73-107 65 10 53 - 81 77 11 63 - 93 94 10 79-106 
600 93 13 74 -108 65 10 54 - 81 77 10 65 - 93 93 9 80 -105 
610 92 12 75 -106 64 10 51 - 79 77 10 66 - 92 91 12 69-103 
620 92 12 78 -105 67 12 51 - 79 78 11 66 - 91 94 10 82-104 
630 91 13 76-105 66 12 50 - 78 77 12 . 65 - 91 95 10 82-105 
640 91 14 77 -105 66 13 48 - 79 77 13 62 - 91 95 10 83-106 
650 90 13 77 -104 65 12 48 - 78 76 13 62 - 91 94 10 82 -105 
660 90 14 75 -105 64 13 45 - 77 75 13 58 - 88 94 10 84 -105 
670 91 14 75 -106 65 14 45 - 78 76 14 58 - 90 96 10 84-106 
600 90 14 74-105 64 14 44 - 77 76 13 58 - 89 94 II 82-104 
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SYSTOLIC 
BLOOD PRESSURE 
(mmHg) 
DIASTOLIC 
BLOOD PRESSURE 
(mmHg) 
MEAN 
BLOOD PRESSURE 
(mmHg) 
HEART 
RATE 
(beats mind) 
TIME average standard range average standard range average data standard range average standard range 
(sec) data deviation data deviation deviation data deviation 
690 90 14 76-104 64 12 46 - 76 76 13 59 - 89 95 10 83-106 
700 90 15 76-107 64 14 45 - 80 76 14 59 - 93 93 11 81-105 	' 
710 91 15 75-107 65 14 45 - 78 76 14 58 - 91 93 10 81-103 
720 91 14 75-106 65 14 45 - 78 76 14 58 - 91 94 11 81-105 
730 90 16 72-106 64 15 42 - 77 75 15 55 - 90 93 12 78-105 
740 91 15 73-107 64 15 42 - 79 76 15 56 - 91 92 11 79-105 
750 91 18 72 -111 65 16 42 - 83 76 17 55 - 95 92 13 78-105 
760 91 17 72 -111 65 16 42 - 83 77 17 55 - 97 93 12 80 -105 
770 91 16 74 -108 64 15 42 - 79 76 16 56 - 93 93 14 77-107 
780 90 17 71 -107 63 16 41 -79 75 16 54 - 93 94 14 78-108 
790 90 16 71-108 63 15 41 - 78 75 15 54 - 90 95 17 77-116 
800 91 18 72-110 64 16 41 - 81 75 16 54 - 92 94 17 77-115 
810 91 19 71-113 64 17 41 - 83 76 17 54 - 96 94 16 78-114 
820 91 17 72-109 63 15 42 - 80 75 16 55 - 93 94 14 79 -111 
830 92 17 73 -111 64 16 42 - 82 76 16 55 - 94 95 15 78-110 
840 92 19 72-112 65 17 41 - 83 77 18 55 - 96 95 16 77-109 
APPENDIX D 27: Haemodynamic data measured using the FinapresTM during induction of anaesthesia with 
thiopentone from Jones et al (1993d) 
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APPENDIX E 
Assay methodology data 
Midazolam 	 272 
Thiopentone 	 274 
Propofol 	 276 
APPENDIX E 272 
Method evaluation data for the assay of midazolam 
Regression parameters of calibration (4 typical curves, mean of 3 for each point) 
Concentration 
(ng mr 1 ) 
1 2 3 4 
40 0.094 0.123 0.089 0.100 
100 0.189 0.128 0.149 0.158 
200 0.286 0.310 0.373 0.373 
500 0.809 0.910 0.839 0.830 
1000 1.710 1.753 1.569 1.643 
2000 3.855 3.753 3.454 
Correlation 0.996 0.998 0.997 0.999 
Slope 0.002 0.002 0.002 0.002 
Intercept -0.072 -0.037 0.012 0.026 
Overall summary: 
Calibration range 0 - 2000 ng m14 
Correlation coefficient 0.997 
Slope 0.00196 
Intercept - 0.01775 
Internal standard 200 ng 
Amount added 
(ng mr1) 
40 
500 
Values found 
(ng m1') 
50.5 	 45.0 	 37.5 
499.5 	 522.5 	 465.0 
mean 	 SD C V CVO 
44.3 	 5.33 	 12.03 
495.7 	 23.63 	 4.77 
APPENDIX E 273 
Within-batch variation (n=3) 
Between-batch variation (mean of 3 for each point) 
Concentration 
(ng mr') 
Mean midazolam/I.S. ratio 
(n=3) mean 	 SD CV ( %) 
	
0.094 	 0.089 	 0.100 
0.189 	 0.149 	 0.158 
0.286 	 0.371 	 0.373 
0.809 	 0.839 	 0.830 
1.710 	 1.569 	 1.643 
3.855 	 3.454 
0.094 	 0.004 	 ' 4:767 
0.165 	 0.017 	 10.363 
0.343 	 0.041 	 11.810 
0.826 	 0.013 	 1.522 
1.641 	 0.058 	 3.510 
3.655 	 0.201 	 5.486 
40 
100 
200 
500 
1000 
2,000 
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Method evaluation data for the assay of thiopentone 
Regression parameters of calibration (5 typical curves, mean of 3 for each point) 
Concentration 
(pg 
1 2 3 4 5 
0.05 0.057 0.035 0.030 0.035 0.0421 
0.1 0.096 0.082 0.059 0.075 0.0657 
1 0.976 0.726 0.620 0.666 0.6544 
5 4.236 3.350 2.661 1482 2.9517 
10 7.104 7.725 5.800 6.926 5.9462 
40 23.061 22.9783 
Correlation 0.991 0.996 0.998 0.997 0.999 
Slope 0.718 0.762 0.573 0.574 0.574 
Intercept 0.169 -0.076 -0.017 -0.004 0.072 
Summary overall: 
Calibration range 0.05 - 40 ps ml - ' 
Correlation coefficient 0.996 
Slope 0.64 
Intercept 0.016 
Internal standard 20 i..tg 
APPENDIX E 275 
Within-batch variation (n=3) 
Amount added 
0.1g 
Values found 
(p.g m1-1) mean SD CV( %) 
	
1.065 	 0.137 	 12.85 
12.013 	 0.351 	 2.92 
1 
10 
0.9524 	 0.9855 	 1.2578 
11.8856 	 12.4916 	 11.6609 
    
Between-batch variation (mean of 3 for each point) 
Concentration 
(1.ig mr') 
Mean thiopentone/I.S. ratio 
(n =3) mean 	 SD CV CYO 
0.05 
0.1 
1 
5 
10 
40 
0.035 	 0.035 	 0.042 
0.082 	 0.075 	 0.066 
0.726 	 0.666 	 0.654 
3.350 	 3.482 	 2.954 
7.725 	 6.926 	 5.946 
23.061 	 22.978 
0.037 	 0.003 	 8.957 
0.074 	 0.007 	 8.994 
0.682 	 0.031 	 4.600 
3.262 	 0.225 	 6.882 
6.866 	 0.727 	 10.595 
23.020 	 0.041 	 0.180 
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Method evaluation data for the assay of propofol 
Regression parameters of calibration (5 typical curves, mean of 3 for each point) 
Concentration 
(1.1g ml-`) 
1 2 3 4 5 
0.010 0.0230 0.0166 0.0237 0.0198 0.0244 
0.025 0.0218 0.0399 0.0314 0.0398 0.0337 
0.050 0.0486 0.0604 0.0523 0.0630 0.0633 
0.100 0.1264 0.1499 0.1319 0.1109 0.1230 
0.250 0.2921 0.3650 0.3406 0.2452 0.2724 
0.500 0.6827 0.8427 0.6632 0.5133 0.6014 
1.000 1.3867 1.5102 1.3215 1.1323 
Correlation 0.9985 0.9964 0.9997 0.9986 0.9988 
Slope 1.3867 1.5388 1.3228 0.9932 1.1324 
Intercept -0.0159 0.0010 0.0007 0.0106 0.0085 
Summary overal: 
Calibration range 0.01 - 1.0 	jig 
Corelation coeficient 0.998 
Slope 1.185 
Intercept 0.00097 
Internal standard 0.12 pg 
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Within-batch variation (n=3) 
Amount added 
(jig mI1) 
Values found (vg mr1 ) 
0.01 
0.5 
0.0147 
0.4923 
0.0161 
0.5114 
0.0217 
0.5021 
mean 	 SD CV (%) 
0.0175 	 0.0022 	 12.61 
0.5019 	 0.0055 	 1.09 
Between-batch variation (mean of 3 for each point) 
Concentration 
(.tg ml-') 
Mean propofol/ I.S. ratio 
(n =3) mean SD CV (%) 
0.01 0.023 0.024 0.024 0.0237 0.0004 1.71 
0.025 0.022 0.031 0.034 0.0290 0.0036 12.58 
0.050 0.049 0.052 0.063 0.0547 0.0044 0.08 
0.100 0.126 0.132 0.123 0.1271 0.0026 2.04 
0.250 0.292 0.341 0.272 0.3017 0.0203 6.72 
0.500 0.683 0.663 0.601 0.6491 0.0245 4.08 
1 1.377 1.322 1.132 1.1323 0.0742 5.81 
APPENDIX F 278 
APPENDIX F 
Pharmacokinetic data 
Fl - F7 Midazolam 	 279 
F8 - F10 Flumazenil 	 286 
Fl - F12 Propofol 	 289 
Time (min) 
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Patient 
number 
0 2 4 6 8 10 20 30 40 50 60 70 100 160 220 260 
1 42 1,558 1,072 829 733 591 300 254 246 200 190 170 138 87 49 31 
2 33 2,022 761 491 385 350 241 190 167 138 124 114 87 72 55 52 
3 54 1,012 689 639 557 440 268 209 153 136 126 116 85 63 48 34 
4 29 974 648 503 396 320 203 173 167 109 100 98 75 41 29 24 
5 36 385 343 286 239 236 157 138 118 105 100 93 54 41 32 18 
6 67 918 655 555 523 438 304 222 210 190 178 170 124 64 30 15 
7 33 640 486 514 505 412 284 220 201 170 142 120 87 40 34 17 
8 46 900 677 623 481 464 245 171 150 129 108 92 70 50 43 30 
9 63 976 847 720 595 505 352 237 201 167 133 126 93 65 46 28 
10 36 701 640 579 466 387 242 199 163 146 138 126 84 48 31 16 
11 43 1,117 788 493 471 407 305 277 250 162 144 125 115 60 38 24 
12 83 828 606 515 500 374 285 191 181 170 151 134 112 82 50 35 
Mean 47.1 1,002.6 648.3 562.3 487.6 410.3 265.5 206.8 183.9 151.8 136.2 123.7 93.7 59.4 40.4 27 
SD 15.8 409.7 173.1 129.2 115.4 86.7 49.7 36.8 37.6 28.6 26.8 24.5 23.1 15.2 8.8 10.1 
Min. 29 385 343 286 239 236 157 138 118 105 100 92 54 40 29 15 
Max. 83 2,022 1,072 829 733 591 352 277 250 200 190 170 138 87 55 52 
APPENDIX F 1: 	 Midazolam concentration (ng ml-1) with time from Jones et al (1993). 
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Patient 
number 0 2 4 6 8 
Time 
10 
(min) 
15 20 30 60 120 
APPENDIX F 
180 	 240 
1 246 220 210 206 200 197 190 184 170 138 87 49 30 
2 173 167 154 152 140 138 136 124 114 87 72 55 52 
3 161 157 153 149 146 138 136 127 108 85 63 55 41 
4 167 154 113 109 107 105 104 100 98 75 41 ' 29 24 
5 118 115 112 111 110 105 101 100 93 54 41 32 18 
6 198 196 190 186 183 180 178 173 168 124 64 30 15 
7 201 196 192 174 170 173 165 142 120 87 41 34 17 
8 108 97 94 92 90 83 81 72 70 52 47 38 23 
9 225 201 185 181 177 114 167 133 126 93 65 46 28 
10 172 166 163 160 151 148 146 138 126 84 48 31 17 
11 261 257 250 216 206 184 162 149 125 115 60 38 24 
12 170 165 159 151 146 141 134 127 120 103 82 50 35 
Mean 183 174 165 157 152 147 142 131 120 91 59 41 27 
SD 44.1 41.8 42.7 36.9 35.3 34.4 31.8 29.7 27.1 24.6 15.4 9.5 10.6 
Min. 108 97 94 92 90 83 81 72 70 52 40 29 15 
Max. 261 257 250 216 206 197 190 184 170 138 87 55 52 
APPENDIX F 2: Midazolam concentration (ng m1-1) at flumazenil sampling times postoperatively from Jones et al (1993). 
Patient 
number 
A 
(ng) 
B 
(ng) 
C 
(ng) 
alpha 
(min-1) 
beta 
(min-1) 
gamma 
(min-1) 
APPENDIX F 
Dose 
(ng) 
1 3,233.88 1,453.65 313.64 0.8228 0.1789 0.00819 9,350,000 
2 3495.00 321.04 117.31 0.5572 0.0414 0.00319 8,000,000 
3 4,764.51 765.02 174.76 0.4158 0.0956 0.00603 10,000,000 
4 1119.60 233.43 82.30 0.2712 0.0271 0.00446 10,000,000 
5 398.39 157.46 130.65 0.1850 0.0357 0.00779 16,000,000 
6 1,288.12 312.33 124.19 0.7478 0.0600 0.01065 19,250,000 
7 697.46 286.88 134.82 0.1275 0.0276 0.00713 7,000,000 
8 960.47 291.25 113.35 0.1809 0.0440 0.00499 12,000,000 
9 1,033.03 658.89 181.94 0.3722 0.0621 0.00658 10,000,000 
10 824.02 162.08 150.69 0.1584 0.0274 0.00729 8,500,000 
11 1,656.38 321.26 199.06 0.4914 0.0371 0.00764 12,500,000 
12 948.79 218.84 211.88 0.2269 0.0576 0.00627 9,500,000 
281 
APPENDIX F 3: Midazolam - 3-compartment analysis from Jones et al (1993). 
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Patient 
number 
Wt. 
(kg) 
Anaesthesia 
time 
(min) 
1( 12 
(ha) 
k21 
(ha) 
k,, 
(ha) 
k,, 
(ha) 
1(10 
(ha) 
k 12 : k2 , k31 : k,„ V 
(L) 
V2 
(L) 
V, 
(L) 
Va 
(L) 
Va / Wt 
(L kW') 
V. 
(L) 
V./ Wt 
(L kg) 
t„" 
(min) 
t,i11 
(min) 
t,: 
(min) 
Clearance 
(ml min- ') 
Clearance / Wt 
(ml mina kg') 
1 18.7 31 1.49 23.67 14.20 1.84 5.96 0.06 0.31 1.9 1.2 19.6 22.7 1.21 21.5 1.15 0.84 3.9 84.6 206 11.02 
2 16.0 33 16.76 5.53 8.50 0.61 4.64 3.01 0.13 2.0 6.3 41.0 49.3 3.08 45.1 2.82 1.24 18.0 189.0 ' 199 12.44 
3 20.0 39 5.76 8.57 8.78 0.85 7.06 0.67 0.12 1.8 1.2 31.3 34.3 1.72 36.4 1.82 1.67 7.3 115.0 285 14.25 
4 20.0 35 8.08 4.64 2.12 0.55 2.76 1.74 0.20 6.9 12.8 52.0 71.7 3.59 41.9 2.10 2.56 26.0 105.0 372 18.60 
5 32.0 43 3.92 5.55 1.33 1.13 1.76 0.71 0.64 23.3 18.0 46.7 88.0 2.75 93.7 2.93 3.75 19.0 89.0 736 23.00 
6 38.5 40 24.38 13.52 4.25 1.37 5.56 1.80 0.25 11.5 21.1 65.0 97.6 2.54 47.2 1.23 0.93 12.0 65.0 547 14.21 
7 14.0 31 2.41 3.74 0.89 0.75 1.93 0.65 0.39 6.3 4.6 17.5 28.4 2.03 21.9 1.56 5.00 25.0 97.0 240 17.14 
8 24.0 58 3.03 4.81 2.83 0.75 2.37 0.63 0.32 8.8 5.9 54.7 69.4 2.89 58.5 2.44 3.80 16.0 139.0 375 15163 
9 20.0 31 7.63 11.77 3.28 1.01 2.74 0.65 0.37 5.3 3.6 28.1 37.0 1.85 30.4 1.52 1.90 11.0 105.0 268 13.40 
10 17.0 31 3.36 3.49 1.27 0.91 2.14 1.08 0.43 6.5 9.2 20.0 35.7 2.10 27.3 1.61 4.40 25.0 95.0 303 17.82 
11 25.0 29 16.78 8.30 2.59 1.06 3.47 2.02 0.30 5.7 12.3 24.9 42.9 1.72 35.0 1.40 1.40 18.0 90.0 355 14.20 
12 19.0 48 4.02 5.98 3.96 1.49 1.98 0.67 0.75 6.9 4.9 24.4 36.2 1.91 34.6 1.82 3.10 12.0 110.0 243 12.79 
Mean 22.0 37 8.17 8.30 4.50 1.03 3.53 1.14 0.35 7.2 8.4 35.4 51.1 2.20 41.1 1.87 2.55 16.1` 107.0 344 15.37 
SD 6.7 8 6.93 5.52 3.83 0.37 1.74 0.80 0.18 5.6 6.1 15.3 23.5 0.66 18.9 0.57 1.37 6.8 30.2 150 3.16 
Min. 14.0 29 1.49 3.49 0.89 0.55 1.76 0.06 0.12 1.8 1.2 17.5 22.7 1.21 21.5 1.15 0.84 3.9 65.0 199 11.02 
Max. 38.5 58 24.38 23.67 14.20 1.84 7.06 3.01 0.75 23.3 21.1 65.0 97.6 3.59 93.7 2.93 5.00 26.0 189.0 736 23.00 
APPENDIX F 4: Midazolam pharmacokinetic findings in the 12 children from Jones et al (1993). Vd = V ± V2 ± V3 . 
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Patient 
number 
Body 
weight 
(kg) 
t, 
(min) 
AUC 
(total) 
(ng min m1 -1) 
Cl 
(ml m1n-1) 
Clearance! Wt 
(ml mie kg4) 
V,(ss) 
(L) 
V, / Wt 
(L kg') 
Vu 
(L) 
Vu/ Wt 
(L kg-') 
MRT 
(min) 
1 18.7 84.6 45410.3 205.90 11.01 21.5 1.15 25.2 1:35 104.6 
2 16.0 179.4 27871.5 198.70 12.42 45.1 2.82 51.5 3.22 227.1 
3 20.0 105.7 29177.5 284.90 14.25 36.4 1.82 43.4 2.17 127.8 
4 20.0 97.6 23983.5 371.64 18.58 42.0 2.10 52.3 2.62 112.9 
5 32.0 100.3 19033.0 735.85 23.00 93.7 2.93 106.5 3.33 127.4 
6 38.5 59.7 33877.5 547.11 14.21 47.2 1.23 47.1 1.22 86.3 
7 14.0 77.8 27292.0 239.55 17.11 21.9 1.56 26.9 1.92 91.3 
8 24.0 148.4 26616.0 374.52 15.61 58.5 2.44 80.2 3.34 156.1 
9 20.0 100.5 33082.0 268.46 13.42 30.4 1.52 38.9 1.95 113.4 
10 17.0 72.4 24979.0 303.46 17.85 27.3 1.61 31.7 1.86 89.8 
11 25.0 82.5 32414.5 355.22 14.21 35.0 1.40 42.3 1.69 98.5 
12 19.0 111.5 32982.5 242.82 12.78 35.6 1.87 39.1 2.06 142.4 
Mean 22.0 101.7 29726.6 344.01 15.37 41.2 1.90 48.8 2.20 123.1 
SD 6.7 31.9 6334.5 149.66 3.16 18.9 0.60 22.2 0.70 37.6 
Min. 14.0 59.7 19033.0 198.70 11.01 21.5 ' 1.10 25.2 1.20 86.3 
Max. 38.5 179.4 45410.3 735.85 23.00 93.7 2.90 106.5 3.30 227.1 
APPENDIX F 5: Midazolam non-compartmental analysis from Jones et al (1993). 
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Patient 
number 
Time to 	 Time to 	 Midazolam 	 Time to self 	 Time to self 	 Midazolam 
eyes open 	 eyes open 	 concentration 	 identification 	 identification 	 concentration 
--/ (sec) 	 (min) 	 (ng mr') 	 (sec) 	 (min) 	 (ng ml') 
2760 	 46 	 215 	 2880 	 48 	 208 
2520 	 42 	 160 	 2640 	 44 	 153 
2880 	 48 	 138 	 3000 	 50 	 136 
2640 	 44 	 154 	 2700 	 45 	 133 
3180 	 53 	 103 	 3240 	 54 	 103 
2940 	 49 	 193 	 2940 	 49 	 193 
2460 	 41 	 198 	 2700 	 45 	 183 ' 
4140 	 69 	 93 	 4200 	 70 	 92 
2400 	 40 	 201 	 2460 	 41 	 180 
2400 	 40 	 164 	 2400 	 40 	 164 
2280 	 38 	 259 	 2340 	 39 	 257 
3480 	 58 	 159 	 3540 	 59 	 155 
2840 	 47.3 	 169.8 	 2920 	 48.7 	 163.1 
518.1 	 8.6 	 44.9 	 510.5 	 8.5 	 43.7 
2280 	 38 	 93.0 	 2340 	 39 	 92 
4140 	 69 	 259.0 	 4200 	 70 	 257 
APPENDIX F 6: Serum midazolam concentration (ng m1-1) on awakening from Jones et at (1993). 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Mean 
SD 
Min. 
Max. 
Patient 
number 
Bulked 24 hour 
urine volume 
(m1) 
a - OH 
Midazolam 
a - OH 
Midazolam 
gIucuronide 
4 - OH 
Midazolam 
4- OH 
Midazolam 
glucuronide 
TOTAL 
APPENDIX F 
Flumazenil 
1 950 0.03 2.09 0.17 0.20 2.49 13.25 
2 650 0.23 13.20 1.12 1.15 15.70 13.80 
3 1,100 0.00 4.06 0.05 0.83 4.94 10.97 
4 900 0.09 1.74 0.08 0.01 1.92 7.06 
5 720 0.08 1.59 0.05 0.00 1.72 6.45 
6 1,240 0.03 0.64 0.04 0.00 0.71 8.58 
7 650 0.03 2.88 0.31 0.23 3.46 6.33 
8 420 0.04 1.19 0.03 0.07 1.33 5.84 
9 550 0.05 2.12 0.59 0.11 2.87 6.45 
10 850 0.03 1.97 0.51 0.11 2.62 11.96 
Total 8,030 0.62 31.48 2.95 2.71 90.69 
Mean 803 0.06 3.15 0.30 0.27 3.78 9.07 
SD 240.17 0.06 3.46 0.34 0.37 4.13 2.96 
Min. 420 0.00 0.64 0.03 0.00 0.71 5.84 
Max. 1,240 0.23 13.20 1.12 1.15 15.70 13.80 
APPENDIX F 7: Percentage of midazolam and flumazenil dose recovered in a bulked 24 hour urine collection 
from Jones et al (1993). 
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Patient 
number 2 4 6 8 10 
Time 
15 
(min) 
20 30 60 120 
APPENDIX F 
180 	 240 
1 18 32 62 93 97 35 33 30 23 16 0 0 
2 16 24 28 24 23 21 14 12 6 0 0 0 
3 25 45 39 37 33 31 27 21 13 4 0 0 
4 10 12 13 28 20 16 12 11 6 3 0 0 
5 17 23 28 33 30 18 15 12 9 0 0 0 
6 19 22 39 28 20 15 13 8 4 0 0 0 
7 27 39 48 56 50 44 42 38 23 16 0 0 
8 11 22 42 30 26. 15 13 10 8 0 0 0 
9 13 25 36 33 30 23 22 15 8 3 0 0 
10 15 31 28 24 18 15 16 9 8 6 0 0 
11 14 15 19 16 14 11 8 7 3 0 0 0 
12 15 21 40 31 24 21 19 15 10 4 0 0 
Mean 16.7 25.9 35.2 36.1 32.1 22.1 19.5 15.7 10.1 4.3 0 0 
SD 4.9 9.0 12.6 19.5 21.5 9.4 9.5 9.1 6.3 5.6 0 0 
Min. 10 12 13 16 14 11 8 7 3 0 0 0 
Max. 27 45 62 93 97 44 42 38 23 16 0 0 
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APPENDIX F 8: Flumazenil concentration (ng ml-') with time from Jones et al (1993). 
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Patient 
number 
Body 
weight 
(kg) 
t, 
(min) 
AUC 
(total) 
(ng min m1 -1) 
Cl 
(ml min') 
Cl / Body Wt. 
(ml min"' kg') 
V,(ss) 
(L) 
V,/ Body wt. 
(L kg4) 
Vg 
(L) 
Vg/ Body Wt. 
(L kg') 
MRT 
(min) 
1 18.7 75.5 4513.1 136.27 7.29 12.7 0.68 14.8 0.79 93.4 
2 16.0 24.8 989.0 465.12 29.07 17.5 1.09 16.7 1.04 38.7 
3 20.0 34.8 2059.9 291.27 14.56 14.7 0.74 14.6 0.73 50.6 
4 20.0 38.9 1087.9 556.14 27.81 32.7 1.64 31.2 1.56 58.7 
5 32.0 29.9 1194.1 686.70 21.46 31.5 0.98 29.7 0.93 45.9 
6 38.5 22.2 778.7 963.17 25.02 30.0 0.78 30.8 0.80 31.2 
7 14.0 42.8 3477.9 158.14 11.30 10.3 0.74 9.8 0.70 65.2 
8 24.0 25.4 972.4 575.90 24.00 23.6 0.98 21.1 0.88 40.9 
9 20.0 33.3 1466.5 358.00 17.90 17.2 0.86 17.2 0.86 47.9 
10 17.0 36.1 1102.9 317.35 18.67 16.8 0.99 16.5 0.97 53.1 
11 25.0 21.5 544.5 771.33 30.85 24.1 0.96 23.9 0.96 31.3 
12 19.0 38.7 1603.5 358.60 18.87 20.7 1.09 20.0 1.05 57.7 
Mean 22.0 35.3 1648.5 469.83 20.57 21.0 1.00 20.5 0.90 51.2 
SD 6.7 13.8 1134.8 239.52 6.92 7.1 0.20 6.7 0.20 16.3 
Min. 14.0 21.5 544.5 136.27 7.29 10.3 0.70 9.8 0.70 31.2 
Max. 38.5 75.5 4513.1 963.17 30.85 32.7 1.60 31.2 1.60 93.4 
APPENDIX F 9: Flumazenil non-compartmental analysis from Jones et al (1993). 
Patient 
number 
Time to 	 Time to 
eyes open 	 eyes open 
(sec) 	 (min) 
Flumazenil 
concentration 
(ng ml') 
Time to self 
identification 
(sec) 
Time to self 
identification 
(min) 
APPENDIX F 
Flumazenil 
concentration 
(ng ml-') 
1 240 	 4.0 32 360 6.0 62 
2 120 	 2.0 24 240 4.0 24 
3 120 	 2.0 25 240 4.0 45 
4 240 	 4.0 12 300 5.0 7 
5 240 	 4.0 23 300 5.0 14 
6 180 	 3.0 20 180 3.0 20 
7 180 	 3.0 33 420 7.0 52 
8 300 	 5.0 32 360 6.0 42 
9 150 	 2.5 13 210 3.5 25 
10 180 	 3.0 23 180 3.0 23 
11 60 	 1.0 14 120 2.0 14 
12 240 	 4.0 21 300 5.0 31 
Mean 187.5 	 3.1 22.7 267.5 4.5 29.9 
SD 65.0 	 1.1 7.0 84.4 1.4 16.1 
Min. 60.0 	 1.0 12.0 120.0 2.0 7.0 
Max. 300.0 	 5.0 33.0 420.0 7.0 62.0 
APPENDIX F 10: 	Flumazenil concentration (ng mr') on awakening from Jones et al (1993). 
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Sample time 
(hr) 
Observations 
(n) 
Mean blood propofol 
concentration 
(ng ml -') 
Standard 
deviation 
(SD) 
Standard 
error of 
mean 
(SEM) 
0.003 7 3047.55 1204.30 455.18 
0.083 12 1866.47 676.14 195.18 
0.167 12 944.25 247.84 71.54 
0.250 12 638.54 147.89 42.69 
0.333 10 437.34 168.23 53.20 
0.5 12 289.23 122.53 35.37 
0.75 10 246.92 115.64 36.57 
1.00 12 165.34 77.19 , 22.28 
1.5 12 96.74 34.60 9.99 
2.0 12 68.85 35.32 10.20 
3.0 12 67.85 122.82 35.43 
4.0 11 30.10 17.18 5.18 
6.0 10 23.89 11.54 3.65 
8.0 9 13.38 12.27 4.09 
10.0 5 10.77 4.92 2.20 
12.0 4 14.38 7.85 3.93 
18.0 3 7.81 4.36 2.52 
24.0 2 4.79 1.76 1.25 
APPENDIX F 11: Mean (SEM) blood propofol concentrations for each 
sampling time in the 12 children from Jones et al (1990a). 
Patient 
number 	 1 2 3 4 5 6 7 9 10 11 12 mean 
APPENDIX F 
SEM 
Ku 4.185 9.151 0.313 11.984 2.889 5.589 5.874 3.170 5.574 13.412 3.712 3.742 5.80 1.12 
K„ 3.789 9.959 9.628 4.757 2.964 3.532 3.904 1.310 8.012 5.192 2.841 2.368 4.85 0.82 
K„ 5.722 9.471 3.748 2.906 1.595 1.115 1.678 0.641 1.378 1.564 2.194 2.125 2.84 0.72 
Km  0.342 0.405 2.700 0.800 0.255 0.440 0.207 0.222 0.179 0.395 0.215 0.206 0.55 0.23 
K„ 6.792 19.549 3.336 14.412 2.942 3.715 4.317 1.811 2.539 5.792 5.449 6.156 6.40 1.53 
VG 265.12 172.22 44.63 63.46 799.10 468.68 402.10 307.39 284.11 268.24 570.11 260.58 325.47 61.22 
VG/kg 11.05 5.56 2.23 3.97 23.50 12.67 18.28 11.82 14.76 6.88 21.93 16.04 12.38 1.98 
AUC 75.10 96.54 61.24 58.83 41.33 37.24 56.44 86.19 90.02 73.63 45.51 62.24 65.35 5.56 
(L) 132.79 61.94 33.70 20.25 345.40 204.13 143.60 157.62 118.56 103.44 196.68 82.10 133.34 . 25.56 
V"/kg 5.53 2.00 1.69 1.27 10.16 5.52 6.53 6.06 6.16 2.65 7.56 5.05 5.01 2.66 
Ts: (min) 2.32 1.01 3.78 1.32 4.67 3.29 2.94 6.44 2.69 1.70 3.33 3.22 3.06 0.43 
T: (min) 15.30 5.87 5.26 15.36 26.42 28.77 24.46 74.99 19.94 25.31 23.43 26.86 24.33 5.13 
T,' (min) 229.98 153.77 37.88 64.68 262.50 131.48 285.97 282.47 368.29 140.38 276.65 276.65 209.22 29.26 
TBC (Lmie) 798 797 816 679 2,056 2,470 974 754 534 1,324 1,428 652 1,106 175 
TBC / kg 33.25 25.70 40.80 42.43 60.47 66.75 44.27 29.00 27.74 33.94 39.66 40.12 40.34 3.60 
(L) 7.06 7.45 14.69 2.83 41.94 39.90 13.54 24.99 12.63 13.72 15.72 6.36 16.31 3.77 
W /kg 0.29 0.08 0.73 0.18 1.23 1.08 -0.62 0.96 0.66 0.35 0.60 0.39 0.60 0.10 
Age (yr) 9 12 5 4 7 12 8 8 7 11 7 5 7.92 0.77 
Weight (kg) 24 31 20 16 34 37 22 26 19 39 26 16 25.83 2.28 
anaesthetic time 
(min) 
eye opening time 
(min) 
propofol 
dose (mg) 
27 
60 
34 
30 
77 
35 
38 
50 
22 
36 
40 
31 
28 
85 
30 
21 
92 
30 
34 
55 
22 
28 
65 
27 • 
15 
• 	48 	- 
31 
61 
98 
36 
11 
65 
21 
33 
41 
28.83 
30:45 
64.35 
1.48 
4.00 
9.70 
APPENDIX F 12: Demographic, awakening and propofol pharmacokinetic data in the 12 children from Jones et al (1990a). 
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APPENDIX G 
Drug blood levels 
Midazolam 	 292 
Thiopentone 	 294 
Propofol 	 295 
Patient 
number 
Age 
(yr) 
Weight 
(kg) 
Induction 
agent 
Premed 
effect 
Picture Score 
after sleep 	 after premed 
APPENDIX G 
Preoperative Serum Midazolam Concentration (ng mr) 
30 min 	 60 min 	 90 min 	 120 min 
6 25.0 T 2 40 0 30.50 74.00 50.75 ' 42.62 
3 10 37.4 T 2 100 100 42.50 78.00 57.00 49.00 
8 7 19.0 T 2 100 100 29.50 77.00 42.00 42.00 
10 6 17.0 T 2 80 80 31.50 48.50 38.50 37.60 
15 12 33.5 T 2 100 100 19.50 68.50 50.00 35.50 
21 5 18.5 T 2 100 80 33.35 55.00 31.25 40.00 
24 8 21.0 T 2 100 80 25.00 93.75 52.50 35.00 
27 8.5 30.0 T 2 100 100 37.00 92.00 47.00 38.00 
28 5 19.0 T 2 100 80 31.38 81.50 57.50 41.00 
29 6 17.0 T 2 100 80 39.50 134.00 68.00 28.00 
2 8.5 28.0 P 2 100 100 16.50 69.00 40.35 34.50 
5 11 33.0 P 4 100 100 26.00 59.00 31.00 30.34 
6 9 25.0 P 2 100 100 31.50 55.00 30.50 32.88 
13 6 18.0 P 2 80 100 31.50 55.10 42.50 30.34 
16 6 25.0 P 2 100 100 19.00 92.00 68.00 38.38 
17 5 22.0 P 2 100 60 40.00 66.00 37.03 21.62 
18 6 18.0 P 2 80 80 28.00 68.35 31.00 31.00 
22 9 27.0 P 2 100 80 35.75 77.00 65.75 20.50 
25 8 27.0 P 2 100 100 23.25 51.38 47.00 38.00 
30 5 16.0 P 2 100 80 27.00 85.50 70.75 52.00 
4 5 17.5 M 2 80 80 35.50 57.00 52.00 42.00 
7 9 25.5 M 2 100 100 29.00 59.50 47.50 30.00 
9 5 21.5 M 2 100 0 33.50 78.00 37.50 26.00 
11 8 22.0 M 2 100 100 21.62 76.00 57.25 46.00 
12 4.5 16.0 M 2 100 100 31.50 57.25 39.13 33.50 
14 6 18.0 M 2 100 100 0.50 43.50 28.50 18.50 
19 9 26.6 M 2 100 100 39.00 74.00 63.00 43.00 
20 10 25.0 M 2 100 100 26.00 100.15 42.00 
23 1 27.0 M 2 100 80 33.35 88.75 76.66 38.35 
26 4 15.0 M 2 100 0 26.15 52.00 44.5 32.00 
APPENDIX G 1: Patient data and preoperative serum midazolam levels from Jones et al (1993e & d). 
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Patient 
number 
Anaesthesia 
duration 
(min) 
Eye-opening 
time 
(min) 
Identification 
time 
(min) 
APPENDIX G 
Post-operative Serum Midazolam Concentration (ng 
awakening 60 (min) 120 (min) 180 (min) 240 (min) 
4 32 24 26 151.00 97.50 59.00 34.00 
7 42 30 36 141.00 93.50 78.50 40.12 33.00 
9 27 29 45 137.00 67.50 39.00 35.00 31.00 
11 39 21 29 134.38 91.00 51.25 37.00 19.50 
12 35 23 24 127.88 58.50 49.75 41.62 29.00 
14 48 27 31 131.00 77.25 52.25 48.50 33.50 
19 32 57 57 134.50 74.00 66.00 53.00 19.50 
20 33 30 30 131.00 79.75 51.00 
23 32 35 35 115.00 90.00 46.25 45.00 28.35 
26 35 42 42 190.70 69.50 49.50 19.50 17.00 
mean 35.5 31.8 35.5 139.35 79.85 54.25 39.30 26.36 
SD 6.0 10.8 10.1 19.22 12.17 10.54 9.71 6.65 
min 27 21 24 115.00 58.50 39.00 19.50 17.00 
max 48 57 57 190.70 97.50 78.50 53.00 33.50 
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APPENDIX G 2: Awakening data and postoperative serum midazolam levels-from Jones et al (1993c & d). 
Patient 
number 
Anaesthesia 
duration 
(min) 
Eye-opening 
time 
(min) 
Identification 
time 
(min) 
APPENDIX G 
Post-operative Serum Thiopentone Concentration (ng mr`) 
awakening 	 60 (min) 	 120 (min) 	 180 (min) 	 240 (min) 
1 27 36 40 0.39 0.26 0.25 0.09 
3 47 25 26 0.42 0.07 0.06 0.06 
8 35 19 19 0.42 0.12 0.09 0.07 0.06 
10 38 33 34 0.82 0.74 0.61 0.51 
15 37 22 22 0.34 0.05 
21 36 16 16 0.21 0.11 0.06 
24 21 23 25 14.44 0.13 0.08 
27 28 26 29 1.46 1.40 0.60 0.53 0.11 
28 25 34 36 2.35 0.16 0.16 0.14 0.11 
29 31 18 23 18.15 0.35 0.11 0.10 0.09 
mean 32.5 25.2 27.0 6.19 0.41 0.22 0.18 0.11 
SD 7.2 6.7 7.3 7.26 0.39 0.24 0.21 0.14 
min 21 16 16 0.34 0.05 0.0 0.0 0.0 
max 47 36 40 18.15 1.40 0.74 0.61 0.51 
APPENDIX G 3: Awakening data and postoperative serum thiopentone levels from Jones et at (1993c & d). 
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Patient 
number 
Anaesthesia 
duration 
(min) 
Eye-opening 
time 
(min) 
Identification 
time 
(min) 
APPENDIX G 
Post-operative Blood Propofol Concentration (ng ml') 
awakening 	 60 (min) 	 120 (min) 	 180 (min) 	 240 (min) 
2 30 21 22 463.5 83.7 44.7 27.4 24.3 
5 39 23 23 162.7 102.8 70.8 70.1 
6 33 24 25 438.5 116.3 80.4 35.8 35.0 
13 25 10 10 176.8 150.2 34.0 29.4 
16 25 33 34 379.0 97.7 85.6 46.9 37.3 
17 28 30 34 323.1 100.2 58.7 56.1 49.4 
18 30 18 22 286.0 105.5 80.1 49.3 25.9 
22 35 11 11 226.0 215.7 113.1 104.2 
25 27 29 29 941.1 306.1 141.7 115.9 69.4 
30 27 20 20 439.4 181.1 91.5 78.7 65.1 
mean 29.9 21.9 23 467.2 155.6 105.2 62.8 51.0 
SD 4.3 7.2 7.8 82.7 22.2 16.1 9.9 8.2 
min 25 10 10 286.0 83.7 44.7 27.4 24.3 
max 39 33 34 941.1 306.1 - 215.7 115.9 104.2 
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APPENDIX G 4: Awakening data and postoperative serum propofol levels from Jones et al (1993c & d). 
APPENDIX H 296 
APPENDIX H 
Data collection sheets 
( 
c 
APPENDIX H 297 
PATIENT DATA PREMEDICATION / SATURATION 
NAME: 	 HOSPITAL NO.: 	 AGE: 	 DATE: 	 / 	 / 90 	 WEIGHT: 	 kg 	 No: 
Medical History 	I PRE-MEDICATION 
1. 	 RESPIRATORY SYMPTOMS 
RTI? 	 N / Y 	 Date: 
SLEEP APNOEA 	 N / Y 	 SIDS SIB? 
TONSILLITIS 	 N / Y 
OBSTRUCTIVE 
SYMPTOMS 	 N / Y 
2. 	 OTHER RELEVANT MEDICAL HISTORY 3. 	PETHIDINE/ATROPINE 
MIDAZOLAM/ATROPINE 
TIME 	 (24 Hr CLOCK) 
PREMED 	 - 
INTO OR 	 • 
INTO RECOVERY 	 : 
TO IDENTIFY SELF 	 • 
4. 	 ANAESTHESIA 
FENTANYL Y / N 	 DOSE 	 Meg 
5. 
TONSILLAR ENLARGEMENT 	 ' 
CORMACK & LEHANE 
, 
6. 	 WARD DETAILS 
	
SLEEPING ON RETURN 	 Y / N 
HOW LONG 
FULLY AWAKE 
APPENDIX H 298 
PAEDIATRIC SATURATION STUDY 
Patient name: 	 Age: 	 Sex: 	 P/M: 	 Hosp. No.: 
Period 1 Period 2 Period 3 Period 4 
Time invalidated by 
satmaster 
Time invalidated by 
operator 
Total time valid 
Mean Sp02 
Time in Range: 
90 - 95% 
85 - 90% 
80 - 85% 
75 - 80% 
70 - 75% 
<70% 
No. of episodes 
90 - 95% 
85 - 90% 
80 - 85% 
75 - 80% 
70 - 75% 
<70% 
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INSTRUCTIONS TO NURSING STAFF 
The aim of this study is to find out what happens to the oxygen saturation of 
children before and after they undergo surgery. 
Do not disconnect any of the plugs from the oximeter, computer or at the 
wal. If the computer is disconnected, even for one second, it loses al the 
information and this is a disaster!!! If disconnecting the oximeter to go to toilet 
etc. Do not remove the micropore from the patient but disconnect at the grey / 
white junction. 
THANK YOU for your help and co-operation! 
Any problem / question - ring 298. 
Please fil in the folowing information below: 
1.Time patient receives pre-med 
2.Times oximeter disconnected and re-connected for procedures. Please keep 
the time disconnected to a minimum. 
3.Times post-op analgesia given and dose also fil in overleaf if patient was 
awake / asleep on returning to the ward and for how long. 
Time 	 Event 
APPENDIX H 300 
PATIENT DATA 
MIDAZOLAM / FLUMAZENIL (ANEXATE) PHARMACOKINETICS 
NAME: 	 HOSPITAL NO: 	 HKID: 
DATE: 	 AGE: 	 WEIGHT: 	 kg 	 CODE NO: 
Condition on arrival in theatre: 
1. Agitated / Crying 	  
3. Drowsy 	  
1. Are you frightened? 
leaving mummy 
going to sleep 
2. Aware, apparently anxiety free 	  
4. Asleep, responds to commands 	  
2. If Y, then what are you frightened of? 
Pain 	 Y / N 	 gweilos Y /N 	 dying Y / N 
needles Y / N 	  
YIN  
Y / N 
Y / N 
Induction: 
Alfentanil 5 micg/kg , then 60 sec later give Midazolam 0.5 mg/kg over 30 seconds 
Commence pharmacokinetic timing at the end of midazolam administration 
Atracurium 0.5 mg/kg 
Time of induction: 	 hr 	 Time of extubation• 	 hr 
	
Duration of anaesthesia 	 min 
Induction comments: 	  
Extubation: 
Commence 6 minute timing and give reversal, 100% oxygen and extubate simultaneously. 
Gently ventilate by mask until spontaneous ventilation recommences 
when breathing transfer to recovery 
6 minutes after reversal give the first undiluted does of flumazenil, 
then wait one minute and commence the diluted flumazenil infusion. 
The infusion is to continue until the child says his name. 
Recovery: 
Actual time Flumazenil given in recovery : 	 hr 
Actual time of spontaneous eye opening • 	 hr 
Time from Flumazenil injection to spontaneous eye opening 	 sec 
Actual time of giving own name: 	 hr 
Volume of ful strength flumazenil: 	 ml Half strength 	 ml 
Total Does of flumazenil 	 mg 
Recovery comments and side effects. 	  
24 Hour URINE volume: 	 ml 	 10 ml urine sample colected Y / N 
APPENDIX H 301 
Sample No. 
MIDAZOLAM FLUMAZENIL 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Time (min) 0 2 4 6 8 10 15 20 30 2 4 6 8 10 15 20 30 60 120 180 240 
Actual Time 
HR 
BP 
RR 
Does patient go back to sleep in the WARD? Y / N COMA SCALE 
Time into recovery: Toy Completion T me (sec) 
1.laughing, euphoric Time of eye opening: 2.happy, contented playful 
Childs mood on awakening 3.calm, drowsy, asleep Time of identification: 4.crying but calmed or iritable 
5.severe pain, screaming, inconsolable 
Actual time patient goes to sleep in the WARD: 	 hrs TOY COMPLETION 
CONSCIOUSNESS: 	 COMA SCALE SET UP: 
Fuly awake, eyes open, conversing 	 =4 
Lightly asleep, eyes opening intermitently 	 = 3 Tray with Box and shapes 
Eyes open on command or in response to name 	 =2 Box at back of tray (Red buton Uppermost) 
Responding to ear pinching 	 = 1 
Not responding 	 = 0 2 Rows of shapes in front in the order below: 
AIRWAY: Cross 	 . 	 Arow 	 Star 	 Animal 
Opening mouth or coughing or both, on command 	 = 3 (Orange) 	 (Blue) 	 (Green) 	 (Yelow) 
No voluntary cough, but airway clear without support 	 = 2 
Airway obstructed on neck flexion but clear without support on extension 	 = 1 Animal 	 Clover 	 Animal 	 Animal 
Airway obstructed without support 	 = 0 (Green) . 	 (Yelow) 	 (Blue) 	 (Orange) 
ACTIVITY: TEST: 	 Pt 	  sec. 	 5'h 	  _ sec. Raising one arm on command 	 = 2 1.Place tray in front of child, 	 2nd 	  sec. 	 6th 	  sec. 
Non purposeful movement 	 = 1 2.Start timing 	 3rd 	  sec. 	 7th 	  sec. 
Not moving 	 = 0 3.Finish timing on completion 	 4th 	 sec. 
Add Scores for Consciousness, Airway and Activity Pre-op. Toy Completion 
WRITE IN THE BOX ABOVE 	 TOTAL SCORE 	 PLEASE DO NOT HELP THE CHILD 	 Fastest Time 	 secs. 
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PATIENT DATA 	 PROPOFOL / PHARMACOKINETIC DATA 
NAME: 	 HOSPITAL NO.: 	 HKID: 
AGE: 	 WEIGHT: 	 kg 
Condition on Arrival in Theatre: 
1. Agitated / Crying 	 2. Aware, apparently anxiety free 	  
3. Drowsy 	  4. Alert, responds to commands 	  
Time of Induction: 	 Time entered recovery (finish time) : 
i.e. Anaesthetic time: 
Induction Grading: 
1.Good 	 absence of side efects. 
2.Adequate 	  side efects not interfering with induction. 
3.Poor 	  side efects severe / protracted. 
ANAESTHETISTS: 	 SAMPLER: 
Movement Grading: 
1. Semi-purposeful 	  2. Tremor / rigidity 	  
3. Convulsions 	 4. Breath holding / apnoea 	  
5. Hiccup / Cough / Laryngospasm 	  6. None 	  
If Apnoea occurs, 	 Peak ETCO, Post apnoea 	 mmHg. 
Duration of apnoea 	 secs. 
Requiring ventilation 	 Y / N 
Desaturation ( < 90% ) duration : secs. 
Induction Comments: 	  
Recovery Comments: 	  
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MINUTES HOURS 
Time 0 2 5 10 15 20 30 45 60 90 120 180 4 6 8 10 12 18 24 
Actual Time 
HR 
BP 
Sp02 
ErCO2 
RR , COMA SCORE a 
MOOD SCORE , 
Time into recovery: 
Times eyes open spontaneously: 
Time of name identification: 
COMA SCALE 
CONSCIOUSNESS: 
Fuly awake, eyes open, conversing 	 = 4 
Lightly asleep, eyes opening intermitently 	 = 3 
Eyes open on command or in response to name 	 = 2 
Responding to ear pinching 	 = 1 
Not responding 	 = 0 
AIRWAY: 
Opening mouth or coughing or both, on command 	 = 3 
No voluntary cough, but airway clear without support 	 = 2 
Airway obstructed on neck flexion but clear without support on extension 	 = 1 
Airway obstructed without support 	 = 0 
ACTIVITY: 
Raising one arm on command ' 	 = 2 
Non purposeful movement 	 = I 
Not moving 	 = 0 
Add Scores for Consciousness, Airway and Activity 
TOTAL SCORE 
MOOD SCORE -' 
I. Laughing / euphoric 
2.Happy, contented, playful 	 , 
3.Calm or asleep 	 - 
4.Crying but calmed 
5.Severe pain, screaming, inconsolable 
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PATIENT DATA 	 MIDAZOLAM / ANEXATE 
NAME: 	 HOSPITAL NO: 	 HKID: 
DATE: 	 AGE: 	 WEIGHT: 	 kg 	 CODE NO: 
Condition on arrival in theatre: 
1. Agitated/Crying 	  2. Aware, apparently anxiety free 	  
3. Drowsy 	 4. Asleep, responds to commands 	  
Induction: 
Time of induction. 	 hr 	 Time of loss of eyelash reflex 	 hr 
Duration of any apnoeic episode Sa02 <90% 	 secs or NONE 
Induction comments. 	  
Recovery - Events: 
Time of arrival in recovery. 	 hr 	 Duration of Anaes: 	 min 
Actual time Trial drug given in recovery: 	 hr 
Actual time of spontaneous eye opening: 	 hr 
Time from reversal injection to spontaneous eye opening 	 sec 
Actual time of giving own name: 	 hr 
1st injection 	 mls 	 2nd injection 	 mls 
3rd injection 	 mls 	 4th injection 	 mls 
Total Dose 	 mls 
Recovery comments and side efects: 	  
Evaluation by doctor: 	 Examination of injection site 
24 hr post op. 
Efficacy of trial drug 	  
Tolerance of trial drug 	  
CODE: 1. Excelent 2. Good 3. Moderate 4. Poor 
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PRE 
INDUCTION 
Minutes Post-induction PRE 
DRUG 
Minutes post drug administration in Recovery & Ward 
1 2 5 15 30 2 5 10 30 60 2 hrs 4 hrs 18 hrs 
Actual Time 
RR 
BP 
HR 
ErCO, Commence injection 3 minutes after arival in recovery 
MOOD SCORE 
Coma 
Scale 
Patient asleep, not arousable 	 = 
Patient asleep, but arousable 	 = 
Patient drowsy 	 = 
Patient awake 	 = 
0 
1 
2 
3 
Mood 
Score 
Toy 
Compl 
Time 
COMMA SCALE TOY COMPLETION 
CONSCIOUSNESS: 
Fuly awake, eye open, conversing 
Lightly asleep, eyes opening intermitently 
Eyes open on command or in response to name 
Responding to ear pinching 
Not responding 
= 4 
= 3 
= 2 
= I 
= 0 
SET UP: 
Tray with Box and shapes 
Box at back of tray (Red Buton Uppermost) 
2 Rows of shapes in front in the order below: 
Cross 	 Arow 	 Star 	 Animal 
(Orange) 	 (Blue) 	 (Green) 	 (Yelow) 
Animal 	 Clover 	 Animal 	 Animal 
(Green) 	 (Yelow) 	 (Blue) 	 (Orange) 
AIRWAY: 
Opening mouth for coughing or both, on command 
No voluntary cough, but airway clear with support 
Airway obstructed on neck flexion but clear without support on extension 
Airway obstructed without support 
= 3 
=2 
= 1 
= 0 
ACTIVITY: 
Raising one arm on command 
Non purposeful movement 
Not moving 
= 2 
= 1 
= 0 
TESTS: 	 Pi 	 secs. 	 5th 	 secs. 
.1. Place tray in front of child 	 2"d 	 secs. 	 6th 	 secs. 
2.Start timing 	 yd 	 secs. 	 7t1  	 secs. 3.Finish timing on completion 	 4th 	 secs. 
Pre-op. Toy Completion 
Fastest time 	 Secs. DO NOT HELP THE CHILD 
Add Scores for Consciousness, Airway and Activity 
TOTAL SCORE 
APPENDIX H 306 
PATIENT DATA SHEET - Propofol, Midazolam, Thiopentone induction study 
NAME: 	 • HOSP No: 	 STUDY No: 
DATE: / 	 / 1992 	 AGE: 	 WEIGHT: 	 kg 
Condition on arrival in 0.T.: 
agitated or crying Are you frightened? y / n 
aware, apparently anxiety free What are you frightened of? 
drowsy leaving mummy 
asleep but responds to commands going to sleep 
PICTURE CARD: 	 Corect 
Features: 1. 	 YIN 
2. 
3. 
4. 
5. 
Score: 	 tyc. 
 g w eil o s 
pain ' 
needles 
dying 
INDUCTION AGENT: 
Time of induction: 	 hr 	 Time to recovery: 	 hr 
Duration of anaesthesia: 	 min. 
Induction comments: 
Time of eye opening: 	 hrs. 	 Time of identification: 	 hrs. 
WISC-R COMPLETION TIME (sec) ERRORS (n) 
1st 
2nd 
3rd 
4th 
5th 
6th 
7th 
fastest time with least errors 
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SAMPLE NO. 1 2 3 4 0. 	 T. 	 induction 5 6 7 8 9 
Time of Sample 30 60 90 120 o 2 4 6 AWAKE 1 hour 2 hour , 	' 3 hour 4 hour 
Actual Time 
heart rate (min-') 
systolic BP (mmHg) 
respiratory rate (min') 
end tidal CO, (kPa) 
Post-Box toy (sec) 
WISC-R test (sec) 
MOOD score 
COMA score 
If the child goes back to sleep after transfer to the ward, mark the COMA score with an A at the time of assessment, awaken the child & perform the test. 
AIRWAY: CONSCIOUSNESS: score ACTIVITY score 
opening mouth or coughing on command 3 fuly awake, eyes open, conversing 4 raising one arm on command 2 
no voluntary cough, clear airway without support 2 lightly asleep, eyes opening intermitently 3 non-purposeful movement 1 
obstruction on neck flexion, clear without support on extension 1 eyes open on command or in response to name 2 not moving 0 
airway obstructed without support 0 responding to ear pinching 1 I 
not responding 0 
Add scores for AIRWAY, CONSCIOUSNESS, ACTIVITY and write score in coma score box above COMA SCORE 
MOOD SCORE: 
laughing, euphoric 1 
POST-BOX TOY COMPLETION TIME: 
Place the box on the left of the tray with the two rows of shapes to the right, in front of the child and 1" 5th 
happy, playful 2 in this order: 	CROSS (orange) 	 ARROW (blue) 	 STAR (green) 	 ANIMAL (yelow) 2nd 6th 
calm, drowsy, sleepy 3 ANIMAL (green) 	 CLOVER (yelow) ANIMAL (blue) 	 ANIMAL (orange) 3rd 7th 
iritable but calmed by mother 4 Record the child's completion time 4th 8th 
screaming, inconsolable 5 PLEASE DO NOT HELP THE CHILD, BUT DO GIVE ENCOURAGEMENT FASTEST 	 TIME 	 (sec) 
